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TRPM7 is an essential, ubiquitously expressed protein which combines the function of a non-
selective ion channel together with a serine- and threonine-phosphorylating alpha-kinase. While the 
channel domain and the role of TRPM7 for cellular Mg2+ and Ca2+ homeostasis and Zn2+ uptake and 
release has been intensively studied, function of TRPM7’s phosphotransferase activity is less well 
understood; among other reasons, this is mainly due to the fact that the so far few identified 
substrates do not show any similarity in the consensus sequence, aggravating determination of a 
universal substrate recognition motif.  
Regarding its importance for physiological functions, TRPM7 has been shown to regulate different 
basic cellular processes such as proliferation, differentiation, migration and apoptosis, wherefore it is 
also implicated in the pathogenesis of different diseases such as inflammation, cancer development 
and progression. More recent studies suggest that this regulation occurs through the control of 
different cell signaling pathways which then lead to the induction of specific gene transcription; thus, 
TRPM7 has been shown to affect the activation of the PI3K/Akt, MAPK/ERK, JAK/STAT3 and 
TGF-β/SMAD2 pathway by controlling Akt, ERK1/2, STAT3 and SMAD2 phosphorylation. 
However, the so far published results are partially contradictory, rendering it impossible to draw final 
conclusions regarding the exact function of TRPM7 in these signaling cascades.  
In this respect, purpose of the present study was to clarify the role of TRPM7 in cellular signaling 
events and closer illuminate how either the channel or kinase unit participate in the regulation of 
TRPM7-affected pathways. Therefore, I utilized two different TRPM7 models generated in a haploid 
chronic myeloid leukemia cell line (HAP1): The HAP1 TRPM7 KO cell clone lacking expression of 
the full-length protein and the HAP1 TRPM7 KI cell clone carrying a functional channel, but an 
inactivated kinase domain. In each experiment, the TRPM7 mutants were compared to their 
respective parental wild-type (WT) clone expressing an intact TRPM7 protein, which were carried 
along as controls.  
The first part of my studies focused on the validation of the effective genetic manipulation of the two 
HAP1 TRPM7 cell models. Western Blot analysis using an antibody targeting the 
autophosphorylation site Ser1511 of the TRPM7 kinase confirmed inactivation of TRPM7’s 
phosphotransferase in the TRPM7 KI clone. Electrophysiological measurements of both clones 
demonstrated that, while the TRPM7 KO clone lacks the typical TRPM7-like current and thus 
confirms functional depletion of the channel-kinase, inactivation of the kinase domain does not 
significantly alter TRPM7 current amplitude and its kinetics.  
After successfully validating the generation of the two TRPM7 cell models, I specifically investigated 





Most importantly, the present work discovers TRPM7 to function in gene expression and catalytic 
activity of the immunologically relevant enzyme COX-2. Thus, real-time quantitative polymerase 
chain reaction (RT-qPCR) experiments in resting and with the adenylyl cyclase activator forskolin 
stimulated HAP1 TRPM7 KO cells illustrated that TRPM7 promotes constitutive as well as inducible 
COX-2 gene expression. Moreover, analysis of the HAP1 TRPM7 KI showed that, while constitutive 
COX-2 gene expression is primarily regulated by TRPM7 kinase activity, the induction of COX-2 
transcription necessitates both a functional TRPM7 channel and kinase domain. In addition, 
performing a COX activity assay demonstrated that TRPM7 augments enzymatic activity of COX-2, 
as knockout of TRPM7 in the HAP1 cells results in diminished COX-2-mediated prostaglandin (PG) 
synthesis. Yet, the experimental setup is not eligible to tell if the observed TRPM7-dependent 
increase in COX-2 activity is due to enhanced COX-2 gene respectively protein expression or if 
TRPM7 facilitates substrate conversion by directly affecting COX-2. 
To address the question which pathway(s) are involved in the observed TRPM7-dependent regulation 
of COX-2 gene expression in the HAP1 cells, I performed Western Blot experiments using phospho-
specific antibodies targeting different signaling molecules being part of the pathways introduced 
above. Comparison of the phosphorylation status of the cell signaling kinases Akt (Ser473) and 
GSK3β (Ser9) in the HAP1 TRPM7 WT and KO cells demonstrated that TRPM7 augments both 
Akt and GSK3β phosphorylation. This is accompanied by nuclear accumulation of the transcription 
factor NFAT, which is known to function in COX-2 gene expression and induction. Thus, I 
hypothesize that TRPM7 regulates COX-2 gene expression through an Akt – GSK3β – NFAT 
signaling axis in the HAP1 cells. However, further evaluating the impact of the TRPM7 kinase activity 
on these signaling molecules revealed that, although the kinase is required for Akt Ser473 
phosphorylation, it is redundant for GSK3β Ser9 phosphorylation and NFAT nuclear localization. 
Hence, the TRPM7 kinase-dependent regulation of COX-2 gene expression must occur through the 
activation of a different TRPM7-affected pathway. Linking my results to the current literature, one 
might speculate that the kinase unit potentially enhances COX-2 gene expression by initiating an Akt 
– NFκB /CREB cascade.  
In order to substantiate the hypothesized domain-specific role of TRPM7 in COX-2 gene expression 
which was drawn from the results summarized above, I analyzed the effect of pharmacological 
inhibition of TRPM7 respectively its kinase domain in primary humane immune cells. RT-qPCR 
experiments showed that blockade of TRPM7 with NS8593 in neutrophils significantly attenuates 
lipopolysaccharide (LPS)-induced COX-2 gene expression. Likewise, administration of the TRPM7 
kinase inhibitor TG100-115 significantly decreases COX-2 gene expression in LPS-stimulated cells. In 
the light of COX-2 being the central target molecule when it comes to treatment of numerous 





but administration of common unselective COX-1 and COX-2 inhibitors showing severe adverse 
effects (e.g. risk elevation of gastrointestinal injuries and cardiovascular diseases), my results uncover 
that TRPM7 might represent a promising alternative target for the therapy of COX-2-mediated 

























































TRPM7 ist ein essentielles, ubiquitär exprimiertes Fusionsprotein, das sich aus einem nicht-selektiven 
Ionenkanal und einer Serine und Threonine phosphorylierenden Alpha-Kinase-Einheit 
zusammensetzt. Während die Kanaldomäne und die Bedeutung des TRPM7 für die zelluläre 
Homöostase von Mg2+ und Ca2+ und die Aufnahme und Freisetzung von Zn2+ recht gut erforscht ist, 
ist die Funktion der Kinasedomäne weitaus weniger gut verstanden, was u. a. daran liegt, dass sich 
bezüglich der Konsensussequenz der Kinaseinheit in den bisher identifizierten wenigen Substraten 
kein eindeutiges und übereinstimmendes Motiv erkennen lässt.  
Hinsichtlich seiner physiologischen Funktion haben Studien der letzten zwei Dekaden gezeigt, das 
TRPM7 maßgeblich an der Regulation einer Reihe elementarer Zellfunktionen wie der Proliferation, 
der Migration, der Differenzierung und der Apoptose beteiligt ist. Die sich daraus ableitende 
Relevanz des TRPM7 für die Pathogenese einer Vielzahl von Erkrankungen, wie die Entstehung und 
das Voranschreiten von Entzündungsreaktionen oder Tumoren, konnte ebenfalls bestätigt werden. 
Aktuellere Arbeiten deuten darauf hin, dass die Regulation dieser zellulären Prozesse durch die 
Kontrolle unterschiedlichster Signaltransduktionswege vermittelt wird, die final die Transkription 
bestimmter Zielgene beeinflussen: So spielt TRPM7 z. B. eine Rolle bei der Weiterleitung von 
Signalen durch die Kaskaden PI3K/Akt, MAPK/ERK, JAK/STAT3 und TGF-β/SMAD2, in dem 
es die Phosphorylierung der zwischengeschalteten Regulatorproteine Akt, ERK1/2, STAT3 und 
SMAD2 beeinflusst. Eine endgültige Aussage hinsichtlich der Regulation dieser Signalkaskaden durch 
TRPM7 ist gegenwärtig jedoch nicht möglich, da einige der bisher hierzu publizierten Befunde sich 
teilweise widersprechen.  
Ziel dieser Arbeit war es daher, den Effekt von TRPM7 auf die genannten Signalwege zu überprüfen 
und dabei explizit zwischen dem Einfluss der Kanal- und der Kinaseeinheit zu unterscheiden. Dazu 
wurden zwei unterschiedliche Klone in einer haploiden, chronisch-myeloiden Leukämiezelllinie 
(HAP1) generiert: Der HAP1 TRPM7 KO Klon, in dem kein funktionelles TRPM7 Protein 
exprimiert wird und der HAP1 TRPM7 KI Klon, der zwar eine intakte Kanaleinheit aber eine 
inaktivierte Kinase aufweist. Diese wurden in allen Experimenten mit ihrem jeweiligen parentalen 
Wildtyp (WT) Klon mit einem intakten TRPM7 Protein verglichen, welche als Kontrollzelllinien 
mitgeführt wurden. 
Zunächst wurden beide TRPM7 Zellmodelle bezüglich ihrer erfolgreichen genetischen Manipulation 
untersucht. Western Blot Analysen mit einem Antikörper, der die Autophosphorylierungsstelle 
Ser1511 der TRPM7-Kinase erkennt, bestätigten die erfolgreiche Inaktivierung der Kinase in dem 
TRPM7 KI Klon. Weiterführende ‚Patch Clamp’ Experimente zur Erfassung der Kanalaktivität 





Zellen fehlt, was als Bestätigung für die erfolgreiche funktionelle Deletion des Proteins gewertet 
werden kann; die Ausschaltung der Phosphotransferase-Aktivität hat hingegen keinerlei 
Auswirkungen auf die Amplitude und die Kinetik des TRPM7-vermittelten Ionenflusses.  
Nach der erfolgreichen Validierung der Herstellung der TRPM7-Zellmodelle wurden anschließend 
gezielte Analysen zur Bedeutung des TRPM7 bzw. dessen Kinase Domäne für die Regulation der 
oben erwähnten Signalwege zur Stimulation von Transkriptionsprozessen durchgeführt. Dabei 
konnte ich im Rahmen dieser Arbeit feststellen, dass TRPM7 einen bedeutenden Einfluss auf die 
Genexpression und die Aktivität der immunologisch relevanten Cyclooxygenase-2 (COX-2) hat. Im 
Detail haben quantitative Polymerase-Kettenreaktions-Experimente (RT-qPCR) an ‚ruhenden’ und an 
mit dem Adenylylcyclase Aktivator Forskolin stimulierten HAP1 TRPM7 KO Zellen gezeigt, das 
TRPM7 sowohl die Genexpression der konstitutiven, aber auch die der induzierbaren COX-2 positiv 
beeinflusst. Parallel durchgeführte Analysen an Zellen des HAP1 TRPM7 KI Klons ergaben weiter, 
dass die Stimulation der konstitutiven COX-2 Genexpression im Wesentlichen auf die Aktivität der 
TRPM7 Kinase zurückzuführen ist, während für die Erhöhung der Genexpression der induzierbaren 
COX-2 die Aktivität beider TRPM7 Domänen erforderlich ist. Ein mit HAP1 TRPM7 KO Zellen 
durchgeführter COX Aktivitätsassay lieferte zudem den Hinweis, dass TRPM7 auch die Aktivität der 
COX-2 begünstigt. Ob die registrierte erhöhte Substratumsetzung der COX-2 allerdings lediglich auf 
die gesteigerte Expression des Enzyms zurückzuführen ist oder ob der TRPM7 die Enzymaktivität 
möglicherweise durch eine direkte Interaktion oder auch Modifikation erhöht, konnte nicht 
abschließend geklärt werden. 
Bezüglich der Frage, welche Signalkaskade(n) an der Stimulation der TRPM7-vermittelten COX-2 
Genexpression in den HAP1 Zellen beteiligt ist, wurden zusätzliche Western Blot Analysen mit 
phosphospezifischen Antikörpern gegen verschiedene Regulatorproteine der oben eingeführten 
Signalwege durchgeführt. Ein Vergleich des Phosphorylierungsgrades von Akt (Ser473) und GSK3β 
(Ser9) zwischen HAP1 TRPM7 WT und KO Zellen ergab, dass TRPM7 offenbar die 
Phosphorylierung von Akt und GSK3β verstärkt; gleichzeitig wurde eine TRPM7-vermittelte 
Akkumulation des Transkriptionsfaktors NFAT im Zellkern beobachtet. Da bekannt ist, dass NFAT 
die Transkription von COX-2 induziert, liegt es nahe, dass TRPM7 die COX-2 Genexpression durch 
die Initiierung einer Akt – GSK3β – NFAT Signalkaskade stimuliert. Weiterführende Studien mit 
Kinase-inaktivierten Zellen ergaben jedoch, dass die Enzymeinheit zwar an der Phosphorylierung von 
Akt beteiligt ist, aber keinen Einfluss auf die GSK3β Phosphorylierung und die nukleare 
Akkumulation von NFAT hat. Dies lässt vermuten, dass der beobachtete Effekt der TRPM7 Kinase 
auf die COX-2 Genexpression durch die Aktivierung eines anderen durch TRPM7 beeinflussten 





dato publizierte Literatur vorstellbar, dass die TRPM7 Phosphotransferase die COX-2 Genexpression 
zusätzlich durch eine Akt – NFκB /CREB Kaskade induziert. 
Um die sich aus den bisherigen Befunden abzuleitende Hypothese zu überprüfen, ob die beiden 
funktionellen Einheiten des TRPM7 tatsächlich an der Genexpression der COX-2 beteiligt sind, 
wurden pharmakologische Blockierungsexperimente an primären humanen Immunzellen 
durchgeführt. Dabei zeigten RT-qPCR Versuche, dass die Inhibition des TRPM7 in Neutrophilen 
mittels NS8593 zu einer signifikanten Reduktion der durch Lipopolysaccharide (LPS)-induzierten 
COX-2 Genexpression führt. Ein ähnlicher Effekt konnte beobachtet werden, wenn die LPS-
stimulierten Zellen stattdessen zuvor mit dem TRPM7 Kinase Inhibitor TG100-115 behandelt 
wurden. Betrachtet man diese Ergebnisse vor dem Hintergrund, dass die COX-2 eine zentrale 
therapeutische Zielstruktur für die Behandlung einer Vielzahl von Erkrankungen, wie z. B. Krebs, 
neurodegenerative oder Autoimmunerkrankungen darstellt, die Gabe der häufig zur therapeutischen 
Anwendung kommenden unspezifischen COX-1 und COX-2 Blocker aber mit dem bekannten 
unerwünschten Nebenwirkungsprofil (Erhöhung des Risikos für gastrointestinale 
Schäden/Verletzungen, kardiovaskuläre Erkrankungen etc.) einhergeht, könnten die hier 






































3.1 TRP channels 
In 1989, Craig Montell and Gerald Rubin proposed that the eye-specific Drosophila trp gene might 
encode for a channel or transporter within the photosensitive rhabdomeral membrane of 
photoreceptor cells [3]. Although studies on this gene go further back in time, this was the first time it 
was assumed that trp might be coding for a light sensitive ion channel affecting the intracellular 
calcium (Ca2+) levels. This hypothesis was confirmed in 1992 by another study from Hardie and 
Minke, showing that ‘transient receptor potential’ (TRP) was indeed a Ca2+ conducting channel 
activated by light [4]. Three years later, the first mammalian TRP homologue, TRPC1, was discovered 
[5, 6]. This laid the foundation for the subsequently following, fast expanding research area on TRP 
channels.  
 Figure 3.1 Phylogenetic tree of mammalian TRP channels. Due to great similarity in their primary 
protein structure, the 28 TRP channels are divided into 6 different subfamilies – named TRPC, TRPM, 
TRPA, TRPP, TRPML and TRPV – according to their amino acid (AA) composition. Each group (except 
TRPA) further splits up into the even closer related family members numbered 1 through maximum 8. 
The point accepted mutation (PAM) index (see left corner for scale bar) reveals how comparatively small 
the difference between the respective TRP channels is. One PAM denotes mutation of one AA of the 





Over the last two decades, intensive exploration led to the knowledge of 28 mammalian TRP 
channels, which can be classified into six different subfamilies due to their sequence similarity: TRPA 
(ankyrin), TRPC (canonical), TRPM (melastatin-like), TRPML (mucolipin), TRPP (polycystin) and 
TRPV (vanilloid) [1, 7]. This classification differs from the usual, as ion channels normally are 
categorized by their activation mechanism and ion specificity. But as ligand binding and function are 
so differing between the TRP channels and in some cases are still unknown, TRP channels were 
grouped by their similarity in amino acid (AA) composition (Figure 3.1) [1].  
3.1.1 Classification, structure and function of TRP channels 
Comparison of all TRP channels among each other reveals only 20 % shared sequence identity [1], 
with the best conserved region being the channel pore region [8]. Nevertheless, they all comprise the 
basic architecture of an intracellular located N- and C-terminus flanking six transmembrane (TM) 
domains, with the channel pore being located between the fifth and sixth segment. The subfamilies 
are again summarized into two groups: Group 1 includes TRPA, TRPC, TRPM, TRPV and TRPN 
channels (TRPN is not existent in mammals though), while group 2 is represented by TRPML and 
TRPP (Figure 3.2) [9]. All members of group 1 except TRPM channels carry several N-terminal 
ankyrin repeat domains, which are, in case of TRPCs, directly followed by a coiled-coil domain. 
TRPC, TRPM and TRPN additionally contain the typical TRP domain – composed of the conserved 
TRP boxes 1 and 2 – positioned right behind the last membrane-crossing segment within the C-
terminus [9]. Another element occurring in at least three of the TRP subfamilies, TRPC, TRPM and 
TRPV, are calmodulin (CaM) binding sites, in some cases overlapping with inositol 1,4,5-triphosphat-
receptor (IP3R) binding sites, domains by which the channels can be modulated [10]. Such sites are 
often found in ion channels, and CaM’s strong interaction with channels even led Saimi and Kung to 
the concept of CaM being an ‘ion channel subunit’ [11, 12]. Furthermore, an extraordinary feature 
can be found within the TRPM subfamily: Member 2, 6 and 7 carry an enzymatic domain attached C-
terminal to the TM region, wherefore they are also called ‘chanzyme’s (channel-enzyme) [13].    
Representing the ancient TRP channels, the group 2 members TRPP and TRPML display high 
sequence homology within their TM region and enclose a C-terminal endoplasmatic reticulum (ER) 
retention signal (Figure 3.2) [9].  Almost all TRPs assemble in tetramers to form functional channels, 
either with themselves (except TRPC1) or other members of the same subfamily [14, 15]. But also 
heterotetramers between different subfamilies have been observed [14]. The resulting functional 
channels conduct mono- and divalent cations, with Ca2+, magnesium (Mg2+) and sodium (Na2+) being 
the most important players. In general, all TRP channels are non-selective, except for TRPM4 and 5 
(permeability (P) ratio PCa/PNa>0.05), which solely conduct monovalent ions, and TRPV5 and 6 that 





Regarding their expression profile, most members of the family are ubiquitously expressed, while 
some show a more restricted distribution. Additionally, multiple TRPs are not only located in the 
plasma membrane, but can also be found in membranes of intracellular compartments [16, 17]. 
There, they impact vesicle trafficking as well as biosynthetic, autophagic, endocytotic and exocytotic 
events [16]. 
Taken together, TRPs are not only important for systemic and cellular ion homeostasis, but are also 
involved in ion flux required for processes such as cell growth, proliferation, migration, 
differentiation and cell death. Hence, they also reveal a strong pathophysiological background, as 
mutations in TRP proteins often cause organ-specific or systemic malfunctioning and severe diseases 
such as cancer, tumor progression and heart diseases such as hypertrophy, ischemic cardiomyopathy, 











Figure 3.2 Topology of the TRP channel subfamilies. All TRP channels comprise one or more 
conserved domains carrying specific functions. Domains being shared among TRP group 1 members are 
the N-terminal ankyrin repeat domain (AnkR; TRPMA, TRPV, TRPC), a coiled-coil domain (CC; TRPC 
and TRPM) and the TRP domain located C-terminal of the transmembrane (TM) region (TRP box; TRPV, 
TRPC, TRPM). In addition, members of the TRPC, TRPM and TRPV subfamily reveal calmodulin (CaM) 
binding sites (not shown) and TRPM2, 6 and 7 exhibit the special feature of a C-terminally located 
enzymatic domain [Ser/Thr (S/T) Kinase in case of TRPM6 and 7]. The small TRP group 2 on the other 
hand is united by an endoplasmatic reticulum (ER) retention signal domain (TRPP and TRPML). 





3.1.2 TRP channels in ion homeostasis 
3.1.2.1 TRP channels in Ca2+ homeostasis 
One of the main attributes of TRP channels is their impact on Ca2+ homeostasis. Many studies 
revealed that there are three different ways of how TRP channels influence the intracellular (cytosolic 
as well as compartimental) Ca2+ concentrations: (a) as direct Ca2+ entry pore, (b) by plasma membrane 
induced depolarization or (c) by orchestrating Ca2+ release from intracellular stores [20].  
(a) As described in 3.1.1, almost all TRP channels are Ca2+ permeable and thereby significantly 
contribute to ion homeostasis by directly mediating Ca2+ influx. Nevertheless, Ca2+ conductivity 
largely differs among the individual TRP channel subtypes due to their large variance in selectivity 
and permeability. But also other factors, such as activators and/or associating proteins, influence 
the magnitude of Ca2+ influx by changing pore dilation and thereby permeability, which is usually 
expressed by PCa2+/PNa+ (according to the Goldman-Hodgkin-Katz theory, see [21] for a short 
overview). Additionally, variable experimental conditions including temperature, pH or 
extracellular Mg2+ or Ca2+ concentrations also influence ion conductance [22, 23].  
(b) Because inward-directed, fractional Ca2+ currents of some TRP channels are relatively small, the 
question arose if TRP channels might exert their (Ca2+-related) functions by additional 
mechanisms. In excitable cells, activated TRP channels cause a slight rise of the cytosolic Ca2+ 
concentration ([Ca2+]i/cyt) which induces a shift in the membrane potential that results in the 
opening of voltage-dependent Ca2+ channels (VDCCs) [24-27] (for overview see [20]). This TRP-
dependent regulatory mechanism also applies for other ion channels, predominantly in non-
excitable cells, where TRP-induced de- or hyperpolarization either causes opening or closing of 
Ca2+-dependent potassium (K+) or Na+ channels [28-30]. Furthermore, many of the TRP 
channels are regulated by Ca2+ themselves, not only through Ca2+- and CaM-binding sites, but also 
via molecules and events involved in Ca2+ signaling, such as phospholipase C (PLC) -modulation 
or protein kinase C (PKC) -activation [20, 31, 32].   
(c) As mentioned before, TRP channels are not exclusively found in the plasma membrane, but also 
inserted in the lipid bilayer of intracellular compartments. Basically, intracellular organelles are 
divided into two groups: Group 1 encloses the endoycytotic, secretory and autophagic 
compartments (with the ER and Golgi apparatus, secretory vesicles, endosomes, 
autophagosomes, and lysosomes), while group 2 comprises the mitochondria, peroxisomes and 
the nucleus. Despite their diverse functions, most of them serve as intracellular Ca2+- stores, and 
the luminal Ca2+ concentrations ([Ca2+]lumen) are much higher than the resting [Ca
2+]i/cyt ([Ca
2+]lumen 





intracellular located TRP channels participate in the release of Ca2+ from the stores into the 
cytosol (for overview see [16]).  
3.1.2.2 TRP channel in magnesium (Mg2+) homeostasis 
While nearly all TRP channels conduct Ca2+, the number of Mg2+ permeable ones is more limited. 
Nevertheless, representatives are found within the TRPA (TRPA1), TRPV (TRPV2 and 4), TRPP 
(TRPP2 and 3), TRPML (TRPM1 and 3) as well as TRPM (TRPM1-3 and 6-7) subfamily [33]. For 
nearly all of those, their Mg2+-associated function(s) remain unclear, whereas the impact of TRPM6 
and 7 on Mg2+ homeostasis and Mg2+-affected processes has been intensively studied. Both of them 
essentially contribute to the cellular Mg2+ household, as manifold conditional and full knockout 
studies showed [34-37].  
TRPM6 was originally identified as central player in Mg2+ uptake and intercellular transport in 
patients displaying hypomagnesemia with secondary hypocalcemia [38, 39]. It is predominantly but 
not exclusively expressed in the kidney and the intestine, two organs that are both important for Mg2+ 
reabsorption [38, 40-42]. Nevertheless, Chubanov et al. found that nephric TRPM6, other than 
intestinal, is dispensable for maintenance of systemic Mg2+ [42]. Furthermore, TRPM6 indirectly 
affects embryonic development, as channel function is required for proper maternal Mg2+ supply to 
the embryo [42]. TRPM7 on the other hand shows a more ubiquitous expression pattern and is 
primarily responsible for cellular Mg2+ balance [41]. Nonetheless, it also participates in systemic Mg2+ 
homeostasis and facilitates reabsorption by forming heteromeric channels with TRPM6 [35, 36, 42-
44]. Thus, it’s not surprising that mutations or disruption of those channels can cause severe 
malignancies or even lead to early embryonic lethality [35, 45]. 
3.2 TRPM7 
The TRPM (sub)family encompasses eight members named after its founding member, TRPM1, and 
numbered consecutively through 8 [46, 47]. Due to shared sequence similarities endowing them with 
group-specific functions, they are paired into four groups: TRPM1/3, TRPM2/8, TRPM4/5 and 
TRPM6/7 [48]. 
Regarding the homolog proteins TRPM6 and TRPM7, both ion channels were found to share two 
features to be highlighted: They (a) are essential for Mg2+ homeostasis (see 3.1.2.2) and (b) contain a 





3.2.1 The TRPM7 channel 
3.2.1.1 Function of the TRPM7 channel unit  
As mentioned in chapter 3.1.2.2, TRPM7 represents a ubiquitously expressed protein important not 
only for Ca2+, but also essential for Mg2+ uptake [49]. The first investigations regarding TRPM7 in the 
chicken-derived DT-40 B cells [50] aimed at its role in Mg2+ homeostasis and demonstrated its 
significance for fundamental cell functions and survival [34]. Since then, requirement of both channel 
and kinase domain for viability and development has been confirmed in many different cell types as 
well as in in vivo experiments [35, 36]. However, some studies claim that the necessity of TRPM7 is 
independent from its function in Mg2+ uptake [45]. Hence, TRPM7’s function as a modulator of 
intracellular Mg2+ levels remains controversial. But the rescue of TRPM7 depletion-caused 
phenotypes by either additional supplementation of Mg2+ to the growth media or overexpression of 
the plasma-membrane Mg2+ transporter solute carrier family 41 member 2 (SLC41A2) supports the 
original idea of it being essential for Mg2+ homeostasis [36].  
K1648R 
Cl-, Br-, I- 
Figure 3.3 TRPM7 structure. TRPM7 is composed of a cytosolic N-terminus, 6 transmembrane (TM) 
domains and a cytosolic C-terminal tail. Its channel pore is formed between the 5th and 6th TM-spanning 
segment and conducts mono-, but primarily divalent cations such as Ca2+, Mg2+ and Zn2+. The channel 
function is physiologically modulated by intracellular Mg2+ concentration and Mg-ATP (but also other Mg-
conjugated nucleotides), pH and the halide anions chloride (Cl-), bromide (Br-) and iodide (I-). While the 
N-terminus contains 4 name-explaining melastatin homology domains (MHD), the C-terminus encloses 
the TRP, the coiled-coil (CC) and the atypical alpha-kinase domain (KD). This Ser/Thr kinase can be 






Besides its importance for Mg2+ and Ca2+ uptake, TRPM7’s permeation profile shows that other 
monovalent and divalent cations can pass the channel as well, with some [in particular zinc (Zn2+) and 
nickel (Ni2+)] exhibiting a driving force even four times higher than Ca2+ [51]. More recent studies 
reveal a possible implication in Zn2+ homeostasis, as TRPM7 is not only relevant for Zn2+ uptake 
through the plasma membrane, but also controls its release from intracellular stores [52-54]. 
Furthermore, protons enter through the pore into the cell and compete with metal ions for entry [55]. 
3.2.1.2 Regulation of channel activity via physiological mediators 
The channel can be regulated by various factors, including intracellular cations, nucleotides, halide 
anions and low pH (Figure 3.3). Mg2+-bound adenosine triphosphate (Mg-ATP) and guanosine 
triphosphate (Mg-GTP) suppress channel function in concentration-dependent manner when applied 
in millimolar concentrations [34]. Testing the effect of free intracellular Mg2+ demonstrated a 
complete channel block at 3 mM, which is above physiological free Mg2+ levels in the cell under 
normal conditions (100 - 900 µM) [56]. Thus, it was postulated that Mg-ATP is the main regulator of 
TRPM7, since cytosolic ATP levels are up to five-fold higher than other nucleoside triphosphates 
such as GTP (ATP: 1 - 10 mM, GTP: 0.2 - 0.5 mM) [57-59]. These findings led to the predominant 
opinion of Mg2+ and Mg-ATP working together in modulating channel opening, which is also 
reflected in the definition of the TRPM7 current: MagNuM (magnesium nucleotide-regulated metal 
ion) and MIC (magnesium-inhibited cation) [60]. Interestingly, the response of TRPM7 to its 
feedback regulators Mg2+ and Mg-ATP is fine-tuned by the heteromerization with TRPM6 in 
transporting epithelia: By complex formation of TRPM6 and 7 into functional heteromeric channels 
(TRPM6/7), TRPM6 reduces TRPM7’s sensitivity to Mg-ATP, while vice versa TRPM7 lowers 
TRPM6’s susceptibility to free internal Mg2+ [44, 61]. Consequently, TRPM6/7 channels are 
constitutively active at physiological cytosolic Mg2+ and Mg-ATP levels. While probably expendable 
in resting cells, this mechanism of desensitization of TRPM6 and TRPM7 homomers to their internal 
natural blockers most likely is required in cells with high metabolic activity or organs that mediate 
transcellular uptake of Mg2+. Accordingly, such TRPM6/7 heteromers have been detected in 
epithelial cells in the intestine, the kidney and the placenta and are possibly being formed in other 
TRPM6-expressing tissues as well [42, 44, 62]. In terms of halide anions, both chloride (Cl-) and 
bromide (Br-) block the channel in synergy with Mg2+, while the inhibition through iodide (I-) is Mg2+-
independent [63].  
Another parameter regulating the channel is the proton concentration. Cytosolic acidification blocks 
the channel, which might be due to shielding negatively charged phosphorylheadgroups from lipids 
involved in channel gating [64]. These findings are particularly of interest, as they connect the pH-
dependence of the channel with current-amplifying effects of the phospholipid phosphatidylinositol-





3.2.2 The TRPM7 kinase 
3.2.2.1 Structure of the TRPM7 kinase 
The TRPM7 protein is not only characterized by its channel domain essentially contributing to ion 
homeostasis, but also is defined through its unique direct fusion to an atypical kinase domain. This C-
terminally located kinase belongs to a class of protein kinases operating in a before unknown mode of 
substrate recognition that was first introduced by Ryazanov et al. in 1999 [66]. Other than 
conventional protein kinases (CPKs), which phosphorylate their targets usually within loops, β-turns 
or irregular structures, the alpha-kinases phosphorylate AAs located in α-helical conformations [67, 
68]. As there are only six mammalian alpha-kinases existent, TRPM7 and TRPM6 are even more 
exceptional in that their alpha-kinases are fused to membrane-spanning channels [34, 69].  
Despite differences in its AA sequence, the crystal structure of the TRPM7 alpha-kinase displays 
similarities to CPKs: It contains a nucleotide binding P-loop (e.g. present in protein kinase A (PKA)) 
and a region promoting protein dimerization, supposedly separable into “activation sequence” (1553-
1562) and “dimerization sequence” (1563-1570) [70]. Both of these elements are essential for kinase 
activity, while the latter additionally facilitates homo- as well as heterodimerization with TRPM6 [43, 
71]. Due to TRPM6’s distinct distribution and ion conductivity, it has been suggested that this 
interaction primarily supports transcellular Mg2+ transport in corresponding tissues (see chapter 
3.2.1.2) [44]. A similar conclusion was drawn from TRPM6 expression in embryonic stem cells 
(ESCs), which require high amounts of Mg2+ for rapid cell division [35].  
The zinc-binding module within the TRPM7 C-terminus upstream of the coiled-coil and alpha-kinase 
domain stabilizes the kinase domain [72]. TRPM6 and 7 kinase share features such as requirement of 
manganese (Mn2+) or Mg2+ for activity and the use of mainly ATP for phosphorylation [73]. This 
refers to substrate- as well as autophosphorylation, the latter occurring at so far 14 discovered 
phosphorylation sites in vitro which are all located within the C-terminus of TRPM7 (serine 
(Ser)/threonine (Thr) ratio = 12/2). Seven of those are found within a Ser/Thr-rich domain, and 
addition of phosphoryl groups to positions Ser1386, Ser1404, Ser1565 and Ser1567 in this sequence 
has been reported to be involved in regulation of the alpha-kinase activity [74, 75]. This finding was 
validated by another in vitro study, which revealed that autophosphorylation within the Ser/Thr-rich 
domain is not only important for subsequent substrate phosphorylation, but also increases the rate of 
substrate recognition[75]. Remarkably, TRPM6 is able to cross-phosphorylate TRPM7 within those 
regulatory sites and thereby modulates its subcellular localization and – in absence of Mg2+ – its 
impact on cell growth [76, 77]. More recent analysis of TRPM7 phosphorylation in vivo via liquid 
chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) suggests 15 residues to be 





Nevertheless, congruent to the in vitro studies, phosphorylation is able to control kinase activity, as 
mutagenesis experiments show [77].  
3.2.2.2 Function of the TRPM7 kinase: Substrate phosphorylation 
As being a phosphoryl group-transferring enzyme, the apparent main feature of the TRPM7 kinase is 
the mechanistic control of cellular processes through target phosphorylation. In 2010, Zhang et al. 
performed TRPM7-polypeptide interaction studies and defined certain regions to be critical for 
substrate binding and recognition via computational analysis [78]. However, TRPM7’s exact target 
phosphorylation motif remains unknown, making it difficult to predict potential TRPM7 kinase 
substrates. Thus, it’s not surprising that, to date, only a few proteins have been identified to be 
phosphorylated by TRPM7. Yet, these substrates and their downstream effectors give a hint how 
widespread TRPM7 kinase function supposedly is. So far, in vitro studies elucidated TRPM7 kinase-
dependent phosphorylation of the immunological relevant molecule annexin A1 (ANXA1), the 
myosin II A heavy chain (MIIA heavy chain) which is implicated in cell structure remodelling and the 
cell signalling triggering molecule PLCγ2 (PLCγ2) [79-82]. In context of another study, we were 
recently able to show that the kinase also directly phosphorylates the transcription factor Mothers 
against decapentaplegic homolog 2 (SMAD2) in vitro and in vivo [83]. An exception among the already 
known substrates is the nuclear protein histone H3, which is phosphorylated upon release and 
nuclear translocation of the TRPM7 kinase domain [84].  
ANXA1 (also referred to as lipocortin 1, 37 kDa) is a glucocorticoid-affected and -regulated protein 
predominantly present in immune cells and counteracting inflammation. Cell activation initiates 
ANXA1’s immediate translocation to the membrane and subsequent secretion [85-88]. In 
accordance, it is involved in granule fusion, exo- and phagocytosis, all processes which are able to 
resolve inflammation [85, 87, 89, 90]. By phosphorylating ANXA1 within its N-terminus at Ser5, 
TRPM7 directly affects its activation and therewith membrane translocation [91]. Conversely, 
structural interaction analysis showed that the negative charge of the phosphoryl group attached to 
Ser5 counteracts membrane binding by hindering the N-terminal tail to form an amphipathic α-helix 
[92]. Together these data suggest that, by phosphorylation at Ser5, TRPM7 participates in the tight 
regulation of ANXA1 membrane localization and interaction. Moreover, the TRPM7 kinase-
dependent Ser5 phosphorylation promotes ANXA1 nuclear translocation inducing apoptosis in 
neurons [93]. Therefore, TRPM7’s catalytic domain seems to control ANXA1 cellular transport in 
general.   
The motor protein myosin II is a hexamer comprising two heavy, two essential light and two 
regulatory chains, all together regulating cell events required for cytoskeletal contraction [94]. 
Processes such as adhesion, migration and cytokinesis as well as regulation of the cell shape in general 





TRPM7 [81, 95]. The TRPM7 kinase domain was shown to phosphorylate MIIA heavy chain 
phosphorylation at Ser1943 and thereby controls tumor migration in breast cancer cells [96]. 
PLCγ2 triggers the conversion of PIP2 into the second messengers diacylglycerol (DAG) and inositol-
1,4,5-trisphosphate (IP3). Thereby, the enzyme contributes to intracellular Ca
2+ increase and signaling 
events resulting in PKC- and thus immune cell activation (PLCγ2/Ca2+/PKC pathway) [97]. Under 
hypomagnesaemic conditions, TRPM7-directed PLCγ2 phosphorylation at the two target sites 
Ser1645 and Thr1045 supports B cell receptor (BCR) -mediated Ca2+ signaling in B cells [80]. 
Studying murine T cells, we discovered SMAD2 as a direct target of the TRPM7 kinase (results are 
published in Romagnani et al., 2017, and are not presented within this thesis) [83]. Mutagenesis-
caused TRPM7 kinase-inactivation in mice reduced the phosphorylation of SMAD2 at Ser465/467 
and thereby decreased transforming growth factor β (TGF-β) -dependent signaling important for T 
cell differentiation [83]. Subsequent in vitro analysis confirmed a direct interaction of TRPM7 and 
SMAD2.  
A whole new aspect regarding the function of TRPM7 was first brought up when Desai et al. 
discovered that TRPM7’s kinase is released by proteolytic cleavage [98]. The truncated C-terminal 
fragment comprising the kinase domain enters the nucleus where it phosphorylates multiple sides of 
histone H3 (Ser10, Ser28) in vitro [84]. The kinase-dependent histone modifications help to control 
chromatin remodelling, DNA repair and facilitate gene transcription [84]. Despite the preceding 
domain separation, the TRPM7 channel contributes to this process, as the nuclear accumulation of 
the kinase domain relies on Zn2+. In particular, increase in cytosolic Zn2+, which is partly conducted 
through TRPM7 the channel, facilitates binding of the kinase domain to zinc-finger containing 
transcription factors or chromatin remodeling complexes and thus promotes its nuclear transport [84] 
(also see 3.2.6 for more details).  
3.2.3 Pharmacological TRPM7 inhibition  
The TRPM7 channel can be inhibited by a broad spectrum of natural and synthetic molecules. Most 
frequently used is the non-specific blocker 2-aminoethyl diphenylborinate (2-APB, IC50=174 µM), 
although it simultaneously blocks numerous other channels and transporters such as IP3Rs, store-
operated Ca2+ channels (SOCCs), sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), TRP 
channels and potassium channels [99-110]. The compounds NS8593 and waixenicin A on the other 
hand are not only more specific for TRPM7, but also display lower IC50
 values (1.6 µM and 16 nM, 
respectively) [101]. NS8593, originally identified as a K+ channel inhibitor [111], reversibly suppresses 
channel activity in dependence of internal [Mg2+] and the kinase domain [112]. Likewise, waixenicin A 
works in synergy with intracellular Mg2+ and inhibits TRPM7 in a kinase-dependent manner; yet, its 





and FTY720 (IC50=0.7 µM), which display even higher binding affinities for TRPM7 than NS8593 
and waixenicin A [114]. A novelty amongst TRPM7 inhibitors was discovered in 2017, when Song et 
al. showed that the known phosphoinositide 3-kinase (PI3K) inhibitor TG100-115 blocks TRPM7 
kinase activity with an IC50 of 1.07 µM [115]. Yet, the same group also demonstrated the TRPM7 
channel activity to be suppressed by TG100-115 in a dose-dependent manner, which lowered the 
chance of the drug being a TRPM7 kinase-specific inhibitor. However, application of 20 µM TG100-
115 in our own measurements (Nadolni et al., in preparation) did not significantly affect channel 
activity, thus demonstrating that TG100-115 is more potent to block the kinase than the channel. 
Hence, the undesired side effect of TRPM7 channel inhibition by TG100-115 can be bypassed by 
reducing the concentration of the drug, and thus, we assume that TG100-115 is the first inhibitor 
discovered blocking TRPM7 kinase, but not channel activity. 
3.2.4 TRPM7 channel and kinase crosstalk  
The unusual conjunction of a channel and a kinase raises the question if those two domains affect 
one another. Most of the mechanisms regulating the channel (described in 3.2.1.2) occur through 
binding of the modulators to the intracellular C-terminus. Hence, one focus of interest is if the kinase 
domain respectively its activity is required for channel function. In vitro experiments revealed that 
HEK-293 cells overexpressing the TRPM7 kinase-lacking mutant TRPM7-ΔK (truncated at AA1569) 
develop WT-like currents, but are more sensitive to Mg2+- or Mg-ATP-caused block [36]. These 
findings are in line with results acquired for mast cells and ESCs derived from heterozygote TRPM7-
ΔK mice analyzed ex vivo, which likewise displayed reduced channel activity [35]. In contrast, Desai et 
al. showed that natural occurring Fas-induced cleavage of TRPM7 at the position D1510 by the 
caspases 8 and 3 yields in higher TRPM7 current amplitudes under normal physiologic conditions 
[98]. Taken together, these results indicate that the site of truncation of TRPM7 is crucial for channel 
properties [98]. 
The kinase inactivating point mutations, K1648R and G1799D, left TRPM7 currents unaltered, but 
reduced sensitivity to inhibition by cellular Mg2+ and Mg-ATP [36, 68]. Similar experiments with a 
corresponding murine construct, K1646R, did not show changes in sensitivity to Mg2+ and Mg-ATP 
[116]. In agreement, mice carrying the point mutation revealed normal current progression and 
regulation under physiological conditions ([Mg2+]cyt=100-900 µM) [83, 117, 118].  
The impact of the channel on the kinase domain is far less understood. One indication for the 
channel also controlling the kinase activity is the fact that the kinase requires divalent cations (such as 
Mg2+, Mn2+ and Zn2+) for its function [73, 84]. Indeed, pharmaceutical inhibition of the channel by 
the synthetic compound NS8593 significantly decreased TRPM7 autophosphorylation in HEK-293 





interactions, as binding of the cleaved kinase domain to zinc-finger containing transcription factors in 
the nucleus relies on Zn2+, which in turn is conducted trough the TRPM7 channel [84]. Overall, these 
findings strongly substantiate an interdependence of the TRPM7 channel and kinase domain.  
3.2.5 TRPM7’s physiological relevance in diseases  
Numerous studies emphasize the importance of TRPM7 for fundamental cellular functions such as 
survival, growth, proliferation, but also differentiation and migration in almost all cell types [120]. 
Thus, the channel-kinase has been shown to be associated with a lot of different pathologies, as 
malfunctioning of these processes often contributes to disease development and progression. Besides 
cancer, TRPM7 is involved in ischemic stroke, neurodegenerative and cardiovascular diseases [121].   
TRPM7’s involvement in cancer has manifested over the last decade. Being aberrantly overexpressed 
in many carcinoma subtypes, it promotes tumor progression and metastasis by regulating 
proliferation, survival, migration and invasion in malignant cells [120, 122-124]. Furthermore, 
polymorphisms of the protein have been discovered in colon, breast or ovarian cancer [125-127]. 
Interestingly, one of these somatic mutations of TRPM7, T1482I, was originally found in patients 
with the Guamanian form of amyotrophic lateral sclerosis (ALS-G) and Parkinsonism dementia (PD-
G) [128]. In the neuronal system, TRPM7’s role seems to be more complex and depends on the 
availability of oxygen. Although it is initially required for brain development in embryonic mice, it 
showed to be dispensable after day 10.5 [129]. Nevertheless, latter studies documented that it 
participates in and preserves synaptic signaling via release of neurotransmitters and fosters neuronal 
survival and growth under normal conditions [130-134]. Under pathological conditions, which are 
characterized by anoxia or hypoxia, respectively, TRPM7 operates towards the opposite direction. In 
an environment low in oxygen, for example following ischemic stroke, the channel-kinase promotes 
neuronal cell death and thus impairs cognitive function [135-137]. Furthermore, a recent study 
detected TRPM7’s kinase activity to promote ischemic disease by facilitating thrombocyte aggregation 
[138].   
TRPM7 was also found to regulate Mg2+ homeostasis, vessel size and other essential cell functions in 
vascular smooth muscle cells (VSMCs) and cardiac fibroblasts (CFs) [139-141]. Despite its 
indispensability for heart development and cardiac function, more and more indices accumulated 
linking TRPM7 to diseases regarding the cardiovascular system [142, 143]. In 2016, Antunes et al. 
brought evidence that TRPM7 is involved in hypertension through its kinase domain [144]. Another 
study revealed that interleukin 18 (IL-18) induced vascular calcification, a common predictor of 
coronary heart disease, necessitates the chanzyme [145]. Additionally, TRPM7 also contributes to 





In summary, the channel-kinase comprises large therapeutic potential for a spectrum of diseases, 
which could be treated through pharmacological modulation of specific TRPM7 functions (channel 
and/or kinase activity). To exclude side effects, it is necessary to investigate TRPM7’s operation 
mode and identify pathways activated downstream.   
3.2.6 TRPM7 in cell signaling 
With proceeding understanding of the TRPM7 channel and kinase functions and its implications in 
health and disease, more focus was put on the downstream effects of ion flux and substrate 
phosphorylation. Indeed, in terms of cell signaling, TRPM7 has been shown to function in Ca2+-
dependent as well as -independent signaling pathways (see Figure 3.4). Importantly, these TRPM7-
controlled signaling cascades not only coordinate general cellular functions but also contribute to 
proliferation and propagation of malignant cells which will be outlined below. 
The PI3K/protein kinase B (Akt) pathway is classically activated by ligand-induced cell surface 
receptors. Activated PI3K generates the second messenger phosphatidylinositol-3,4,5-trisphosphate 
(PIP3) by phosphorylating PIP2. PIP3 recruits pleckstrin homology (PH) domain-containing proteins 
to the membrane, such as phosphoinositide-dependent kinase-1 (PDK1) and Akt. In turn, Akt is 
activated by two phosphorylations occurring in the activation loop (Thr308 by PDK1) as well as in 
the C-terminal region (Ser473 by PDK2). Akt itself has several downstream phosphorylation targets, 
modulating many proteins involved in cell cycle progression, cell survival and proliferation [148]. 
These modulatory effects are either inhibitory [e.g. inhibition of glycogen synthase kinase 3 (GSK3) 
activity] or activating [initiating survival gene transcription by 3’,5’-cyclic adenosine monophosphate 
(cAMP) response element-binding protein (CREB) and other transcription factors] [148-150]. In 
2008, Sahni et al. published that TRPM7-deficient lymphocytes display impaired phosphorylation of 
PI3K and downstream kinases such as Akt and mechanistic target of rapamycin (mTOR) in a Mg2+-
dependent manner [151]. A TRPM7-dependent PI3K pathway regulation was later reconfirmed in 
osteoblasts, hepatic stellate cells (HSCs), chondrocytes and oncogenic cell types and in many cases 
facilitates disease progression [152-159]. In glioblastoma, prostate and bladder cancer cells, for 
example, TRPM7 induces tumor cell proliferation and migration by increasing Akt phosphorylation 
[155, 157]. The PI3K downstream kinase is also relevant for hepatic fibrosis triggered by TRPM7, but 
dispensable for TRPM7-dependent breast cancer migration [154, 160].  
Another TRPM7 affected signaling cascade is the mitogen-activated protein kinase/extracellular 
signal-regulated kinase (MAPK/ERK) pathway typically involved in proliferation and apoptosis [161, 
162]. Free Ca2+ entering the cell binds to and thereby activates CaM, and together they activate 
members of the Ca2+/CaM-dependent kinase family (CaMKs) [163-166]. This initiates a 





activation of the Ser/Thr kinase ERK1/2, which further phosphorylates members of the MAPK-
activated protein kinase (MAPKAPK) family (MNKs and RSKs) and is directly as well as indirectly 
involved in regulation of cell proliferation and cell cycle progression [149, 167, 168]. In breast cancer 
cells, TRPM7 promotes invasion via the (MAPK/ERK) pathway by phosphorylation of ERK1/2 
(alias MAPK3), c-Jun terminal kinase (JNK) and p38 [160]. A TRPM7-dependent control of the 
MAPK/ERK pathway has also been observed for other cancer cell types, VSMCs and astrocytes, but 
TRPM7’s impact on ERK phosphorylation seems to be ambiguous. While several groups detected a 
reduction in ERK phosphorylation upon TRPM7 deletion, other experiments displayed an increase 
[155, 169-172].  
Moreover, murine knockout studies suggested a role for TRPM7 in the phosphorylation of signal 
transducer and activator of transcription 3 (STAT3) [45]. This protein belongs to the Ca2+-inducible 
transcription factor family STAT [173, 174]. Typically activated by the Janus kinase (JAK), STAT 
proteins homo- respectively heterodimerize upon phosphorylation, translocate to the nucleus and 
eventually stimulate specific gene transcription. All seven family members have been shown to be 
important (in some cases even essential, STAT3) regulators of development, cell proliferation and - 
due to their cytokine responsiveness - immunity [175, 176]. Further analysis of TRPM7-dependent 
STAT3 phosphorylation in in vitro experiments showed that TRPM7 promotes tumorigenesis of 
different carcinoma subtypes by activation of JAK/STAT3 signaling [174, 177, 178]. Vice versa, 
TRPM7 inward current can be inhibited through the IL-6/JAK2/STAT3 pathway independently of 
Ca2+ or the kinase domain, as Liu et al. demonstrated [179]. A positive feedback loop on the other 
hand was observed for TGF-β-dependent TRPM7 regulation. Through binding to its receptor TGF-
β type II, TGF-β induces phosphorylation of the TGF-β type I receptor, thereby initiating 
subsequent phosphorylation of the receptor-regulated SMADs (R-SMADs) of which two of those are 
SMAD2 and 3 [180, 181]. Together with the collaborating SMAD4, SMAD2 and 3 translocate into 
the nucleus were they activate gene transcription [180, 181]. The TGF-β/SMAD signaling axis has 
been associated with processes such as cell proliferation and differentiation, cytoskeletal remodeling 
and – as being a cytokine – regulation of immune reactions [182, 183]. In HSCs, TGF-β elicits 
TRPM7 expression via the SMAD pathway, which in turn enhances SMAD2 and SMAD3 
phosphorylation [184]. Very recently, members of our group discovered that SMAD2 represents a 
direct target of the TRPM7 α-kinase in CD4+ T cells, where the channel-kinase aids TGF-β-mediated 
signaling (also see 3.2.2.2) [83].   
Next to its impact as an upstream activator of many signaling cascades in the cytosol, the channel-
kinase is also able to modify gene transcription by directly targeting proteins located in the nucleus. 
Happening in vitro and in vivo, the before mentioned cleavage of TRPM7 results in the separation of 





the kinase domain migrate into the nucleus were they bind to nuclear components [84]. 
Computational analysis revealed that this nuclear translocation could occur through a putative nuclear 
localization sequence within the C-terminus of TRPM7 (AAs 1780-1807). Nevertheless, Krapivinsky 
et al. hypothesized that nuclear transport of the kinase domain could also be facilitated by the 
interaction with nuclear proteins itself. Once in the nucleus, the kinase associates with numerous 
transcription factors respectively subunits of chromatin-remodeling complexes, such as Yin Yang 1 
(YY1), Ring1 and YY1 binding protein (RYBP) or enhancer of zeste homolog 2 (EZH2). Valid for 
those proteins containing a zinc-finger motif, binding of the kinase domain to these molecules is 
Zn2+-dependent; hence, the TRPM7 channel most likely aids these interactions through its Zn2+ 
conductance. Furthermore, kinase inactivation in some cases prevents or augments binding to the 
nuclear proteins, indicating that kinase activity defines its own selectivity regarding potential 
interaction partners. The active kinase also participates in histone phosphorylation. Overexpression 
experiments in TRPM7-deficient mouse ESCs (mESC) illustrate a TRPM7 kinase-dependent 
phosphorylation of histone H3 at Ser10, Ser28 and Thr3, and an in vitro kinase assay strongly suggest 
that both Ser10 and Ser28 are directly phosphorylated by the enzyme. Together with the TRPM7-
promoted histone H3 acetylation at Lys9 and Lys27, these modifications correlate with increased 
expression of genes important for early developmental processes and cell differentiation. Thus, both 
the TRPM7 channel and kinase are proposed to differentially contribute to gene expression essential 
for embryonic development for example [84]. More recently, the same group demonstrated that 
TRPM7’s close related family member, TRPM6, likewise is cleaved, modulates gene transcription and 





































Figure 3.4 TRPM7 in cell signaling. Both JAK/STAT and PI3K/Akt signal transduction followed by 
target gene expression have been shown to be facilitated by TRPM7. In addition, TRPM7 was 
demonstrated to affect the MAPK/ERK pathway by targeting the cells signaling kinases ERK1/2, JNK 
and p38; yet, its impact on ERK1/2 activation is still not clear and most likely is cell type specific. 
Besides, the TRPM7 kinase promotes TGF-β-induced signaling through SMAD2, 3 and 4 by directly 
phosphorylating SMAD2 at Thr465/467. Moreover, the TRPM7 kinase domain also regulates gene 
expression by directly targeting nuclear located proteins. Thus, the TRPM7 C-terminus enclosing the 
kinase unit is truncated and translocates into the nucleus where it interacts with different binding partners 
(BP) and facilitates histone H3 phosphorylation, thereby inducing specific gene transcription.  
α-K – alpha-kinase domain, Akt – protein kinase B (PKB), BP – binding partners, COOH – C-terminus, 
ERK – extracellular signal-regulated kinase, H3 – histone H3, JAK – Janus kinase, JNK – c-Jun terminal 
kinase, mTORC - mechanistic target of rapamycin complex, NH2 – N-terminus, PI3K – phosphoinositide 
3-kinase, SMAD – Mothers against decapentaplegic homolog, STAT – signal transducer and activator of 





3.3 The HAP1 cells  
In 1999, a subclone of the heterogeneous human chronic myelogenous leukemia (CML) cell line 
KBM-7 initiated the beginning of a new cell line [186, 187]. At this time, these cells presented 
haploidy for almost all chromosomes except for the chromosome 8 and, in some cases, 15 
(dependent on the subclone) and retained their karyotypes in cell culture for up to 12 weeks [187]. In 
general, haploid cells represent an exceptional tool for studying protein-specific effects by target 
modification and genetic screens, as they lack the second set of chromosomes which normally covers 
introduced mutations [188, 189].  
Thus, in the following years, researchers focused on elimination of the one respectively two 
remaining chromosome copies (8 and 15) existent in the above-mentioned KBM-7 subclone to 
generate a fully haploid cell line. First experiments lead to the extinction of the second copy of 
chromosome 8, and about five years later, application of the new futuristic technology CRISPR/Cas9 
[190, 191] finally resulted in full haploidy, wherefore the cells were named HAP (haploid) 1 [192, 
193]. Since then, it turns out that HAP1 cells present an extremely valuable cellular knockout system 
to study the molecular function of a respective target protein, which was also already applied for 






3.4 Aim of the work 
Different experimental approaches within the last two decades impressively document the 
fundamental role of TRPM7 for a vast variety of physiological processes including embryonic 
development, cell growth, proliferation and differentiation as well as adhesion and migration. In many 
cases, the impact of TRPM7 on these essential (cell) functions is mediated by regulation of various 
cell signaling pathways. However, with the exception of two papers [78, 79], all of the so far 
published work refers to the TRPM7 full-length protein, thus lacking differentiation between the 
action of the ion channel and the kinase domain.  
Yet, to get a better understanding of the TRPM7 channel-kinase, it is more than important to 
discriminate between TRPM7-mediated ion influx and its phosphotransferase activity.  
Given these aspects, overall aim of this work was to first confirm and expand the knowledge about 
TRPM7’s functional role in already identified signaling pathways in HAP1 cells and secondary to 
unravel the impact of the TRPM7 kinase domain on particular mediators of these signaling cascades. 
To accomplish this goal, I will utilize two different HAP1 cell lines mutated for TRPM7: One lacks 
TRPM7 full-length protein expression (abbreviated TRPM7 KO), whereas the other mutated variant 
carries a point mutation within the kinase domain that leads to the loss of phosphotransferase activity 
(abbreviated TRPM7 KI). This enables me to at first decipher the role of full-length TRPM7 for 
distinct cellular signal transduction as well as gene transcription processes and secondly to relate 
TRPM7-directed actions directly to TRPM7`s kinase activity.  
In particular, the following procedure is scheduled:  
With use of DNA-based genetic sequencing, I will first verify the correct insertion of the two 
mutations (TRPM7 KO, TRPM7 KI) in the HAP1 cell line. These experiments will be completed by 
whole-cell patch clamp measurements: By a systematic comparison of currents typically displayed by 
TRPM7, the results not only allow confirming a successful deletion of TRPM7 but additionally enable 
me to detect current alterations which can be attributed to an inactivated TRPM7 kinase domain. In 
respect to TRPM7’s function in ion homeostasis, impact of TRPM7 respectively its kinase activity on 
intracellular ion concentrations will be reviewed using inductively coupled plasma mass spectrometry 
(ICP-MS).   
In a next step, I plan to investigate the phosphorylation state of signaling molecules which already 
have been identified to be part of TRPM7-controlled cascades, such as Akt and GSK3β (PI3K/Akt 
pathway), ERK1/2 (MAPK/ERK pathway), STAT3 (JAK/STAT pathway) and SMAD2 (TGF-β 
/SMAD pathway). Phosphorylation of these target proteins will be determined using phospho-
specific antibodies in Western Blot analysis. In the event of indeed discovering a TRPM7- 





next want to check for potential alterations of downstream effectors such as transcription factors. 
Employment of a luciferase-based reporter gene assay will help to clarify domain-specific function of 
TRPM7 in transcriptional activity of potentially affected transcription factors. Furthermore, TRPM7 
respectively kinase activity-dependent regulation of gene expression will subsequently be examined 
with the sensitive real-time quantitative polymerase chain reaction (RT-qPCR) technique which allows 
the simultaneous analysis of multiple genes. By directly comparing the results obtained for the 
TRPM7 KO and the KI clone, respectively, this strategy makes it possible to precisely differentiate 
between TRPM7 full-length protein and kinase-directed actions on distinct signaling molecules.  
To finally verify results obtained by the genetic manipulations of TRPM7, I plan to selectively inhibit 
either TRPM7 or its kinase domain in primary cells. With the myeloid origin of the HAP1 cells in 
mind, I intend to utilize primary human neutrophils, which are developed from myeloid progenitor 
cells and can easily be isolated from blood samples. The results of such an experimental approach 
should permit the conclusion if identified target proteins of TRPM7 and/or its kinase domain in 

































such as CREB, mTOR, NFκB, NFAT, MAPKAPKs  
Target gene expression 
Deployed TRPM7 modified HAP1 cell lines 
HAP1 TRPM7 WT HAP1 TRPM7 KO HAP1 TRPM7 KI 
X X 
Figure 3.5  Scientific working strategy to study TRPM7 protein respectively TRPM7 kinase-
specific function in cell signaling.  
TRPM7 has been shown to modify various components of different cell signaling cascades such as the 
kinases Akt and ERK1/2 as well as the transcription factors STAT3 and SMAD2. However, whether the 
effect of TRPM7 is mediated by an ion flux through its channel pore and/or is catalyzed by a 
phosphorylation of target proteins by the fused kinase domain is currently not clear. To elucidate the 
exact role of the two TRPM7 domains in cell signaling, different HAP1 cell models modified for TRPM7 
will be utilized and compared to a HAP1 TRPM7 wild-type (WT) model (black). First is the HAP1 TRPM7 
knockout (KO) clone (red) lacking expression of the correct full-length protein, which enables one to 
study TRPM7-specific function(s) in general. Secondly, the HAP1 TRPM7 knock-in (KI) clone (blue), 
which carries a point mutation within the TRPM7 kinase domain inactivating its phosphotransferase 
activity, will be utilized to uncover the impact of the TRPM7 kinase unit.  
Initially, each HAP1 cell model will be employed to assess the domain-specific effect of TRPM7 on the 
phosphorylation of Akt and GSK3β, ERK1/2, STAT3 and SMAD2. If indeed discovering a TRPM7 or 
kinase activity-dependent phosphorylation of these proteins, I will next focus on potential alterations 
regarding downstream effectors of the affected signaling pathway(s), such as further downstream located 
kinases or transcription factors. Finally, attempts will be made to depict the effect of TRPM7 and/or its 
kinase activity on specific target gene expression.   
Akt – protein kinase B (PKB), COOH – C-terminus, CREB – cAMP response element-binding protein, 
ERK – extracellular signal-regulated kinase, GSK3β – glycogen synthase kinase 3 β, MAPKAPK – 
mitogen-activated protein kinase-activated protein kinase, mTOR – mechanistic target of rapamycin, 
NFAT – nuclear factor of activated T cells, NFκB – nuclear factor kappa-light-chain-enhancer of activated 
B cells, NH2 – N-terminus, SMAD – Mothers against decapentaplegic homolog, STAT – signal 






4 Material  
4.1 Devices and laboratory equipment 
Device Supplier 
Agarosegelelectrophoresis system model 40-1214 PeqLab, Erlangen (Germany) 
CCD AxioCam MRm camera  Zeiss, Jena (Germany) 
Chemiluminescence detection system         
Chemi-Smart™-5100 
Peqlab, Erlangen (Germany) 
 
Cell incubator New BrunswickTM Galaxy 170 S Eppendorf, Hamburg (Germany) 
Centrifuge 5424 R Eppendorf, Hamburg (Germany) 
Centrifuge 5804 R Eppendorf, Hamburg (Germany) 
Centrifuge HERAEUS Biofuge Stratos Thermo Fisher Scientific, Waltham (USA) 
Centrifuge HERAEUS Pico 17 Thermo Fisher Scientific, Waltham (USA) 
Cytostatic safety cabinet FlowSafe®  
C-[MAXPro]3-190 
Berner, Elmshorn (Germany) 
 
Easypet® 2 Eppendorf, Hamburg (Germany) 
Faraday cage HEKA, Lambrecht (Germany) 
FlexCycler2 PCR Thermal Cycler Analytik Jena, Jena (Germany) 
Flow cytometer Guava® easyCyte 5 Merck Millipore, Billerica (USA) 
Fluorescence Light Source Olympus, Hamburg (Germany) 
Fluorescence Micropscope Olympus IX70 Olympus, Hamburg (Germany) 
Fluostar Omega BMG Labtech, Ortenberg (Germany) 
Freezer -80°C Eppendorf, Hamburg (Germany) 
Heating block HX1 PeqLab, Erlangen (Germany) 
Hematocytometer (Neubauer chamber) Brand, Wertheim (Germany) 
Inverted microscope system IX71 Olympus, Hamburg (Germany) 
Inverted microscope Axio Vert.A1  Zeiss, Jena (Germany) 
LED light source for fluorescence Colibri 2 Zeiss, Jena (Germany) 
LightCycler® 480  Roche, Rotkreuz  (Austria) 
Light microscope Axiovert 35 M Zeiss, Jena (Germany) 
Magnetic stirrer C-MAG HS7  IKA, Staufen (Germany) 
Micromanipulator PatchStar ΨScientifica, Uckfield (UK) 
Micro scale  Sartorius, Göttingen (Germany) 






Monochromator Polychrom V Till Photonics, München (Germany) 
Monochrome camera X10 Olympus, Hamburg (Germany) 
Mini-Protean® Tetra Handcast Systems Bio-Rad, Hercules (USA) 
Mini Trans-Blot® Cell Bio-Rad, Hercules (USA) 
Osmometer VAPRO 5600 Wescor, Logan (USA) 
Patch clamp Amplifier EPC-10 HEKA, Lambrecht (Germany) 
pH meter FiveEasy Plus  Mettler Toledo, Columbus (USA) 
Platform shaker Duomax 1030 Heidolph, Kehlheim (Germany) 
PowerPacTM Basic Power Supply Bio-Rad, Hercules (USA) 
PowerPacTM HC High-Current Power Supply Bio-Rad, Hercules (USA) 
Puller DMZ-Universal Puller  Zeitz, Martinsried (Germany) 
Rocking shaker Duomax 1030 Heidolph Instruments, Schwabach (Germany) 
Spectrophotometer BioPhotometer plus UV- 
Visible  
Eppendorf, Hamburg (Germany) 
 
Thermomixer® Compact Eppendorf, Hamburg (Germany) 
Tube rotator 
 
Workshop of the Walther-Straub-Institut, LMU 
Munich, Munich (Germany) 
UV-gel documentation system Infinity 3026 Peqlab, Erlangen (Germany) 
Vibration isolation table TMC, Peabody (USA) 
Vortex mixer MS 3 basic IKA, Staufen (Germany) 
4.2 Consumables 
All consumables (sterile cell culture equipment, pipettes and pipette tips, reaction tubes etc.) were 
sourced from Sarstedt, Nürmbrecht if not stated otherwise. General glassware (glass bottles, 
Erlenmeyer flasks, beakers etc.) was purchased from Carl Roth, Karlsruhe.   
Item Product Number  Supplier 
Blotting Paper BP0035860 Hahnemühle, Dassel (Germany) 
Borosilicate glass with firepolished 
ends with filament  
GB150TF-8P 
 
Science products, Hofheim 
(Germany) 
Corning® cell strainers,   





Glass Coverslips,  
diameter of 12 mm 
P231.1 
 






Item Product Number  Supplier 
Glass Coverslips,  












Amersham Protran 0.45 µM  
10600002 
 






Pechiney Plastic Packaging, Chicago 
(USA) 
Pasteur pipettes  4522 Carl Roth, Karlsruhe (Germany) 
4.3 Chemicals and reagents  
Substance Product Number Supplier 
4-(2-hydroxyethyl)piperazine-1-












Acetic acid 3738 Carl Roth, Karlsruhe (Germany) 
Agarose 3810 Carl Roth, Karlsruhe (Germany) 





Carl Roth, Karlsruhe (Germany) 
 










Carl Roth, Karlsruhe (Germany) 
 






cOmpleteTM, Mini, EDTA-free 































Dithiothreitol (DTT) 6908 Carl Roth, Karlsruhe (Germany) 
Deoxynucleostide triphosphate 
(dNTP) mix (10 mM) 
R0192 
 
Thermo Fisher Scientific, 
Waltham (USA) 







Ethylene glycol-bis  (β-
aminoethyl ether)- N,N,N’,N’-








alkaline phosphatase (1 U/µl) 
EF0654 
 
Thermo Fisher Scientific, 
Waltham (USA) 






Glycine  0079 Carl Roth, Karlsruhe (Germany) 




EMD Millipore Coop., Billerica 
(USA) 
LightCycler® 480 SYBR  
Green I Master 
04707516001 
 






























































PolymorphPrepTM 1114683 Progen, Heidelberg (Germany) 
Poly-D-lysine (PDL) 











Potassium chloride (KCl) HN02 Carl Roth, Karlsruhe (Germany) 




Carl Roth, Karlsruhe  
(Germany) 
Oligo(dT)12-18 Costum order Metabion, Planegg (Germany) 
Sodium chloride (NaCl) HN00 Carl Roth, Karlsruhe (Germany) 
Sodium dodecylsulfate (SDS) 0183 Carl Roth, Karlsruhe (Germany) 
SpectraTM Multicolor Broad 
Range Protein Ladder 
26634 
 




















Roti® GelStain 3865 Carl Roth, Karlsruhe (Germany) 





























Trichlorol® 43546 Lysoform, Berlin (Germany) 
Tris 4855 Carl Roth, Karlsruhe (Germany) 





Thermo Fisher Scientific, 
Waltham (USA) 










Thermo Fisher Scientific, 
Waltham (USA) 










Thermo Fisher Scientific, 
Waltham (USA) 
4.4 Cell culture media and supplements 
Substance Product Number Supplier 




Thermo Fisher Scientific, Waltham 
(USA) 
Dulbecco’s modified eagle medium 
(DMEM), no phenol red 
21063029 
 
Thermo Fisher Scientific, Waltham 
(USA) 










Thermo Fisher Scientific, Waltham 
(USA) 





























4.5 Kits and assays  
Kits Product Number Supplier 




Abcam, Cambridge (UK) 
 
MyTaqTM Extract-PCR Kit 21126 Bioline Reagents, London (UK) 
MyTaqTM HS Red Mix 25047 Bioline Reagents, London (UK) 




Thermo Fisher Scientific, Waltham 
(USA) 
Nuclear Extract Kit 40010 Active motif, Carlsbad (USA) 
4.6 Inhibitors and activators 
Name  Activator of Product Number Supplier 
Forskolin 
 







Name Inhibitor of Product Number Supplier 




PI3K-δ S7937 Selleckchem, Munich 
(Germany) 
NS8593 TRPM7 and KCa2 channels N-196 Alomone Labs, 
Jerusalem (Israel) 






4.7 cDNA expression constructs  
Plasmid  Product Number Supplier 




Thermo Fisher Scientific, Waltham 
(USA) 




Thermo Fisher Scientific, Waltham 
(USA) 
NFAT reporter gene pGL4.30 
[luc2P/NFAT-RE/Hygro] Vector  
E8481 
 
Promega, Mannheim (Germany) 
 




Promega, Mannheim (Germany) 
 
 







Institute, LMU Munich [196] 
TRPM7 WT          
pIRES-eGFP 
 
WT mouse TRPM7 
protein 
Dr. Chubanov, Walther-Straub-





kinase-dead variant of 
mouse TRPM7 
Dr. Chubanov, Walther-Straub-
Institute, LMU Munich [197] 
4.8 Solutions 
4.8.1 Buffers for electrophysiology and Fura-2 AM based Ca2+ 
imaging 
Buffer/Solution Components 






140 mM NaCl 
2.8 mM KCl 
10 mM HEPES-KOH 
0.2 % (w/v) Glucose 
3 mM CaCl2 
(pH 7.20, ~285 mM mOsm/kg) 
Internal solution for patch clamp 
measurements 
 
140 mM Cs-glutamate (pH 7.2) 
8 mM NaCl 









5 mM EDTA 
10 mM EGTA 
(pH 7.20, ~300 mM mOsm/kg 







140 mM NaCl 
2.8 mM KCl 
10 mM HEPES-KOH 
0.2 % (w/v) Glucose 
2 mM CaCl2 
1 mM MgCl2 
(pH 7.20, ~285 mM mOsm/kg) 










140 mM NaCl 
2.8 mM KCl 
10 mM HEPES-KOH 
0.2 % (w/v) Glucose 
2 mM CaCl2 
1 mM MgCl2 
0.02 % Pluronic® F-127 
0.1 % BSA 
2 µM Fura-2 AM 
(pH 7.20, ~285 mM mOsm/kg) 





40 mM Tris 
20 mM acetic acid 
1 mM EDTA  
4.8.3 Buffers for protein analysis (via SDS-PAGE and Western Blot) 
Buffer/solution Components 
4 x Laemmli buffer (SDS-sample buffer) 
 
 
62.5 mM Tris/HCl 
20 % (v/v) Glycerol 






 4 % (w/v) SDS 
0.1 % (w/v) Bromophenol blue 
SDS separation gel  8 % respectively 10 % acrylamide/bisacrylamide 
375 mM Tris/HCl (pH 8.8) 
0.1 % SDS 
0.1 % APS  
0.1 % TEMED 
SDS stacking gel 3% acrylamide/bisacrylamide 
125 mM Tris/HCl (pH 6.8) 
0.1 % SDS 
0.1 % APS 
0.1 % TEMED 
SDS running buffer 
 
 
192 mM Glycine 
25 mM Tris/HCl 
1 % (w/v) SDS 
Transfer buffer 
 
25 mM Tris/HCl 
192 mM Glycine 
Ponceau S Solution 
 
0.1 % Ponceau S (v/v) 




50 mM Tris/HCl 
150 mM NaCl 
0.1 % (v/v) Tween-20 




100 mM Tris/HCl 
1% (v/v) Luminol 
0.44 (v/v) p-Coumaric acid 
pH 8,5 
ECL solution 2 
 
 
100 mM Tris/HCl 














25 mM Tris/HCl (pH 8,5) 
4 mM EGTA 
8 mM MgCl2 
1 mM DTT 
1 % (v/v) Triton X 
pH 7,4 
4.9 Antibodies 
4.9.1 Primary antibodies 


























































































































Institute, LMU Munich  
4.9.2 Secondary antibodies  





























BioRad, Hercules (USA) 
 
4.10 Primers 
4.10.1 Sequencing primers 
The genomic human TRPM7 primers were designed according to the primers published by 
Chubanov et al. [195]. Primers for the human TRPM7 cDNA were designed using the software 
Primer-Blast by the National Center for Biotechnology Information (NCBI).   





(+) 5’ – TAT TTG TAT GCA CCT TTG TA – 3’ 





(+) 5’ – TCA CTT CTC CAT TTA AGC CAG C – 3’ 
(−) 5’ – ACT GTC CTG CTG AAT GGC AA – 3’ 
4.10.2  RT-qPCR primers 
All primers listed below were designed with the Universal ProbeLibrary from Roche (Rotkreuz, 
Germany) using the corresponding PubMed entry. In some cases, the resulting primers were found to 












(+) 5’ – AAG CTT GCT GGT GAA AAG GA – 3’ [198] 






(+) 5’ – TGT ATG TAT GAG TGT GGG ATT TGA C – 3’ 






(+) 5’ – GTC ACA AAC AGT GCA CCT AC – 3’ [200] 






(+) 5’ – AAT GAA AAG GCC CCC AAG GTA GTT ATC C – 3’ 
[201] 






(+) 5’ – TAT TTT GCA CAG GTG CAG ATG TCC – 3’ 
(−) 5’ – CAG AGT CTC ACC TAT GCT GTT CG – 3’ 
4.11 Cell lines 









Lacks TRPM7 protein 
expression 





Carries a TRPM7 kinase 
inactivating point mutation  
(K1648R) 
Generated by HorizonGenomics via 
CRISPR/Cas9 technology 
 
HEK-293 WT wild-type  Dr. Breit, Walther-Straub-Institute, LMU Munich 
HEK-NFAT 
 
Stable expression of an 
NFAT luciferase reporter  
Generated from the HEK-293 WT cell line as part 
of this project 
HEK-G5α 
 
Expresses the Ca2+ sensor 
apoaequorin fused to GFP  
Dr. Breit, Walther-Straub-Institute, LMU Munich 
[196, 202] 
4.12 Software  











Software  Version  Supplier 





GraphPad Software, Inc., San 
Diego (USA) 
Igor Pro 6.2.2.2 Wavemetrics, Portland (USA) 







LightCycler® Software  Version 1.5.0.39 Roche, Rotkreuz (Austria) 












PatchMaster 2x69 HEKA, Lambrecht (Germany) 














5 Methods  
5.1 Cell lines and primary cells 
5.1.1 HAP1 cells 
As described in the introduction (see 3.3), the HAP1 cell line originates from the CML cell line KBM-
7 which was genetically modified via the CRISPR/Cas9 technology to become fully haploid [186, 187, 
192, 193]. Due to their haploidy, HAP1 cells present a convenient tool to study protein-specific 
functions as they lack the second set of chromosomes which usually masks particular effects caused 
by genetic deletion, inactivation or mutation of the respective target (for more details, see 3.3).  
5.1.1.1 HAP1 TRPM7 models 
To study TRPM7 function, two different HAP1 TRPM7 cell models were applied: The HAP1 
TRPM7 knockout (TRPM7 KO) model lacking the full.-length protein and thus presenting a suitable 
tool to study the function of the entire dual-function protein TRPM7 and the kinase-dead HAP1 
TRPM7 K1648R clone (TRPM7 KI) carrying an inactivated kinase domain and therefore allowing 
precise distinction of specific TRPM7 kinase-related functions. Both clones were manufactured by 
HorizonGenomis, Vienna, Austria using the CRISPR/Cas9 technology [190, 191]. The knockout of 
TRPM7 was generated by depletion of 17 nucleotides within exon 4 of the TRPM7 gene which leads 
to a frame shift that causes ablation of TRPM7 function (also see 6.1.1) [194, 195]. The kinase 
inactivating point mutation on the other hand was inserted by replacing three nucleotides within the 
TRPM7 gene (AAA to CGG) changing the genetic code for the AA position 1648 from lysine (K) to 
arginine (R) (K1648R) (also see 6.2.1). For the experiments, each of these two cell lines was 
compared to their corresponding parental clone, which is - for facilitation of data interpretation - not 
to be further distinguished and simply named HAP1 TRPM7 WT.  
5.1.2 HEK-293 cells   
The human embryonic kidney cell line 293 (HEK-293), first introduced 1977, is still one of the most 
common cell lines used nowadays. Back then, the post-doctoral researcher Frank Graham 
successfully transformed human embryonic kidney cells with the human adenovirus type 5 - 
supposedly in his 293rd experiment explaining the name HEK-293 [203]. Despite the initial origin and 
the comprehensive view, a more recent large-scale genetic analysis and comparison to five other cell 
types revealed that the ‘kidney’ cells rather show analogies to adrenal than to kidney cells [204]. 
Nevertheless, they resemble a nice tool for a broad spectrum of functional studies, as they proliferate 






5.1.2.1 HEK-293 NFAT reporter (HEK-NFAT) cell line 
For investigations regarding TRPM7’s impact on NFAT transcriptional activity, the HEK-293 cells 
were used to create clones stably expressing an NFAT-luciferase reporter (named HEK-NFAT). For 
the exact generation protocol, see chapter 5.10.1 
5.1.2.2 Aequorin HEK-293 (HEK-G5α) cell line 
To examine Ca2+ concentrations in HEK-293 cells, HEK cells having the vector G5α inserted were 
used [196, 202]. By stably expressing the biological Ca2+ sensor apoaequorin N-teminally fused to the 
green fluorescent protein (GFP), these cells represent a suitable system to measure internal Ca2+ levels 
with a high accuracy and independently of fluorescent markers or additional excitation. For more 
detail, also see 6.1.6.       
5.1.3 Primary human neutrophils 
Neutrophils are a type of immune cells that originates from multipotential hematopoietic stem cells. 
These hematopoietic stem cells develop into myeloid progenitor cells that represent the direct 
precursors of neutrophils [205]. Thus, human neutrophils and HAP1 cells share the same myeloid 
background, which increases the chance of the acquired results being transferable from one cell type 
to another. Accordingly, freshly isolated primary neutrophils of human origin were applied to test if 
pharmacological inhibition of TRPM7 respectively its kinase activity affects COX-2 gene expression.  
5.2 Cell culture  
5.2.1 HAP1 cells 
5.2.1.1 Maintenance and splitting 
HAP TRPM7 WT and KI cells were cultivated in IMDM supplemented with 10 % FBS (‘HAP WT 
medium’), while the medium for the TRPM7 KO cells additionally contained 10 mM MgCl2 for 
proliferation (otherwise the cells tend to go into growth arrest due to magnesium deficiency) [195]. 
All reagents used for splitting were prewarmed to 25°C. At a confluence of ~70-80 %, cells were 
washed once with 5 ml DPBS, incubated with 0.5 ml trypsin-EDTA solution for 3-5 min at 37°C and 
subsequently the reaction was stopped with 5.5 ml medium. Dependent on the next time of usage, an 
appropriate fraction (between a 1:10-1:30 ratio) of the cell suspension was then transferred into a new 
flask already filled with medium for further cultivation and incubated in the cell incubator at 37°C, 5 






For experiments, cells were washed, treated with trypsin-EDTA solution and then the reaction was 
stopped equivalent to splitting (see 5.2.1.1). Then, 10 µl of the cell suspension was diluted with 10 µl 
trypan blue (1:1 ratio) and subsequently, cell number was manually counted using a Neubauer 
chamber [206]. The cell number per ml was calculated with the following equation: 
 
𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑐𝑒𝑙𝑙 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 !"##$
!"
= !"#$%& !" !"##$ ∗ !"#$%"&' !"#$%& 
!"#$%& !" !!!"#$% !"#$%& !"





Dependent on the experiments, the required cell number was then transferred into therefore suitable 
well plates or dishes already prepared with the corresponding medium. Note that for all experiments 
except the characterization of the HAP1 cell clones, the medium of the HAP KO cells was changed 
to IMDM + 10 % FBS without additional magnesium in the afternoon of the day prior to the 
experiment. All cells were incubated overnight at 37°C, 5 % CO2.  
5.2.1.3 Starvation  
To starve the cells (e.g. for Western Blot analysis), cells were incubated with IMDM without FBS 3 h 
prior to the experiment. This step was introduced as FBS contains a plethora of growth factors and 
other proteins which can affect signaling molecules and thus distort the respective experimental 
results [207].  
5.2.1.4 Stimulation of the HAP1 cell with forskolin  
For stimulation with the adenylyl cyclcase activator forskolin, medium of the cells was changed to 
fresh IMDM + 10 % FBS and cells were subsequently treated with 50 µM forskolin for 1 h at 37°C, 5 
% CO2. Reactions were stopped by placing the cells on ice and washing the cells with cold DPBS.   
5.2.2 HEK-293 cell lines  
5.2.2.1 Maintenance and splitting 
All HEK-293 cell lineages were cultured in high glucose DMEM supplemented with 10 % FBS and    
1 % Penicillin-Streptomycin solution. All reagents used for splitting were prewarmed to 25°C. At a 
confluence of ~80-90 %, cells were carefully washed once with 5 ml DPBS and detached by 
incubation at 37°C for 3-5 min with another 0.5 ml of DPBS. The reaction was stopped with 5.5 ml 
medium, and, dependent on the next time of usage, an appropriate fraction (between a 1:10-1:30 
ratio) of the cell suspension was then transferred into a new flask already filled with medium for 






For experiments, cells were washed, detached and the reaction was stopped equivalent to splitting 
(see 5.2.2.1). Then, 10 µl of the cell suspension was diluted with 10 µl trypan blue and manually 
counted using a Neubauer chamber. The cell number per ml was calculated with the following 
equation: 
𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑐𝑒𝑙𝑙 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 !"##$
!"
= !"#$%& !" !"##$ ∗ !"#$%"&' !"#$%& 
!"#$%& !" !!!"#$% !"#$%& !"





Dependent on the experiments, the required cell number was then transferred into therefore suitable 
well plates or dishes already prepared with fresh medium.  
5.2.2.3 Starvation 
To starve the cells for dual-luciferase reporter gene assay, cells were incubated with DMEM without 
supplements 4 h prior to the experiment. Also here this step was introduced as FBS contains a 
plethora of growth factors and other proteins which can affect the investigated NFAT-dependent 
gene expression and thus distort the experimental results [207].  
5.2.3 Primary human neutrophils 
5.2.3.1 Isolation and separation 
The neutrophils were isolated from fresh human blood samples (50-100 ml). The blood was carefully 
layered over the room temperature (RT)-warm density gradient media PolymorphPrepTM (1:1 ratio) in 
50 ml reaction tube and centrifuged at 600 rcf for 35 min. After carefully removing the two topmost 
layers (blood plasma and mononuclear cells), the intermediate layer containing the 
polymorphonuclear leucocytes (PMNs) was harvested and transferred into a new 50 ml reaction tube. 
PMNs, also called granulocytes, include three immune cell types: Neutrophils, basophils and 
eosinophils. However, the amount of basophils and eosinophils is comparably low in contrast to 
neutrophils [208, 209], wherefore the abbreviation ‘PMN’ often exclusively stands for 
polymorphonuclear neutrophils [210]. Hence, as it is commonly accepted [210], the obtained fraction 
can be referred to as human neutrophils. Further following up the protocol, the neutrophils were 
washed once with 40 ml DPBS, centrifuged at 300 rcf for 10 min and, after removing the 
supernatant, resuspended in 10 ml HBSS buffer and counted with the Guava® easyCyte Flow 
Cytometer (Merck Millipore, USA) following the manufacturer’s instructions. According to the 





5.2.3.2 Treatment of the neutrophils with TRPM7- and PI3K-inhibitors followed 
by LPS stimulation for RT-qPCR  
To investigate the effect of TRPM7 inhibition respectively the inhibition of its kinase activity on 
COX-2 gene expression in the neutrophils, the immune cells were first incubated with either NS8593 
(30 µM), TG100-115 (20 µM) or – due to the side effects of TG100-115 on different PI3K isoforms 
[211, 212] – a combination of the PI3K inhibitors IPI-549 (160 nm) and GSK2292767 (100 nM) for 
30 min at 37°C. In addition, two additional samples serving as controls were left untreated (ø) 
respectively exposed to 0.1 % DMSO (concentration matching the highest DMSO concentration 
used to dilute the applied drugs). Subsequent to incubation with the inhibitors, COX-2 gene 
expression was induced by addition of 10 ng/ml LPS to each sample [213]. According to Cadieux et 
al., LPS significantly increases COX-2 mRNA production as early as one hour after drug 
administration [214]. After two hours of incubation at 37° and 5 % CO2, the cells were pelleted by 
centrifugation at 300 rcf for 5 min, the supernatant was removed and cells were further processed for 
RT-qPCR experiments. 
5.3 Genotyping of the HAP1 cell clones 
To validate the genetic mutations of the HAP1 TRPM7 KO and KI cell clones, the respective 
modified DNA-sequence was analyzed and compared to the individual parental clones (HAP1 
TRPM7 WT). For HAP1 TRPM7 WT and KO, DNA was extracted and amplified using the 
MyTaqTM HS Red Mix (Bioline, UK) according to the manufacturer’s instructions. Alternatively, 
HAP1 TRPM7 WT and KI RNA was extracted, translated into cDNA (for detailed description, see 
5.7.1  respectively 5.7.2) and then amplified with the MyTaqTM HS Red Mix (Bioline, UK) according 
to the manufacturer’s instructions. The approaches for the two clones differed as the primer pairs for 
sequencing were once designed for the genomic sequence (TRPM7 KO cells) and once designed for 
the spliced mRNA (TRPM7 KI cells). The amplified products were separated by gel electrophoresis 
using 1 % agarose gels (150 ml TAE-buffer, 1.5 g agarose, 20 µl Roti® GelStain), visualized via the 
gel documentation software Infinity-Capt (Vilber, Germany) and extracted using the GeneJet Gel 
Extraction Kit (Thermo Fisher Scientific, USA) according to the manufacturer’s instructions. The 
purified samples were sequenced by Eurofins Genomics, Munich, Germany.      
5.4 Electrophysiology 
To assess TRPM7 currents in the HAP1 cell clones, the whole-cell patch clamp technique was 
applied [34, 83]. Therefore, cells were trypsinized and seeded onto PDL-coated glass coverslips (12 





the coverslip, as the positively charged homopolymer and the negatively charged cell membrane(s) 
form an ionic bond [215]. After incubating the samples at 37°C and 5 % CO2, the coverslips were 
transferred into culture dishes (35 mm) and covered with external solution. All measurements were 
recorded with the EPC10 patch-clamp amplifier controlled by the PatchMaster software (HEKA, 
Germany). Cells were patched with borosilicate glass pipettes, which were pulled to an opening size 
of 2-3 MΩ resistance with a pipette puller (Zeitz, Germany) and filled with the corresponding internal 
solution. Because of the different ionic components of the solutions applied, the voltage was 
corrected by a liquid potential of +10 mV prior to the measurements [216]. TRPM7 currents were 
elicited by a voltage ramp ranging from -100 to +100 mV run within 50 milliseconds (ms), measured 
with a frequency of 0.5 Hz and a holding potential of 0 mV. Both the capacitance currents and the 
series resistance were determined and corrected before each ramp via the automated capacitance 
compensation of the software. For illustrations, data were further processed and analyzed via the 
FitMaster (HEKA Lambrecht, Germany) and Igor Pro software (Wavemetrics, USA). TRPM7 inward 
and outward current amplitudes at -80 mV respectively +80 mV were extracted, normalized to the 
individually measured capacitances (current density, pA/pF) and plotted vs. the time (s). Furthermore, 
representing traces were extracted at 150 s and plotted as current-voltage relationships (I/V-curve). 
5.5 ICP-MS 
To determine the internal Mg2+, Ca2+, Zn2+ and Cu2+ concentrations in the HAP1 TRPM7 cell clones, 
element concentrations were analyzed via ICP-MS. Therefore, cells were cultivated overnight to a 
confluence of ~80 %. The next day, cells were washed once with DPBS, scraped off from the dish 
with 11 ml fresh DPBS and cell suspension was transferred into 50 ml reaction tubes. After 
centrifuging at 1.500 rpm for 5 min, the supernatant was discarded and cells were resuspended in 1.5 
ml fresh DPBS and transferred into 2 ml reaction tubes. The centrifugation step was repeated, and 
after removing the supernatant, the cells were incubated at 70°C overnight to dry the cell pellet. On 
the next day, the dried cell pellets were weighed and subsequently sent of to ALS Scandinavia, Luleå, 
Sweden on dry ice for analysis. 
5.6 Ca2+ imaging  
Internal Ca2+ concentrations in the HAP1 TRPM7 cell clones were additionally analyzed using the 
Fura-2 AM based Ca2+ imaging technique [217]. Therefore, the cells were seeded onto PDL-coated 
glass coverslips (24 mm) 2 h prior to the experiment. Subsequently, cells were stained with the Fura-2 
AM containing staining solution for 30 min in the dark. The incubation was stopped by washing the 





a Ca2+ imaging chamber, washed another time with the 2 mM CaCl2 external solution and eventually 
covered with the same solution for the measurement. Initially, cells were visualized and encircled as 
regions of interest (ROIs) at an excitation wavelength of 360 nm. To assess the cytosolic Ca2+ 
concentration, cells were alternatingly excited at 340 nm respectively 380 nm (exposure time of 10 
ms) and emission was measured at 510 nm for 2 min using the software TillVision (TillPhotonics, 
Germany) [217]. Potential background signals were acquired by simultaneously measuring the 
emission of a small, cell-free region, and were subsequently subtracted of the actual values for 
correction. The basal Ca2+ concentration was determined by calculating the mean of 15 consecutive 
measurements of each cell.  
5.7 Molecular biological methods 
5.7.1 RNA Isolation 
Treated or untreated cells were washed twice with DPBS and lysed by resuspension in 1 ml trizol 
followed by a 5 min incubation at RT [218, 219]. Then, 200 µl chloroform was added to each sample, 
the tube was shaken for 15 s and incubated for another 3 min at RT. For separation of the aqueous 
and the organic phase, samples were centrifuged at 12 000 rpm for 15 min at 4°C and the RNA-
containing aqueous phase was subsequently transferred into a new 2 ml reaction tube. By addition of 
500 µl Isopropanol to each sample and incubating the solution for 10 min at RT, RNA was 
precipitated. Another centrifugation at 12 000 rpm for 10 min at 4°C served to pellet the RNA, which 
was subsequently washed with 1 ml 75 % ethanol and centrifuged again at 7 500 rpm for 5 min at 
4°C. After removal of the supernatant, the pellet was air-dried at RT, dissolved in 10-20 µl DEPC-
treated H2O (dependent on pellet size) and heated to 55°C for 10 min. Concentrations and purity 
were determined by measurement of the absorbance at 260 nm respectively 280 nm and calculating 
the 260/280 nm ratio using a spectrophotometer [220] and, corresponding to the individual 
concentrations, samples were aliquoted and stored at -80°C until usage.   
5.7.2 cDNA synthesis 
For further analysis via normal or quantitative PCR, RNA was converted into cDNA via reverse 
transcription. Therefore, 2-5 µg of RNA were mixed with 0.5 µg Oligo(dT)12-18 and 0.5 mM dNTPs, 
filled up to 12 µl with DEPC-treated H2O and incubated for 5 min at 65°C. Samples were chilled on 
ice for a few seconds, shortly centrifuged and mixed with 1x first strand buffer (provided with the 
Superscript II Reverse Transcriptase) and 5 mM DTT. After incubation for 2 min at 42°C, the 





at 42°C. Subsequently, the reaction mix was inactivated by heating to 70°C for 15 min. Samples were 
either stored at -20°C or directly used.  
5.7.3 PCR  
To test primers designed for RT-qPCR, the corresponding primer pairs for the gene to be tested 
(forward and reverse primer, end concentration of 0.4 µM each) were mixed together with the 2 x 
MyTaqTM  Mix (Bioline, UK) and diluted with DEPC-treated H2O (see Table 5.1 for example): 
Table 5.1 Mastermix composition for conventional PCR using the RT-qPCR primers 
 
 
Then, 1 µl (0.5-2 µg) of cDNA template was added and the following PCR protocol was applied for 
amplification (Table 5.2): 
Table 5.2 PCR program for validation of the RT-qPCR primers  
PCR program 
Process Temperature [°C] Time   




94 30 s 
30 cycles  62 30 s 
 72 30 s 
Final elongation 72 10 min  
Cooling  8 ∞	 	
 
5.7.3.1 Analysis of amplified products via agarose gel electrophoresis  
The amplified products were either stored at -20°C or directly loaded onto a 3 % agarose gel (150 ml 
TAE buffer, 4.5 g agarose) containing 20 µl of the gel stain Roti®Safe. The gel was run at 110 V for 
30-40 min and bands detected via the gel documentation software Infinity-Capt (Vilber, Germany).  
Mastermix  
Substance Concentration Volume [µl] 
Forward primer 10 µM 1 
Reverse primer 10 µM 1 
MyTaqTM Mix 2x 12.5 
DEPC-treated H2O  9,5 






To compare cells regarding their mRNA expression of target genes, RT-qPCR was performed [221]. 
Therefore, a mastermix containing 0.5 µM of both forward and reverse primer of the gene to be 
analyzed and the 2 x LightCycler® 480 SYBR Green I Master Mix (Roche, Austria) diluted with 
DEPC-treated H2O was prepared and transferred into a 96-well plate. For reference, an additional 
mastermix was prepared with primers for the housekeeping gene Hypoxanthine-guanine 
phosphoribosyltransferase 1 (HPRT1). The cDNA templates were prediluted with DEPC-treated 
H2O to a concentration of ~ 250 ng and added to the corresponding wells. RT-qPCR was performed 
with the LightCycler® 480 (Roche, Austria) according to the following program (Table 5.3):  
Table 5.3 RT-qPCR program for analysis of the respective target genes in HAP1 cells and neutrophils  
RT-qPCR program 
Process Temperature [°C] Time   
Preincubation 
 
50 2 min  




95 15 s 
40 cycles  62 30 sec 
 72 30 sec 
Melting curve acquisition  
 
95 10 min  
60 1 min  
Cooling 40 10 min  
 
Data was acquired using the LightCycler® 480 Software (Roche, Austria).  
5.8 Protein analytics 
5.8.1 Preparation of whole-cell lysates  
Treated or untreated HAP1 cells were placed on ice and washed once with cold DPBS. Cells were 
then lysed in RIPA buffer (Sigma Aldrich, Germany) containing phosphatase and protease inhibitors 
and incubated for at least 5 min on ice. Cell lysis was completed by rotation for 30 min at 4°C, and 
remaining cell debris was removed by centrifugation for 5 min with 12 500 rpm at 4°C. The 
supernatant representing the whole-cell lysate was transferred into a new reaction tube and either 





5.8.1.1 Phosphatase treatment  
To validate phospho-specificity of the self-made TRPM7 pSer1511 antibody (kindly provided by Dr. 
Chubanov, Walther-Straub-Institute, LMU Munich) used for characterization of the HAP1 TRPM7 
KI clone (see 6.2.1), HAP1 whole-cell lysates were treated with the FastAP Thermosensitive alkaline 
phosphatase (Thermo Fisher Scientific, USA) prior to Western Blot analysis. Thus, the corresponding 
samples were first diluted with the respective amount of 10 x FastAP buffer, mixed together with 10 
U (~10 µl) of FastAP phosphatase and subsequently incubated for 1 h at 37°C. The reaction was 
stopped by directly placing the mixtures on ice and diluting them with 4 x Laemmli buffer. The 
samples were either directly applied to the SDS-PAGE or stored at -20 °C until usage.  
5.8.2 Nuclear extraction 
In order to separate the nucleus from the cytosol, the ‘Nuclear Extract Kit’ (Active Motif, USA) was 
utilized. Before beginning the experiment, all reagents were prepared according to manufacturer’s 
instructions. Treated or untreated cells were placed on ice, washed once with DPBS/Phosphatase 
Inhibitors solution and incubated with Hypotonic Buffer for 15 min on ice. Then, the ‘Detergent’ 
(provided with kit) was added and cells were vortexed at high speed for 10 s. Samples were 
transferred into 1.5 ml reaction tubes and centrifuged at 14 000 rcf for 30 s. The supernatants 
(cytoplasmic fraction) were transferred into new 1.5 ml reaction tubes and placed on ice. Meanwhile, 
pellets were resuspended in Complete Lysis Buffer, vortexed at high speed for 10 s and shaken for 30 
min at 4°C. After another centrifugation at 14 000 rcf for 10 min at 4°C, the supernatant (nuclear 
fraction) was transferred into a new reaction tube; finally, all fractions were stored at -80°C until 
usage.  
5.8.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
To analyze cells regarding their proteome (e.g. protein levels, phosphorylation state), SDS-PAGE was 
applied. Dependent on the size of the protein of interest, separation gels containing either 8 % or    
10 % percent of acrylamide/bisacrylamide were used for adequate segregation (see Table 5.4). If not 
yet done, samples were diluted with 4 x Laemmli buffer and the cells were subsequently heated for 5 
min (temperatures indicated in Table 5.4) for complete protein degradation. Samples were then 
directly applied to the gels which were run at 100-120 V for 2-3 h (dependent on percentage of gel 






Table 5.4 SDS-gel percentages and lysate heating temperatures in respect to the individual proteins to be 
analyzed in the HAP1 cells  
Protein of interest Amount of acrylamide/bisacrylamid [%] Heating temperature [°C] 
Akt 10 95 
ERK1/2 10 95 
GSK3 10 95 
NFATc1-c4 10 95 
TRPM7  8 60 
 
5.8.4 Western Blotting and immunodetection  
For further antibody-based detection, proteins were transferred onto a previously in transfer buffer 
equilibrated nitrocellulose membrane via the Western Blot technique using the tank-blotting system. 
For sufficient transfer of all protein, blots were run with either 400 mA for 2.5-3 h or 180 mA 
overnight at 4°C and the success of transfer was visualized using Ponceau S solution which reversibly 
and unspecifically stains proteins of all sizes. The dye was removed by washing blots with TBST and 
the remaining free binding sites of the membrane were blocked with 5 % BSA in TBST for 1 h at RT 
or 3 h at 4°C on a rocking shaker. For protein detection, blots were incubated with the corresponding 
primary antibody diluted in 5 % BSA TBST (for dilution factors of the applied primary antibodies see 
4.9.1) overnight at 4°C. The next day, membranes were washed three times with TBST for 5 min 
each at RT and incubated with the corresponding HRP-conjugated secondary antibody diluted in 
TBST (for dilution factors, see 4.9.2) for 1 h at RT. Blots were washed again three times with TBST 
for 5 min each and, subsequently incubated with ECL-1 and ECL-2 solution (1:1 ratio) for 1 min and 
immunoreactive bands were detected using the software Chemi-Capt 5000 (Vilber, Germany). Data 
was subsequently analyzed using ImageJ (Wayne Rasband, NIH).  
5.9 COX activity assay 
To measure basal COX enzymatic activity in the HAP1 cells, a fluorometric COX activity assay kit 
(Abcam, UK) was applied. One day prior to the experiment, cells were seeded in cell dishes (10 cm) 
with a density of 3-5 x 106 mio/dish and grown overnight at 37°C and 5 % CO2. The next day, cells 
were first washed once with 4 ml cold DPBS. Then, cells were detached in 1.5 ml fresh DPBS with a 
cell scraper, resuspended and transferred into a 50 ml reaction tube. After rinsing of the dishes once 
more with 4 ml DPBS and combining these washing fractions with the corresponding cell 





for 5 min, the supernatant was discarded and cells were diluted in lysis buffer (0.1 M Tris/HCl, pH 
7.8 with 1 mM EDTA and cOmpleteTM protease inhibitor cocktail) at a density of 2.5 x 107 cells/ml, 
transferred into a 1.5 ml reaction tube and kept on ice. Cell lysis was completed by sonicating the 
suspensions for 1 min on ice, and another centrifugation at 10 000 rcf for 15 min served to pellet the 
cell debris. The supernatant was again transferred into a new 1.5 ml reaction tube and the samples 
were kept on ice until usage. 
Before starting with the actual experiment, all reagents from the kit were prepared as instructed in the 
assay protocol so that they were ready to use. The assay was performed according to the 
manufacturer’s instructions, and each condition was prepared as duplicate. After final addition of the 
substrate solution (arachidonic acid/NaOH), fluorescence was measured immediately at a wavelength 
of 587 nm (excitation at 535 nm) in a kinetic mode every 25 s for 30 min using the Fluostar Omega 
(BMG Labtech, Germany); data were extracted with the MARS data analysis software (BMG 
Labtech, Germany).   
5.10 General transfection protocol for HEK-293 cells  
For transfection (e.g. for generation of the stable HEK-NFAT cell line or the dual-luciferase reporter 
gene assay, see 5.10.1 respectively 5.11), HEK-293 cells were seeded in 6-well plates one day prior to 
transfection. When they preferably reached a confluence of ~ 60% on the next day, culturing medium 
was changed to medium without supplements. While the cells adjusted to the immediate FBS-
withdrawal, the transfection mix containing the plasmid of interest and the transfection reagent 
(Lipofectamin or Turbofect) was prepared. Therefore, both the plasmid DNA (1 µg/well) and 
transfection reagent (3 µl/1 µg DNA) were independently diluted in medium without supplements 
(50 µl/well) and incubated for 5 min at RT. Then, the plasmid DNA and the transfection reagent 
mixes were added together and incubated for another 30 min at RT. The solution was subsequently 
carefully added to the wells (100 µl/well) drop by drop and the cells incubated for 4 h at 37°C, 5 % 
CO2. Afterwards, medium was changed back to medium with supplements for cultivation overnight 
at 37°C, 5 % CO2. Cells were used for experiments after 16-24 h after transfection. 
5.10.1 Generation of a stable HEK-293 NFAT reporter (HEK-NFAT) 
cell line 
To create the stable HEK-NFAT reporter cell line for validation of the results observed in the 
transiently transfected HEK-293 cells, HEK-293 cells were transfected with the NFAT reporter gene 
(Promega, Germany) and a pcDNA4 vector (Thermo Fisher Scientific, USA) introducing Zeocin 





clones later surviving the selection with the antibiotic, four different approaches (named II-V) using 
different amounts and thus ratios of DNA as well as a positive (I) and a negative control (VI) were 
taken (see Table 5.5). The positive control was a combination of pcDNA4 giving the Zeocin 
resistance and the ‘empty’ vector pcDNA3.1 carrying no information worth mentioning in context of 
this experiment. Accordingly, the negative control included the NFAT-luciferase reporter and the 
pcDNA3.1 vector.    
Table 5.5 Composition of the different approaches for generation of the HEK-NFAT cell line 
Name  Positive control (I) II III IV V 
Negative 
control (VI) 
pcDNA3.1 [ng] 450 / / / 50 100 
pcDNA4 [ng} 50 50 50 100 50 / 
NFAT-luc [ng] / 450 950 900 400 900 
Total DNA amount [ng] 500 500 1000 1000 500 1000 
Ratio pcDNA4/NFAT-luc / 1:10 1:20 1:10 1:5 / 
Lipofectamin [µl] 1,5 1,5 3 3 3 1,5 
 
Cells were transfected in 6-wells using Lipofectamin according to the conventional protocol (see 
5.10). After the transfection, cells remained in medium without supplements for overnight cultivation. 
Early on the next day, cells were carefully washed with 2 ml DPBS once and detached with another 2 
ml DPBS. A twentieth of each well was transferred into a new T175 flask prepared with 25 ml of 
medium with supplements. Approximately 6-8 h later, 500 µg/ml Zeocin were added to start the 
selection. New medium with fresh Zeocin was added every two to three days for 3-4 weeks. While all 
cells derived from the negative control as well as from the approach III and V died, both the positive 
control and the approaches II and IV yielded to clones surviving Zeocin treatment. Testing NFAT-
reporter activity by addition of the reconstituted luciferase substrate and measuring luminescence at 
560 nm (also see 5.11 for more details), cells from both cultures II and IV proved to be stably 
expressing the NFAT reporter gene and were therefore used for further experiments.    
5.11 Dual luciferase reporter assay in HEK-293 cells 
For both transfection methods, cells were initially seeded in PDL-coated 12-well plates 2 days prior to 
the actual experiment with a concentration of 2 x 105/well. 
a) Dual luciferase reporter assay in transiently transfected HEK-293 cells:  
To investigate NFAT activity in transiently transfected cells, a dual-luciferase reporter gene assay was 





the TRPM7-coding plasmid, a third construct - the Renilla luciferase - needed be inserted (for more 
background information, also see 6.1.5). Thus, HEK-293 cells were co-transfected with 500 ng NFAT 
reporter plasmid, 50 ng Renilla luciferase control vector and 400 ng either GFP-tagged TRPM7 WT 
or TRPM7 KI construct or pcDNA3.1 (according to 5.10 using Lipofectamin). After the overnight 
incubation in normal growth medium, supplemental FBS was removed for 4 h to starve the cells. 
After the incubation, medium was withdrawn and cells were lysed with 200 µl reporter assay lysis 
buffer for 5-10 min at RT. Meanwhile, the luciferase substrate solution and the Stop & Glo® substrate 
solution were prepared according to the manufacturer’s instructions (Promega, Germany). Then, 180 
µl of cell lysate were transferred into a solid white 96-well plate which was placed in the Fluostar 
Omega (BMG Labtech, Germany) for data acquisition. After initially measuring the GFP-signal at 
509 nm (excitation at 488 nm; intensity is proportional to expression of TRPM7 constructs), a time-
resolved measurement of the firefly luciferase activity at 560 nm was performed: first, the 
‘background’ luminescence was acquired for 2 s, and then 20 µl of the reconstituted luciferase 
substrate were injected and luminescence was measured with a frequency of 1 Hz for another 8 s. 
The firefly luciferase signal was later determined by calculating the mean of the acquired 8 values for 
each sample corrected for the background. The experiment was finalized by addition of 10 µl of the 
diluted Stop & Glo® substrate to measure Renilla luciferase activity at 480 nm. Data were extracted 
using MARS data analysis software (BMG Labtech, Germany).  
b) Dual luciferase reporter assay in the stable HEK-NFAT reporter cell line: 
Given the stable expression of the NFAT-reporter in the HEK-NFAT cell line, no additional vector 
for normalization (Renilla luciferase) was required. HEK-NFAT cells were co-transfected with either 
GFP-tagged TRPM7 WT or TRPM7 KI construct and pcDNA3.1. To analyze if TRPM7-driven 
effects are expression level dependent, different quantities of TRPM7 WT or KI cDNA expression 
constructs ranging from 100-1000 ng were transfected. As all samples were to be transfected with the 
same amount of DNA, pcDNA3.1 was used to reach 1000 ng total in each well. The assay was 
performed as described in 5.11 a).  
5.12 Aequorin-based Ca2+ measurements in HEK-293 cells 
The analysis of TRPM7’s impact on the basal Ca2+ levels in HEK-293 cells was done in the Ca2+-
sensing HEK-G5α cell line (see 5.1.2.2). Accordingly, cells were seeded in 6-well plates with a density 
of 1.5 x 105/well and co-transfected with 500 ng either TRPM7 WT or TRPM7 KI construct and 500 
ng pcDNA3.1 (according to chapter 5.10 using Turbofect). After the overnight incubation in normal, 
supplemented growth medium, supplements were withdrawn for 4 h to starve the cells. The medium 





1:1000 in pure DMEM without phenol red). Cells were incubated for 20 min at RT in the dark, 
washed down and 90 µl of each well was transferred into a solid white 96-well plate (each sample was 
measured as triplicate). Signal intensity of each sample was acquired at 509 nm using the Fluostar 
Omega (BMG Labtech, Germany) and data were extracted using MARS data analysis software (BMG 
Labtech, Germany).  
5.13 Statistical analysis  
Data evaluation and statistical analysis was performed using the softwares Igor Pro, Microsoft Excel 
and GraphPad Prism. Data are displayed as mean ± standard error of the mean (SEM). Statistical 
significance was determined using either the paired or unpaired student’s t-test or the two-way 



























6.1 TRPM7 in cell signaling 
6.1.1 Characterization of the HAP1 TRPM7 KO clone 
Before studying TRPM7’s impact on cell signaling events, the knockout of TRPM7 in the HAP1 cell 
model needed to be confirmed. Therefore, genomic DNA of both HAP1 TRPM7 wild-type (WT) 
and KO cells was extracted and – in cooperation with Eurofins Genomics (Munich, Germany) – 
sequenced with primers amplifying the altered region of the human TRPM7 gene.  
The TRPM7 KO is generated by depletion of 17 nucleotides within exon 4 of the TRPM7-coding 
sequence, which is located on chromosome 15 of the human genome (Figure 6.1A) [222]. Alignment 
of the sequencing results acquired for the TRPM7 WT and KO clone reveals that the TRPM7 KO 
indeed lacks 17 nucleotides when compared to WT (Figure 6.1B). Comparison of Figure A and B 
shows that this missing sequence exactly matches the base pair region 50,648,788 – 50,648,804 in the 
forward strand of chromosome 15 (compare Figure 6.1A and 6.1B). As published by our coworkers 
Chubanov et al., this deletion within the TRPM7-coding sequence causes a frame-shift within the 
TRPM7 gene [195].  
However, since only a small part of the TRPM7 gene is depleted, it remains unclear if this mutation 
results in total protein ablation – for example if gene transcription or mRNA translation are 
hampered and/or the products are degraded immediately – or if parts of the protein are still being 
expressed in a correct or scrambled form. Western Blot analysis with a C-terminal α-TRPM7 
antibody suggested that the HAP1 TRPM7 KO cells do not express TRPM7 [195]. However, any 
specific antibody detecting TRPM7 usually binds only a small region of the protein, wherefore 
expression of functional parts of TRPM7 can’t be fully excluded by immunoelectrophoresis.  
Hence, I further validated TRPM7 protein extinction by testing functionality of the TRPM7 channel; 
therefore, channel activity of the HAP1 TRPM7 WT and KO clone was acquired via 
electrophysiological measurements. To maximize currents, both the internal pipette solution and the 
external bath solution contained 0 mM Mg2+, since TRPM7 is inhibited by internal Mg2+ and Mg-ATP 
(also see introduction, 3.2.1.2). In order to be able to adequately compare single measurements, currents 
of individual cells were normalized to the respective cell sizes (defined by the capacity, also see methods, 
5.4) and expressed as current density (pA/pF, left panel) [223, 224]. Furthermore, representative traces 
were extracted at 150 s and plotted as current-voltage relationship. This I/V-curve enables the 






In the performed patch clamp experiments using whole-cell configuration, the TRPM7 WT clone 
displays the typical TRPM7 current development over time – which is a large outwardly rectifying 
current created by monovalents with only small inward-directed divalent cation flux – and current-
voltage (I/V) relationship, while the KO clone shows no increase in TRPM7-like currents (Figure 
6.1C). Thus, the genetic modification in the HAP1 TRPM7 KO cell clone disrupts the expression of 






























Homo sapiens chromosome 15, GRCh38.p12 
TRPM7 gene, Exon 4, base pair region 50,648,788 - 50,648,804   
5‘ – C C T G A T T A A A A T G G T C A – 3‘ 
3‘ – G G A C T A A T T T T A C C A G T – 5‘  
E n d B e g i n n i n g 
Alignment sequenced HAP1 TRPM7 DNA
         
WT    5’ CCATTCTTCTATTGCCTGATTAAAATGGTCACCCAATTTCACATCTGAGTATT 3’
         ||||||||||||||                    ||||||||||||||||||||||
KO    5’ CCATTCTTCTATTG-----------------CCCAATTTCACATCTGAGTATT 3’
Figure 6.1 Verification of the HAP1 TRPM7 KO clone. (A) The TRPM7 knockout (KO) clone is 
generated by deletion of 17 nucleotides within exon 4 of the human TRPM7 gene on chromosome 15; the 
exact region of the mutation is highlighted (see enlargement in blue) and spans the base pairs (bps) 
50,648,788 – 50,648,804 of chromosome 15. (B) Alignment of sequenced DNA from wild-type (WT, 
upper row) and TRPM7 KO (lower row) HAP1 cells shows that the deletion of the 17 nucleotides (see 
above) in the KO was successful. (C) Functional analysis of TRPM7 currents in HAP1 TRPM7 WT (black) 
and KO (red) cells by patch clamp experiments (n=4-5). Measurements were conducted in the whole-cell 
configuration in the absence of extra- and intracellular Mg2+ to avoid TRPM7 inhibition and thus maximize 
TRPM7 currents. Current densities at +80 and -80 mV are plotted vs. time in seconds (left panel) and 
representative current-voltage (I/V) relationships of traces extracted at 150 s are presented (right panel). 






6.1.2 Impact of TRPM7 on ion homeostasis  
As outlined in the introduction (see 3.1.2), the ubiquitously expressed TRPM7 channel-kinase plays 
an important role in systemic and cellular Mg2+ and Ca2+ homeostasis. Accordingly, depletion of the 
TRPM7 protein in the HAP1 cells could affect the intracellular concentrations of Mg2+ and Ca2+, as 
well as – due to the conductivity of the channel to other divalent cations – affecting other cellular ion 
concentrations [51].  
To investigate potential alterations, I performed ICP-MS for both clones in cooperation with ALS 
Scandinavia (Luleå, Sweden). This method allows a highly accurate analysis of the abundance and 
concentration of different inorganic compounds in liquid or solid material (i.e. metals and traces 
metals). Like every mass spectrometric technology, the process is subdivided into three working 
steps: Ionization, ion separation (by mass selection) and detection. In ICP-MS, ICP describes the 
ionization source. Generation of a high-frequency current creates a microwave field that induces the 
ionization of the inert gas argon. The resulting argon plasma reaches temperatures up to 10 000°C 
which are used to resolve chemical bonds within a sample and ionize the single atoms (‘ionization’). 
In the subsequently following sector field (SF) mass analyzer, the ions are accelerated in a static 
electric and/or magnetic field and separated by trajectory deflection, according to their mass-to-
charge (M/Z) ratio [225]. Ion separation is thereby based on the principle that the lighter and more 
charged an ion is, the more its trajectory will be bent. Finally, the incoming signal is amplified by an 
electron multiplier integrated in the detector, which – in combination with the SF mass analyzer – 
guarantees a high resolution (‘detection’).  
Ion content of resting HAP1 cells was determined in parts per million (ppm), and each ion 
concentration was individually normalized to sulfur (S) (correspondingly to [195]). As this element is 
present in the AAs cysteine and methionine, its concentration serves as indication for the protein 
amount which is correlated to the mass of the respective sample [226]. In addition, sulfur-normalized 
data of the KO were also calculated as percent of WT (set to 100 %), thereby allowing a direct 
comparison of both genotypes. 
Comparing first Mg2+ concentration in HAP1 cells of both genotypes, it is obvious that absolute Mg2+ 
levels are significantly lower in TRPM7-deficient HAP1 cells (Figure 6.2A, left panel). The same is 
true directly comparing Mg2+ concentrations of TRPM7 WT to KO cells which reveals a reduction of 
~30 % (Figure 6.2A, right panel). In contrast, internal Ca2+ concentrations under resting conditions 
are not significantly affected by TRPM7 deletion (Figure 6.2B).  
TRPM7 also conducts essential trace metal ions, such as Zn2+, Mn2+ or cobalt (Co2+), with the highest 
preference for Zn2+ [51]. Examining trace metal ion concentrations, it becomes obvious that 





Zn2+ concentrations (Figure 6.2C, left panel). Calculating the relative Zn2+ amount, it becomes evident 
that HAP1 TRPM7 KO cells display a decrease of about ~13 % in Zn2+ levels when compared to 
WT (Figure 6.2C, right panel). Furthermore, it was found that TRPM7 depletion also significantly 
reduces the cellular copper (Cu2+) concentration, as TRPM7 KO cells only contain about two thirds 
as much as WT (reduction of ~34 %, Figure 6.2D, right panel). Due to their low abundance, most of 
the other permeates of the TRPM7 channel – such as Ni2+, Co2+, Mn2+ – were not detectable via ICP-
MS, as intracellular concentrations of these trace-metals is usually very low. Therefore, these data 
were not included.  
I conclude that TRPM7 controls cellular Mg2+ levels in HAP1 cells, but is also relevant for Zn2+ and 
Cu2+ homeostasis, which both play an important role as enzymatic cofactors [227-229]. In addition, 
the results indicate that TRPM7 is dispensable for maintenance of basal cellular Ca2+ concentrations. 
However, the existing large gradient (~20 000 fold) between physiological external and internal cytosolic 
Ca2+ concentration ([Ca2+]ext= 1-2 mM, [Ca
2+]i/cyt=~100 nM) predisposes ICP-MS measurements of 
cytosolic Ca2+ relatively sensitive to contamination by residual external Ca2+ [230]. Therefore, albeit 


















































































Figure 6.2 Ion levels in HAP1 TRPM7 WT and KO cells. Concentrations of (A) Mg2+, (B) Ca2+, (C) Zn2+ 
and (D) Cu2+ measured via ICP-MS in resting HAP1 TRPM7 WT (black) and KO (red) cells (n=4). 
Concentrations are displayed as raw data (counts of respective ion in ppm normalized to counts of sulphur (S) 
in ppm, left panels) as well as normalized to WT for direct comparison (set to 100 %, right panels). Both 
evaluations reveal that Mg2+, Zn2+ and Cu2+ are all highly significantly reduced in HAP1 TRPM7 KO cells 
compared to WT cells, while internal Ca2+-concentration is not affected by TRPM7 depletion. Data are 






ICP-MS analysis, especially the values for Ca2+ could be distorted by Ca2+-ions remaining from the 
culture medium sticking to the outer cell membrane. To exclude such a falsification of the results 
acquired with ICP-MS, I next employed the ratiometric Fura-2 AM based Ca2+ imaging technique 
[217] as additional method to determine internal Ca2+ concentrations in the HAP1 TRPM7 clones. 
Other than ICP-MS, Ca2+ imaging visualizes levels and alterations of intracellular Ca2+ in individual 
living cells instead of measuring the total ion content present in dried cell pellets.  
In order to detect internal Ca2+, the cells are stained with the Ca2+-sensitive dye Fura-2 AM, which 
allows time-resolved quantification of Ca2+ concentrations using fluorescence microscopy. Fura-2 AM 
is composed of two components: One is the Ca2+-chelator and thus -indicator (Fura-2) and the other 
is the AM ester group, which ensures membrane crossing and thus facilitates the cellular uptake of 
the dye; moreover, subsequent cleavage of the AM group by cellular esterases then traps Fura-2 inside 
the cell [217]. Importantly, binding of free Ca2+ to Fura-2 changes its excitation wavelength from 
originally 380 nm (Ca2+-free/-unbound form) to 340 nm (Ca2+-bound form) while its emission 
wavelength of 510 nm remains the same [217]. Thus, Ca2+ concentration can be directly calculated 
with the ratio of signal intensities acquired at 380 nm and 340 nm excitation, respectively. One 
advantage of this method is the use of the ratio of 340/380 nm, which cancels out confounding 
valuables such as differing indicator concentrations or cellular distribution.  
 
As illustrated in Figure 6.3, the HAP1 TRPM7 KO cells again show no significant difference in basal 
intracellular Ca2+ concentrations compared to WT cells. Hence, the Ca2+ imaging experiments 
confirm the ICP-MS results obtained for Ca2+, which neither revealed alterations upon TRPM7 
depletion. Consequently, TRPM7 is indeed redundant for Ca2+ household in resting HAP1 cells. 
Figure 6.3 Single cell analysis of internal Ca2+ concentration in HAP1 TRPM7 WT and KO cells. 
Ca2+ levels in resting HAP1 TRPM7 WT and KO cells were acquired via ratiometric Fura-2 AM based 
Ca2+ imaging (n=10-19). Ca2+ concentrations are displayed as ratio of fluorescence at 340 and 380 nm 
excitation. Although the basal intracellular Ca2+ is slightly reduced in the HAP1 TRPM7 KO clone compared 
to WT, this decrease is not significantly. Data are presented as mean ± s.e.m. Statistics: unpaired student’s t-






















6.1.3 TRPM7-directed phosphorylation of cell signaling molecules 
Within the last decade, several studies suggested that TRPM7 controls basic cellular functions and 
thereby also contributes to tumor development and progression by facilitating the phosphorylation 
and thus activation of different cell signaling kinases and transcription factors such as Akt, ERK1/2, 
STAT3 [154-157, 160, 169-172, 174, 177, 178]. However, the published results are partially 
controversial, and in some cases (for example ERK1/2 phosphorylation) the exact function of 
TRPM7 remains unclear. Thus, in order to validate respectively further elucidate the impact of 
TRPM7 on the above-mentioned signaling cascades, I first analyzed the phosphorylation status of 
different cell signaling molecules in HAP1 TRPM7 WT and KO cells using Western Blot analysis. 
Regarding the herein examined targets for TRPM7, the experiments included not only proteins 
implicated in TRPM7-controlled cancerous processes (Akt, ERK1/2 and STAT3), but also involved 
the Akt downstream kinase GSK3β and the very recently published target of the TRPM7 kinase, 
SMAD2 [83, 231]. Dependent on the size of the target protein to be detected, either the 
glyceraldehyde 3-phosphatase dehydrogenase (GAPDH) or LaminB1 served as loading control of the 
analyzed whole-cell lysates; the enzyme GAPDH (molecular weight, MW: 38 kDa) was used for Akt, 
STAT3 and SMAD2 (all >50 kDa), wherefore LaminB1 (MW: 65 kDa) was used for GSK3β and 
ERK1/2 (both <50 kDa).  
Figure 6.4 shows representative Western Blot images and the corresponding statistical analysis upon 
quantification of the phosphorylated forms of the signaling kinases Akt, GSK3β and ERK1/2 in 
HAP1 TRPM7 WT and KO cell lysates. As the FBS, which is usually supplemented to the cell culture 
medium, contains a broad spectrum of growth factors and other proteins that could influence 
signaling pathways to different extents [207], HAP1 cells were cultured with (+) and without (-) FBS 
for 3 hours. The signal intensity of each phosphorylation band was determined via the ImageJ software 
and normalized to its corresponding loading control. For adequate comparison, the WT signal intensity 
ratio of each protein was set to 100 % and the KO put in relation.  
To uncover potential FBS-caused changes in the phosphorylation state of the examined proteins, cells 
cultured in media containing 10 % FBS or cells incubated in FBS-free media were analyzed separately 
(Figure 6.4). Compared to WT, TRPM7 KO cells show a strong reduction in phosphorylation of both 
Akt Ser473 and GSK3β Ser9 (Figure 6.4A and B). Although the total signal intensity decreases upon FBS 
withdrawal in both genotypes, the reduction in phosphorylation is always stronger in the KO cells in 
comparison to WT (Figure 6.4A and B, left panels). Evaluating the phosphorylation state via ImageJ, it 
becomes clear that under both culturing conditions – with and without FBS – the KO shows reduced 





shows that the phosphorylation of Akt (with FBS) and GSK3β (without FBS) is significantly reduced in 
the TRPM7 KO clone in comparison to WT (Figure 6.4A and B, right panels). 
In contrast to Akt and GSK3β, the Western Blot image suggests that ERK1/2 is more phosphorylated in 
KO than in WT cells when cultured with 10 % FBS (Figure 6.4C, left panel). Although FBS withdrawal 
reduces ERK1/2 phosphorylation in both the TRPM7 WT and KO clone, ERK1/2 phosphorylation still 
seems to be stronger in the KO cells (Figure 6.4C, left panel). These findings are partially confirmed 
quantifying the amount of phosphorylated ERK1/2 with ImageJ: Treating the cells with FBS indeed 
increases ERK1/2 phosphorylation upon TRPM7 depletion, although not in a significant extend (Figure 
6.4C, right panel, right columns). However, the increase in ERK1/2 phosphorylation is no longer 






























































Figure 6.4 Basal phosphorylation levels of cell signaling molecules in HAP1 TRPM7 WT and KO cells. 
Representative Western Blot images (left panels) and statistical analysis (right panels) of (A) AKT pSer473 
(pAKT, 60 kDa) (B) GSK3β pSer9 (pGSK3β, 47 kDa) and (C) ERK1/2 pTyr204 (pERK, 42/44 kDa) in FBS-
treated (+) and untreated (-) HAP1 TRPM7 WT and KO cells (n=3-4). Band intensities of each 
phosphorylation signal was determined via ImageJ and normalized to its respective loading control (GAPDH, 
38 kDa; LaminB1, 65 kDa). To cancel out larger variances between the individual experiments, KO values are 
calculated as percent of WT (set to 100 %). Evaluation of treated and untreated samples illustrates a 
significant reduction of pAKT (A) in FBS-treated and pGSK3β (B) in untreated HAP TRPM7 KO cells 
when compared to WT. In contrast, independently of FBS presence, no significant changes are 
observable for pERK (C). Protein size is expressed in kilo Dalton (kDa). Data are presented as mean ± 





Next, I analyzed the phosphorylation state of the two transcription factors STAT3 and SMAD2, as they 
were previously put in relation to TRPM7 [83, 178, 232]. However, the detected basal phosphorylation 
levels were really low in both FBS-treated and untreated cells and almost not detectable (Figure 6.5). Thus, 
the blots were not further evaluated via ImageJ, as signal intensities allowed no accurate analysis.  
Taken together, I was able to show that TRPM7 significantly affects the phosphorylation of both Akt and 
GSK3β but not ERK1/2 in resting HAP1 cells. The investigated phosphorylation of Akt at Ser473 is 
activating the kinase and promotes further phosphorylation of downstream targets such as GSK3β [231]. 
In contrast to Akt, the investigated GSK3β phosphorylation site Ser9 acts as self-inhibitory mechanism 
[231, 233]. Being located in both the cytosol and the nucleus, this glycogen synthase kinase controls 
various cell functions through its impact on numerous transcription factors. Among others, GSK3β 
phosphorylates the nuclear factor of activated T cells (NFAT) within a nuclear export sequence (NES) 
and thereby induces its nuclear export [234]. Thus, the increase in GSK3β activity in KO clones could 
potentially alter NFAT localization within the HAP1 cells, wherefore I investigated nuclear NFAT levels 
next. 
6.1.4 Effect of TRPM7 on subcellular NFAT localization 
As explained above, increase in the GSK3β Ser9 phosphorylation reduces its activity and thereby leads to 
accumulation of NFAT in the nucleus [234, 235]. Hence, the observed reduction of GSK3β Ser9 
phosphorylation in the TRPM7-depleted HAP1 cells might cause a decrease in nuclear NFAT levels while 
increasing its cytosolic concentrations; therefore, the TRPM7 KO could show alterations in subcellular 
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Figure 6.5 Basal phosphorylation levels of the transcription factors SMAD2 and STAT3 in HAP1 
TRPM7 WT and KO cells. Representative Western Blot images of SMAD2 pSer465/467 (pSMAD2, 60 
kDa, upper panel) and STAT3 pTyr705 (pSTAT3, 86/91 kDa, bottom panel) in FBS-treated (+) and 
untreated (-) HAP1 TRPM7 WT and KO cells (n=3-4). Due to the very low phosphorylation status of these 
transcription factors in resting cells, no phospho-specific signals were detectable. Loading control: GAPDH 






Before examining cellular distribution via separate analysis of nuclear and cytoplasmic fraction of NFAT 
in HAP1 TRPM7 WT and KO cells, I first examined which NFAT family members are expressed in the 
HAP1 cells. Therefore, I performed Western Blot analysis of whole-cell lysates of WT HAP1 cells. The 
representative Western Blot images in Figure 6.6 illustrate that all Ca2+-regulated NFATs (NFATc1-4) are 
present except for NFATc2. NFATc1 and NFATc4 show multiple bands with different intensities, which 
indicate the presence of different isoforms (NFATc1) or protein phosphorylation states (NFATc4), 
respectively [236-239]. Nevertheless, also other posttranslational modifications, such as poly ADP-
ribosylation, sumoylation and ubiquitination could influence protein size and thus migration of NFAT in 
the SDS-PAGE [240-244]. While band intensities of NFATc1 and c3 proved to be repeatedly stable in 
consecutive experiments, both the de- and hyperphosphorylated forms of NFATc4 – supposedly 
indicated by the bands at 140 and 160 kDa according to the supplier (Santa Cruz, Germany) [236, 237] – 
showed more variations in the individual experiments (data not shown) aggravating interpretation. Thus, I 
focused on the first-mentioned NFAT family members (c1 and c3) when analyzing NFAT nuclear 
accumulation in resting HAP1 TRPM7 WT and KO cells.  
For separation of the nucleus from the cytosol, I utilized a commercial nuclear extract kit (Active Motif, 
USA), which allows obtaining cytosolic cellular components through a ‘mild’ osmosis-based lysis. The 
applied ‘hypotonic lysis buffer’ induces swelling and thus permeabilization of the cell membrane, and 
addition of the supplemented ‘detergent’ subsequently results in the release of cytosolic components. The 



























Figure 6.6 NFATc1-c4 expression in HAP1 TRPM7 WT and KO cells. Representative Western Blots 
of the Ca2+-responsive NFAT family members (A) NFATc1 (90/110/140 kDa), (B) NFATc2 (135 kDa), 
(C) NFATc3 (130 kDa) and (D) NFATc4 (140/160 kDa) expressed in HAP1 TRPM7 WT and KO cells 
(n=2-4). Numbers in brackets indicate protein sizes of the respective bands expected for the different 
NFAT family members. Multiple respectively double bands indicate different protein isoforms (NFATc1) 
or phosphorylation states (NFATc4) as well as other possible posttranslational modifications. Note that 
all family members are expressed in both HAP1 cell clones except NFATc2. Loading control: LaminB1 





treatment of the remaining pellet with a more stringent ‘cell lysis buffer’ dissolves the so far untouched 
nucleus, and the nuclear fraction is then obtained by separating the lysate from remaining cell debris with 
another l centrifugation. Figure 6.7A displays representative Western Blots images and quantification 
analysis of 4-8 individual nuclear cell preparations of NFATc1 (upper panel) and NFATc3 (lower panel). 
Due to their prevalence in the respective compartments (nucleus, cytosol), LaminB1 and GAPDH served 
as loading controls for the corresponding fractions. For data evaluation, signal intensities of the NFAT 
immunoreactive bands were measured by densitometry, expressed relative to the corresponding loading 
control and KO values were then normalized to WT samples set to 100 %. For both NFAT family 
members, the Western Blot images (left panel) as well as the statistical analysis (right panel) reveal a 
significant reduction of nuclear NFAT levels in the HAP1 TRPM7 KO clone when compared to WT. 
While the concentration of nuclear NFATc1 decreases by about ~12 %, NFATc3 levels decrease by even 
~40 % in the KO cells. 
To check if the reduced nuclear NFAT levels are accompanied by an increase in the NFAT concentration 
in the cytosol, I examined the corresponding cytoplasmic fractions. Although the representative Western 
Blot images suggest that the cytosol contains slightly more NFATc1 and c3 in the KO (Figure 6.7B, left 
panel), normalization to the loading control proofs that there are no significant differences between the 
TRPM7 WT and KO HAP1 cells regarding NFAT cytosolic concentrations (Figure 6.7B, right panel).   
Since the decrease of nuclear NFAT levels in the KO apparently is not directly associated with an increase 
in cytosolic NFAT concentrations, I addressed the question if the total concentrations of NFATc1 and c3 
are reduced in the HAP1 TRPM7 KO clone in comparison to WT as an additional control. To compare 
total protein expression of NFATc1 and c3 independently from their localization, I prepared HAP1 
TRPM7 WT and KO whole-cell lysates and analyzed them via antibody-directed detection of NFATc1 
respectively c3 in Western Blot. Signal intensities of the NFAT bands were normalized to the signals of 
the corresponding loading controls (LaminB1), and the resulting KO values were subsequently calculated 
as percent of WT (set to 100 %). Representative Western Blot images and bar graphs of these control 
experiments (Figure 6.7C) depict that, although KO cells overall express ~6 % more NFATc1 and ~16 % 
less NFATc3 than WT cells, neither expression of those two family members is significantly altered upon 













I conclude that TRPM7 antagonizes NFAT nuclear export and thus facilitates NFAT nuclear 
accumulation through promotion of GSK3β Ser9 phosphorylation. Nevertheless, the TRPM7 KO-
induced reduction of nuclear localized NFAT does not necessarily imply a decline in NFAT-dependent 
gene expression. Hence, I next analyzed if the HAP1 TRPM7 KO cells also show a defect in NFAT 

















































































































































Figure 6.7 Subcellular NFAT localization in resting HAP1 TRPM7 WT and KO cells. Representative 
Western Blot images and quantification analysis of NFATc1 (90/110/140 kDa, upper panels) and 
NFATc3 (130 kDa, lower panels) in (A) the nucleus and (B) the cytosol in resting HAP1 TRPM7 WT and 
KO cells (n=4-8). For statistical analysis, signal intensities of both family members were normalized to 
their corresponding nuclear (LaminB1, 65 kDa) or cytosolic (GAPDH, 38 kDa) loading control and HAP1 
TRPM7 KO values were calculated as percent of WT (set to 100 %). Note that both NFATc1 and 
NFATc3 are significantly reduced in the nuclear fraction of the HAP1 TRPM7 KO mutant, while their 
concentration is not significantly altered in the corresponding cytoplasmic fractions. (C) Representative 
Western Blot images and quantification analysis regarding the total protein concentration of NFATc1 (left 
panel) and NFATc3 (right panel) in whole-cell RIPA lysates of resting HAP1 TRPM7 WT and KO cells 
(KO expressed as percent of WT). Although detecting a slight increase (NFATc1) respectively a 
moderate reduction (NFATc3) regarding the expression levels of NFATcs in HAP TRPM7 KO cells, 
neither NFATc1 nor NFATc3 total protein expression is significantly changed in the HAP1 TRPM7 KO 
cells. Protein size is expressed in kDa. Data are presented as mean ± s.e.m. Statistics: paired student’s t-





6.1.5 Impact of TRPM7 on NFAT-dependent gene expression using 
the dual-luciferase reporter gene assay  
A convenient method for studying gene expression induced by particular transcription factors is the dual-
luciferase reporter gene assay. It is based on a reporter gene encoding for a fluorescent protein or enzyme 
- here: firefly luciferase – that is directly attached to a promoter region recognized by the transcription 
factor of interest. Thus, the expression of the firefly luciferase depends on induction of gene expression 
by binding of the corresponding transcription factor to its promoter, and accordingly, transcription factor 
activity is directly correlated to the enzymatic activity, which can be measured by bioluminescence. The 
oxidative decarboxylation of the firefly luciferase substrate D-luciferin results in oxyluciferin, which is – by 
its nature – singlet-excited, meaning that one of the paired electrons is excited to an higher energy level 
but still retains its original spin. Therefore, when returning to its ground state, it emits light with a 
wavelength of λmax = 560 nm [245, 246]. Yet, the activity of the firefly luciferase does not exclusively 
depend on transcription factor activity, but also varies with cell number and, even more important, the 
transfection rate. To exclude falsification of the results by these parameters, a second luciferase named 
Renilla serves as reference [247-249]. This luciferase converts coelenterazine to coelenteramide which 
emits light at a wavelength of λmax = 470-480 nm [250, 251]. The Renilla luciferase expression relies on 
the above-mentioned factors varying general gene expression, such as cell number and transfection rate, 
but occurs independent of specific transcription factors. Thus, its activity can be used for normalization of 
the firefly luciferase signal [249]. 
Accordingly, my initial approach was to transfect the HAP1 TRPM7 WT and KO cells with an NFAT 
reporter gene and a Renilla luciferase vector as internal expression control and thereafter to measure 
NFAT-dependent gene expression and thus determine NFAT transcriptional activity. But before directly 
applying the dual-luciferase NFAT reporter gene assay, transfection efficiency of the HAP1 cells had to be 
evaluated first. To simplify these test experiments and be able to rapidly visualize transfection rates, a G5α 
construct was used which comprises GFP emitting a green fluorescent signal (λmax = 509 nm) upon 
excitation at 488 nm (also see 6.1.6).  
Unfortunately, the fluorescence-based monitoring revealed that transfection of the HAP1 cells with 
G5α resulted in very low transfection rates. Neither changing the transfection reagent from 
Lipofectamin to Turbofect or Xfect nor varying the DNA- and/or transfection reagent amount was 
able to increase the transfection rate which ranged between ~15 and ~30 % (not visually logged). 
Therefore, in default of obtaining a suitable amount of transfected HAP1 cells, I switched to wild-type 






6.1.5.1 Effect of the TRPM7 on NFAT-dependent gene expression using the 
dual-luciferase NFAT-reporter gene assay in transiently transfected 
HEK-293 cells  
As described for the initial experiments with HAP1 cells, the dual-luciferase reporter gene assay system 
was performed in HEK-293 cells using transient overexpression (for detailed description see methods, 
5.11). Next to the NFAT reporter gene and the Renilla luciferase vector, HEK-293 cells were either 
transfected with a control vector pcDNA3.1 (‘mock’) or the vector containing the murine wild-type 
TRPM7 (TRPM7 WT) protein fused to the fluorescent tag GFP (λmax = 509 nm).  
As described in 6.1.3, the mix of various growth factors present in FBS is able to induce numerous 
signaling pathways and consequently could potentially cover TRPM7-dependent effects on NFAT 
transcriptional activity [252]. To avoid such an FBS-dependent gene regulation, cells were serum-starved 
for 4 hours prior to the luciferase measurements. Data evaluation was done by normalization of the firefly 
to the Renilla luciferase activity obtained for mock- respective TRPM7 WT-overexpressing HEK-293 


















































































Figure 6.8 NFAT transcriptional activity in TRPM7 WT overexpressing HEK-293 cells. (A) NFAT 
transcriptional activity in transiently transfected HEK-293 cells co-expressing the NFAT luciferase reporter 
(500 ng) and the Renilla luciferase control vector (50 ng) together with either 400 ng pcDNA3.1 as control 
([mock], grey) or 400 ng TRPM7 WT protein ([TRPM7 WT], black, displayed as percent of mock, n=7]). 
(B) NFAT transcriptional activity in a stable HEK-NFAT cell line transiently co-expressing pcDNA3.1 as 
control (‘mock’) or TRPM7 WT protein ([TRPM7 WT], displayed as percent of mock, n=19). Amount of 
transfected TRPM7 WT DNA ranged from 100-1000 ng and was complemented by pcDNA3.1 DNA if 
necessary to reach a DNA amount of 1000 ng total. (C) NFAT transcriptional activity plotted as function of 
TRPM7 WT expression in the stable HEK-NFAT cell line (n=19). TRMP7 WT data were normalized to the 
control (pcDNA3.1 alone, [mock], set to 100 %), and subsequently, NFAT activity of the control (which 
equals 100 %) was subtracted from the resulting TRPM7 WT NFAT activity values. Thus, TRPM7-
dependent increase in NFAT activity is expressed as ‘Δ above mock in %’. Amount of transfected TRPM7 
WT DNA ranged from 100-1000 ng and was complemented by pcDNA3.1 DNA if necessary to reach a 
DNA amount of 1000 ng total. NFAT activity was measured in and is displayed as relative light units 
(RLU) of the firefly luciferase substrate oxyluciferin (λmax = 560 nm) and TRPM7 expression is displayed 
as RLU of GFP (λmax = 509 nm). In both transient and stable HEK-293 NFAT reporter cells, TRPM7 
overexpression significantly elevates NFAT transcriptional activity in comparison to mock (A and B). 
Furthermore, NFAT-dependent gene transcription is augmented with increasing TRPM7 expression levels 





Figure 6.8A shows that transient TRPM7 WT overexpression significantly increases NFAT activity 
around ~17 % compared to mock, indicating that TRPM7 facilitates NFAT-dependent gene expression. 
However, although the use of Renilla luciferase for normalization helps to exclude variables which could 
distort measurements of NFAT-dependent gene expression (see above), it is useful to substantiate the 
results with a cell line stably expressing the NFAT luciferase reporter. Thus, the luciferase experiments 
were repeated in a stable HEK-NFAT reporter cell line that allows standardization of NFAT-coupled 
luciferase expression.  
6.1.5.2 Effect of TRPM7 on NFAT-dependent gene expression in a stable HEK-
NFAT reporter cell line 
As described above, the stable HEK-NFAT reporter cell line has the advantage of all cells uniformly 
expressing the NFAT firefly luciferase reporter gene, thus making additional expression of the Renilla 
luciferase for normalization redundant. Hence, a HEK-293 cell line constantly expressing an NFAT firefly 
luciferase reporter was generated (herein named ‘HEK-NFAT’, see methods, 5.10.1) and transfected with 
the control vector mock or the GFP-tagged TRPM7 WT construct. Again, cells expressing mock were 
used as controls with the NFAT activity set to 100 %, and the activity of TRPM7 WT-expressing cells was 
calculated as percent of mock. As illustrated in Figure 6.8B, TRPM7 WT overexpression highly 
significantly (p<0.005) enhances NFAT transcriptional activity about ~45 % in comparison to mock. 
Moreover, the TRPM7-induced increase in NFAT-dependent gene expression is concentration 
dependent, as higher TRPM7 WT expression levels – measured via the fluorescent tag GFP – correlate 
with augmented NFAT firefly luciferase activity (Figure 6.8C).    
Taken together, TRPM7 WT overexpression indeed promotes NFAT transcriptional activity in HEK-293 
cells. Although this result matches the conclusions regarding NFAT localization drawn from the 
comparison of the HAP1 TRPM7 WT vs. KO model (see Figure 6.7), it not necessarily given that the 
HAP1 cells show the same TRPM7-dependent NFAT-driven gene induction. As a matter of fact, an 
overexpression system largely differs from a KO system and potentially shows additional alterations 
induced by enhanced protein expression; hence, the TRPM7 overexpression in the HEK-293 cells might 
influence other factors – which not necessarily must be affected by TRPM7 KO in the HAP1 cells – 
promoting NFAT transcriptional activity. One main mechanism triggering NFAT nuclear translocation 
and activity is the increase in cytosolic Ca2+ [253]. Given that TRPM7 is a Ca2+-conducting channel, its 
overexpression might influence intracellular Ca2+ levels in HEK-293 cells; therefore, I next analyzed 
internal Ca2+ concentrations in TRPM7 WT overexpressing HEK-293 cells.       
6.1.6 Effect of TRPM7 on Ca2+ homeostasis in HEK-G5α cells 
In order to monitor basal Ca2+ levels in TRPM7 overexpressing HEK-293 cells, another stable cell line 





Munich) constitutively express a fusion protein composed of the enzymatic part of the biological Ca2+ 
sensor aequorin (apoaequorin) and GFP, a combination that allows relatively sensitive measurements 
of the cytosolic Ca2+ concentration [196, 202]. In the presence of bound Ca2+, (apo)aequorin is able to 
oxidize its substrate coelenterazine to coelenteramid which then emits blue light (λmax = 470-480 nm) 
[251, 254]. Instead of directly measuring the emission, the relatively low light quantum yield (number 
of emitted photons per Ca2+-bound protein) of this enzymatic reaction is increased by 
chemiluminescence resonance energy transfer (CRET). Through the close proximity of the two 
components, the energy is not being emitted by coelenteramid but directly transferred to GFP, which 
is excited and in turn emits green light (λmax = 509 nm). Accordingly, this system allows sensitive Ca2+ 
measurements without introducing an external fluorescent dye or requiring excitation at a specific 
wavelength and thereby bypasses problems such as toxicity, photobleaching or autofluorescence 
[196].  
For the measurements, HEK-G5α cells were transfected with either the control vector pcDNA3.1 
(‘mock’) or the TRPM7 WT construct (both introduced above, see 6.1.5). To adequately compare the 
results, data of the TRPM7 WT were calculated as percent of mock (set to 100 %).     
Transient overexpression of TRPM7 WT in HEK-G5α cells significantly elevates Ca2+ levels by ~22 
% in comparison to mock-transfected cells (Figure 6.9). Hence, the TRPM7 overexpression-induced 
increase in NFAT transcriptional activity (see 6.1.5) is directly associated with a rise in intracellular 
Ca2+ concentrations upon TRPM7 overexpression, suggesting that in HEK-293 cells, the observed 
upregulation of NFAT-dependent gene expression is most likely caused by increased Ca2+ influx 






















Figure 6.9 Basal Ca2+ levels in TRPM7 WT overexpressing HEK-G5α cells. Ca2+ concentration in 
mock-transfected (grey) and TRPM7 WT-overexpressing (black) HEK-G5α cells (n=8). Ca2+ 
concentration is illustrated as relative light units (RLU) of GFP (λmax = 509) and WT data are normalized 
to mock (set to 100 %). When compared to mock, TRPM7 overexpression highly significantly elevates 
internal Ca2+ concentration in HEK-G5α cells. Data are presented as mean ± s.e.m. Statistics: paired 





In contrast, knockout of native TRPM7 in HAP1 cells significantly reduces the level of nuclear 
localized NFAT (as shown in 6.1.4) but does not alter the basal intracellular Ca2+ concentration 
(shown in 6.1.2). Consequently, in HAP1 cells, TRPM7 promotes NFAT nuclear localization 
independently of Ca2+, indicating the existence of a different mechanism by which the channel-kinase 
interferes with NFAT.  
Irrespective of the differential outcome regarding Ca2+ in the TRPM7-depleted HAP1 cells and the 
TRPM7-overexpressing HEK-293 cells, the results demonstrate that TRPM7 substantially affects 
NFAT localization and transcriptional activity in human cells. Since NFAT controls the expression of 
various genes, I decided to employ another technique, namely RT-qPCR, to closer examine NFAT-
dependent gene expression in HAP1 TRPM7 WT and KO cells.   
6.1.7 Impact of TRPM7 on NFAT-dependent target gene expression 
using RT-qPCR 
NFAT affects a variety of genes and induces their expression either alone or in cooperation with other 
transcription factors and cofactors. Thus, TRPM7 might be involved in the up- and/or downregulation of 
these genes through its impact on NFAT localization in HAP1 cells (see 6.1.4). To closer examine target 
genes induced by NFAT in the HAP1 TRPM7 WT and KO cells, I applied the widely used RT-qPCR 
which allows to determine specific gene expression by mRNA quantification [255-257].  
Therefore, I investigated the expression of four genes previously shown to rely on NFAT activity: 
Cyclooxygenase-2 (COX-2), Interleukin-2 (IL-2), Inositol 1,4,5-triphosphate receptor type 1 (IP3R1) and Myc [258-
264]. Before starting the actual quantification of the respective mRNA transcripts, classical reverse 
transcription PCR (RT-PCR) followed by agarose gel electrophoresis was used to determine if the HAP1 
cells actually express the described NFAT target genes.  
Figure 6.10 reveals that both HAP1 cell clones express COX-2, IP3R1 and Myc but lack IL-2. Accordingly, 







Figure 6.11 documents the results obtained from 6-20 independent preparations of the two genotypic cell 
lines. Data of every gene of interest were normalized to the housekeeping gene HPRT1 and expressed as 
relative gene expression (2(-ΔCP)).    
Regarding IP3R1, depletion of TRPM7 leads to a significant increase in transcription when compared to 
WT (~0.012 compared to ~0.022, Figure 6.11A). In contrast, Myc gene expression is not affected by 
TRPM7, as there is no apparent difference in the amount of Myc mRNA comparing WT and KO samples 
(Figure 6.11B). Opposed to these findings, COX-2 mRNA levels are significantly reduced if TRPM7 is 
absent (Figure 6.11C): Relative to WT, HAP1 TRPM7 KO cells express only about two thirds as much 
COX-2 (~0.0063 compared to ~0.0042).  
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Figure 6.10  Expression of NFAT-inducible genes in HAP1 TRPM7 WT and KO cells. Analysis of the 
mRNA expression of the NFAT-dependent genes IL-2, IP3R1, COX-2 and Myc in HAP1 TRPM7 WT and 
KO cells. Water (H2O) served as negative control; the DNA ladder (Marker [M]) indicates the size of the 
amplified PCR products measured in base pairs (bp). Note that the IP3R1, COX-2 and Myc are expressed 








































































Figure 6.11 Quantity of IP3R1, Myc and COX-2 mRNA in HAP1 TRPM7 WT and KO cells. Relative 
mRNA expression (measured via RT-qPCR) of (A) IP3R1 (n=6), (B) Myc (n=6) and (C) COX-2 (n=18-20) 
in resting HAP1 TRPM7 WT and KO cells. For analysis, the particular signals were normalized to the 
reference gene HPRT1 and expressed as relative gene expression (2(-ΔCP)). Note a significant increase in 
IP3R1 expression (A) as well as a significant reduction in COX-2 expression (C) in HAP1 TRPM7 KO cells 
compared to WT. Myc mRNA levels however are not effected by TRPM7-depletion (B). Data are presented as 





In summary, both mRNA levels of IP3R1 and COX-2 differ in the KO clone. Surprisingly, TRPM7 
differentially affects IP3R1 and COX-2 gene regulation: While IP3R1 gene expression is significantly 
augmented upon TRPM7 depletion, COX-2 gene expression is – in contrast – dramatically 
downregulated. 
6.1.8 Effect of TRPM7 on COX-2 activity 
COX-2, also known as prostaglandin-endoperoxide synthase 2 (PTGS2), is – together with the other 
cyclooxygenase isoform COX-1 – the rate-limiting enzyme for prostaglandin (PG) synthesis and thus 
plays an essential role in pain, inflammation and other diseases, such as several types of cancer and 
neuropathological disorders [265-274]. Given its clinical relevance, I next addressed the question if the 
substantial reduction of COX-2 mRNA in the HAP1 TRPM7 KO cells results in diminished COX-2 
enzymatic activity, which not necessarily must be the case [274-277]. To investigate COX-2 activity, I 
utilized a fluorometric COX Activity Assay (Abcam, UK), which quantifies COX activity by the 
conversion of its substrate arachidonic acid into PG G2 (PGG2); the amount of subsequently metabolized 
PGG2 and thus COX activity is reflected by an increase in fluorescence (measured at an emission 
wavelength of λmax = 587 nm, excitation at 535 nm; for more details, see specification by the supplier). 
Thus, following preparation of the assay, the enzymatic reaction was initialized by arachidonic acid 
administration (resembling time point 0, t=0), and subsequently, the increase in fluorescence (measured in 
relative fluorescence units, RFU) was monitored every 25 s for 30 min. 
Figure 6.12A displays the respective increase in fluorescence in the DMSO-treated (see below) HAP1 
TRPM7 WT and KO samples plotted versus time (raw data sets, displayed as [RFU]). First of all, it 
becomes apparent that the assay exhibits a very high background signal (RFUs at t=0, RFUt0). 
Nevertheless, looking at the kinetic of the substrate conversion resembling COX activity, TRPM7 WT 
cells clearly show a small, but continuous increase in fluorescence over time, while no substantial elevation 
in fluorescence was detectable for the TRPM7 KO cells (Fig. 6.12A). To exclude larger variations between 
the individual experiments regarding the background signal, raw data were further evaluated by calculating 
the increase in fluorescence over time (expressed as ΔRFU) by subtracting the background signal (RFUt0) 
from each time point of the corresponding measurement. Instead of making these calculations for the two 
graphs shown in 6.12A resembling the mean of all TRPM7 WT and KO samples, this was done for each 
experiment (n) individually. Subsequently, the means and the standard error of the means (SEMs) of both 
TRPM7 WT and KO were calculated, and the results are displayed in Figure 6.12B. Similar to Figure 
6.12A, the kinetics show that, while WT demonstrates a considerable increase in fluorescence over time, 
no elevation in fluorescence and thus COX activity is observed for the TRPM7 KO mutant. Furthermore, 
this calculation demonstrates that the large variations visible before in Fig. 6.12A (resembled by the large 





experiments and are not actually genotype-dependent fluctuations in the effect of TRPM7 on COX 
activity. Comparing and statistically analyzing each time point individually by a two-way ANOVA 
illustrates that the TRPM7 KO mutant displays a significant (p<0.05) reduction of COX activity from 
time point 17 min 55 s respectively highly significant reduction (p<0.01) from time point 20 min until the 
end of the measurement in comparison to WT. 
As both illustrations, Figure 6.12A and B, demonstrate that the TRMP7 KO shows no increase in 
fluorescence over time, I conclude that depletion of TRPM7 almost fully extinguishes COX activity in the 
HAP1 cells. To further investigate how the two COX family members COX-1 and COX-2 contribute to 



































Figure 6.12 COX-2 activity in HAP1 TRPM7 WT and KO cells. Basal cyclooxygenase (COX) 
enzymatic activity in HAP1 cell lysates was measured via conversion of the substrate arachidonic acid 
to a fluorescent substance (λexcitation = 535 nm, λemission = 587 nm; n=4); the resulting increase in 
fluorescence was measured every 25 s for 30 min. (A) Increase in fluorescence (resembling COX 
activity) over time in the DMSO-treated HAP1 TRPM7 WT and KO cells. Data are displayed as relative 
fluorescence units (RFU, raw data) plotted versus time. Note that, despite the very high fluorescent 
background signal recorded for both genotypes, the TRPM7 WT cells clearly display an increase in 
fluorescence and thus COX activity over time, while the signal in the TRPM7 KO cells does not 
substantially change. (B) Total increase in fluorescence resembling COX activity over time in the HAP1 
TRPM7 WT and KO cells. To exclude larger variances between the individual experiments (n), 
fluorescent background signal were subtracted from every time point of the measurement for each 
trace individually before averaging and calculating the statistics. The resulting kinetics are displayed as 
ΔRFU and plotted versus time. As in (A), the KO shows diminished COX activity in comparison to WT, 
as the kinetic displays no increase in fluorescence. Statistics reveal that, when comparing the 
respective monitored fluorescence of the TRPM7 WT and KO samples for each time point separately, 
COX activity is significantly attenuated in the HAP1 TRPM7 KO cells from time point 17 min 55 sec 
(indicated by the bar, *) respectively highly significantly attenuated from time point 20 min (indicated by 
the bar, ***) until the end of the measurement. (C) Effect of the inhibition of COX-1 respectively COX-2 
on the fluorescent increase resembling COX activity monitored for the HAP1 TRPM7 WT cells. To 
analyze if the observed increase is indeed COX related and to further specify which of the two COX 
isoforms, COX-1 and/or COX-2, is responsible for substrate conversion in the HAP1 cells, two different 
inhibitors specific for COX-1 (SC-560) and COX-2 (Celecoxib) were applied; inhibitor-treated samples 
were compared to samples treated with DMSO as solvent-control. Analogues to (B), data was 
evaluated by subtracting the fluorescent background signals from every time point of the measurement 
for each experiment individually before averaging and calculating the statistics; the resulting kinetics 
are displayed as ΔRFU and plotted versus time. The illustration shows that both the COX-1 and the 
COX-2 inhibitor affect COX activity by attenuating the increase in fluorescence in comparison to 
DMSO. Thus, both COX-1 and COX-2 seem to contribute to substrate conversion in HAP1 TRPM7 WT 
cells, and conclusively, depletion of TRPM7 affects both COX isoforms. Data are presented as mean ± 





the observed increase in fluorescence resembling substrate conversion in the HAP1 TRPM7 WT cells and 
thereby also conclude which of these two isozymes is affected by the depletion of TRPM7, I applied the 
two inhibitors SC-560 and Celecoxib (supplied with the assay) specifically blocking COX-1 (SC-560) and 
COX-2 (Celecoxib) [278, 279]. As both substances were dissolved in DMSO, the solvent (used in the 
same dilution as applied for the inhibitors, 2 %) was added to the control samples containing no inhibitor. 
Again, fluorescence was measured every 25 s for 30 min after initialization of the reaction by arachidonic 
acid administration. Analogous to Figure 6.12B, raw data were evaluated by subtracting the background 
signal (RLUt0) of each trace for every sample (WT DMSO, WT + COX-1 inh., WT + COX-2 inh.) 
individually before calculating the means and the statistics; the resulting kinetics are displayed in Figure 
6.12C. Despite the partly high errors of the DMSO-, COX-1 inhibitor- and COX-2 inhibitor-treated 
samples, Figure 6.12C shows that, in comparison to DMSO, both inhibitors diminish the total increase in 
fluorescence and thus COX activity observed for the HAP1 TRPM7 WT cells to almost the same extent. 
Statistically analyzing the data via a two way ANOVA this time comparing the means of all time points of 
the DMSO-, the COX-1 inhibitor- and the COX-2 inhibitor-treated WT samples demonstrates that both 
the COX-1 and the COX-2 inhibitor highly significantly (p<0.01) attenuate the fluorescent increase 
(significance not shown). Thus, I conclude that the observed increase in fluorescence in the DMSO-
treated WT samples is attributable to both isozymes. Linking this result to the finding that the HAP1 
TRPM7 KO mutant almost shows no substrate conversion (see Figure 6.12A and B), I hypothesize that 
the depletion of TRPM7 significantly diminishes the enzymatic activity of both COX-1 and COX-2. 
Associating these results with the previous findings for COX-2, I conclude that TRPM7 is not only 
essential for controlling COX-2 gene expression but also significantly affects COX-2 enzymatic activity.” 
6.1.9 Effect of TRPM7 on the induction of COX-2  gene expression 
One difference between the cyclooxygenases 1 and 2 is that COX-1 is constitutively present in most 
organs, while COX-2 synthesis, showing low to no expression in most tissues, is induced by various 
factors including hormones, growth factors, bacterial endotoxins and cytokines [280-282]. However, 
defining COX-2 as the ‘inducible’ isoform, which is still a widespread habit, is not absolutely correct, since 
the enzyme is at least constitutively expressed in some organs (kidney, brain, gastro-intestinal tract) [283-
285]. Nevertheless, activation of COX-2 gene expression resembles a critical mechanism in many 
inflammatory processes, wherefore I chose to investigate if TRPM7 is involved in inducible COX-2 
mRNA production. As HAP1 cells do not display the surface receptors such as toll-like receptor 4 (TLR4) 
[286] established for proper activation of COX-2 mRNA synthesis (demonstrated by a non-official 
genomic analysis of Horizon Discovery, Cambridge, UK; not shown), I chose forskolin as stimulus [214]. 
This natural compound stimulates adenylyl cyclase which in turn converts ATP to the second messenger 





exposed to 0.1 % DMSO – which served as drug diluent and was therefore applied in the same dilution as 
forskolin – or left untreated to uncover potential DMSO-dependent, TRPM7-unspecific effects on COX-
2 gene expression.     
HAP1 TRPM7 WT and KO cells were either stimulated with 50 µM forskolin, incubated with 0.1 % 
DMSO or left untreated for one hour. Inducible COX-2 expression was subsequently analyzed via mRNA 
quantification using RT-qPCR as before (also see 6.1.7). Also here, COX-2 data of untreated, DMSO-
exposed and forskolin-treated samples were normalized to the housekeeping gene HPRT1 (shown as        
2(-ΔCP)).  
In comparison to DMSO, stimulation with 50 µM forskolin significantly increases COX-2 mRNA levels 
in the HAP1 TRPM7 WT cells around threefold (DMSO: ~0.0033, forskolin: ~0.010, Figure 6.13). In 
contrast, forskolin treatment causes only a slight, but not significant increase of the initial low COX-2 
mRNA concentration in HAP1 TRPM7 KO cells when compared to DMSO (DMSO: ~0.0006, 
forskolin: ~0.002, Figure 6.13). Hence, forskolin indeed significantly stimulates COX-2 mRNA 
production and thus induces COX-2 gene expression in HAP1 TRPM7 WT, but not KO cells. Moreover, 
direct comparison of the forskolin-treated HAP1 TRPM7 WT and KO clone reveals that TRPM7 
facilitates this inducible COX-2 mRNA synthesis, as the forskolin-triggered augmentation of COX-2 
mRNA levels is about five times higher in WT than in KO (WT: ~0.010 compared to KO: 0.002, Figure 
6.13). Importantly, although comparison of the untreated and DMSO-exposed control samples 
demonstrates that one hour incubation with 0.1 % DMSO minimally increases COX-2 mRNA levels in 
both HAP1 TRPM7 WT and KO clone (Figure 6.13), this change is not significant. Consequently, one 
can conclude that DMSO has no substantial impact on COX-2 gene expression.   






























Figure 6.13 Inducible COX-2 mRNA expression in HAP1 TRPM7 WT and KO cells. Relative 
expression of COX-2 mRNA (measured via RT-qPCR) in HAP1 TRPM7 WT and KO cells stimulated with 
50 µM forskolin or treated with DMSO as control for 1 h (n=4). For analysis, the particular signals were 
normalized to the reference gene HPRT1. Treatment with forskolin substantially increases COX-2 mRNA 
expression in HAP1 TRPM7 WT cells, while COX-2 gene induction is significantly less pronounced in the 













6.2 Role of the TRPM7 kinase domain in the cell signaling 
pathways  
To understand if and to what extent the TRPM7 kinase is involved in Akt, GSK3β, NFAT and COX-2 
directed signaling cascades, I utilized the novel kinase-dead HAP1 mutant cell model. As introduced 
above, the HAP1 TRPM7 KI clone carries a point mutation at the active site of the kinase (K1648R) 
depleting kinase activity. Hence, this cell line provides a suitable tool to precisely discriminate TRPM7 
protein vs. kinase activity-specific functions.  
6.2.1 Characterization of the kinase-dead HAP1 TRPM7 KI clone  
Initially, the mutant HAP1 TRPM7 KI cells had to be analyzed analogously to the HAP1 KO clone (see 
6.1.1). The correct insertion of the kinase inactivating point mutation was first examined by alignment of 
HAP1 TRPM7 WT and KI cDNA sequences. As mentioned in the methods (see 5.1.1.1), kinase activity 
is depleted by replacing lysine (K) to arginine (R) at position 1648 located within the enzymatic pocket of 
the kinase domain (K1648R). Therefore, the respective lysine-coding base triplett (AAA) was exchanged 
to an arginine-coding one (CGG). Sequencing of the HAP1 TRPM7 WT and KI cDNA illustrates that 
the genetic mutation was successful (Figure 6.14A); furthermore, computational translation (via Expasy 
Translate Tool) of the mutated genetic sequence into the corresponding protein sequence demonstrates 
that the nucleotide substitution results in the anticipated exchange of lysine to arginine (Figure 6.14B). For 
proving that the mutation at the catalytic site of the kinase is indeed causing its inactivation, Western Blot 
technique was applied. As only a few targets of the TRPM7 kinase are known yet (also see introduction, 
3.2.2.2), I chose a polyclonal antibody kindly provided by Dr. Chubanov (Walther-Straub-Institute, LMU 
Munich) which binds to the phosphorylated TRPM7-autophosphorylation site Ser1511 [75]. In HAP1 
TRPM7 WT cells displaying intact autophosphorylation, this antibody should detect the Ser1511-
phosphorylated form of TRPM7 and thus show a band at approx. 220 kDa (molecular weight of full-
length TRPM7). If kinase enzymatic function is indeed depleted in the TRPM7 KI clone, TRPM7 
autophosphorylation is disrupted and the anti-TRPM7 pSer1511 antibody should not bind, which is 
reflected by lack of the corresponding signal. To additionally validate phospho-specifity of this antibody 
and thus verify the TRPM7 Ser1511 phosphorylation signal, half of the HAP1 TRPM7 WT and KI cell 
lysates were additionally treated with an alkaline phosphatase (in specific: FastAP Thermosensitive 
Alkaline Phosphatase, Thermo Fisher Scientific, USA) and subsequently compared to the untreated WT 
and KI samples. This enzyme ensures the rapid dephosphorylation of proteins and thus can be used to 
distinguish between phospho-specific and phospho-unspecific bands resulting from potential antibody 





The Western Blot shown in Figure 6.15A illustrates that the phospho-specific anti-TRPM7 pSer1511 
antibody labels a protein band at 220 kDa (molecular mass of full-length TRPM7) in the HAP1 
TRPM7 WT cells (Figure 6.15A, first left lane). However, the respective signal is missing in the 
TRPM7 KI clone (Figure 6.15A, second left lane) as well as in the phosphatase-treated WT and KI 
samples (Figure 6.15A, right lanes). This indicates that the detected band in the WT indeed represents 
Ser1511-phosphorylated full-length TRPM7, and the result is substantiated by the absence of the 
corresponding signal in the phosphatase-treated sample. Thus, my results confirm that the TRPM7 KI 
cells indeed lack kinase activity.  
Next, it was essential to clarify if kinase inactivation affects channel conductivity. This is of special 
importance since it was previously published that modifications regarding the kinase domain can alter 
channel conductivity (also see introduction, 3.2.4) [34, 36, 98]. Although K1646R-caused kinase disruption 
in mice, which is identical to the here inserted human mutation K1648R, did not change properties of the 
TRPM7 channel [83, 117, 118], this finding needed to be reaffirmed for the human TRPM7 KI cell line.  
A
B
Amino Acid Sequence HAP1 TRPM7 WT
Met R L S Q S I P F T P V P P R G E P V T V Y R L E E S S P N I L N N 
S Met S S W S Q L G L C A K I E F L S K E E Met G G G L R R A V K V Q 
C T W S E H D I L K S G H L Y I I K S F L P E V V N T W S S I Y K E D 
T V L H L C L R E I Q Q Q R A A Q K L T F A F N Q Met K P K S I P Y S 
P R F L E V F L L Y C H S 
Amino Acid Sequence HAP1 TRPM7 KI
Met R L S Q S I P F T P V P P R G E P V T V Y R L E E S S P N I L N N 
S Met S S W S Q L G L C A K I E F L S K E E Met G G G L R R A V K V Q 
C T W S E H D I L K S G H L Y I I R S F L P E V V N T W S S I Y K E D 
T V L H L C L R E I Q Q Q R A A Q K L T F A F N Q Met K P K S I P Y S 
P R F L E V F L L Y C H S  
Alignment sequenced HAP1 TRPM7 cDNA
WT       ACATGATATCCTCAAATCAGGGCATCTTTATATTATCAAATCTTTTCTTCC   
         |||||||||||||||||||||||||||||||||||||   ||||||||||| 
KI       ACATGATATCCTCAAATCAGGGCATCTTTATATTATCCGGTCTTTTCTTCC   
Figure 6.14 Verification of the HAP1 TRPM7 KI clone. (A) Alignment of sequenced wild-type (WT) and 
TRPM7 knock-in (KI) cDNA. For direct comparison of HAP1 TRPM7 WT and KI genetic sequences, 
mRNA of both cell clones was extracted, translated into cDNA and the respective altered region 
subsequently sequenced by Eurofins Genomics (with primers flanking the site of mutation). Extracted 
section shows the kinase inactivating base triplett exchange of the three nucleotides coding for lysine 
(AAA) to arginine (CGG) (B) Amino Acid (AA) sequences of the TRPM7 WT and KI clone resulting from 
the mRNA transcript (corresponding cDNA sequence partially shown in (A)). Note the substitution of 





Therefore, TRPM7 currents of HAP1 TRPM7 WT and KI cells were measured via the whole-cell patch 
clamp technique (for more detailed description, see 6.1.1 or methods, 5.4). Overall comparison of the 
HAP1 TRPM7 KI clone with WT reveals that neither kinetics nor the amplitude of the TRPM7 current is 
significantly altered (Figure 6.15B). Intriguingly, data suggest that the HAP1 TRPM7 KI displays a higher 
basal current density than WT (see beginning of the measurement; WT: 3.17 pA/pF compared to KI: 
7.28 pA/pF) and a slower and less steep current development over time; however, these differences are 
not significant (Figure 6.15B, left panel). Furthermore, traces at 150 s show the same current-voltage 
relationship for HAP1 TRPM7 WT and KI cells (Figure 6.15B, right panel). Overall, the presented data 
suggest that kinase depletion does not significantly change basic channel parameters of TRPM7 in the 
human HAP1 cell line, which is in accordance with the results acquired for the K1646R mutation in mice 
[117, 118]. Thus, the K1648R mutation inactivates the TRPM7 kinase domain without altering channel 
conductance, wherefore the HAP1 TRPM7 KI cells present a suitable tool to closer examine TRPM7 
kinase activity function independently of the TRPM7 channel.   
6.2.2 Impact of the TRPM7 kinase activity on ion homeostasis 
Despite the registered intact function of the channel in the HAP1 TRPM7 KI clone (see Figure 6.15B, 
channel conductance), inactivation of the kinase could potentially alter cellular ion homeostasis indirectly 
by other mechanisms [119, 138, 291, 292]. To address this question, cell lysates of the kinase-dead mutant 
were analyzed via ICP-MS identical to the KO mutant (see 6.1.2). With regard to TRPM7’s described 





































Figure 6.15  Characterization of the HAP1 TRPM7 KI clone. (A) Western Blot image of untreated (left) 
and phosphatase-treated (serving as control, right) HAP1 TRPM7 WT and KI lysates stained for the 
autophosphorylation site Ser1511. Note that the corresponding signal visible for the TRPM7 WT is 
missing in the TRPM7 KI clone (left lanes) as well as in the phosphatase-treated samples (right lanes). 
Loading control: LaminB1 (65 kDa). (B) Functional analysis of TRPM7 currents in HAP1 TRPM7 WT 
(black) and KI (blue) cells by patch clamp experiments (n=5-8). Measurements were conducted in the 
whole-cell configuration in the absence of extra- and intracellular Mg2+ to maximize TRPM7 currents. 
Current densities at +80 and -80 mV are plotted vs. time in seconds (left panel) and representative 
current-voltage relationships of traces extracted at 150 s are presented (right panel). Although TRPM7 
current kinetics are slightly altered in HAP1 TRPM7 KI cells compared to WT, current development over 





evaluated by normalizing the values of each ion to sulfur (S) (Figure 6.16, left panels) and by calculating 
the KI data in percent of WT (set to 100 %, Figure 6.16, right panels).   
Other than the HAP1 TRPM7 KO cells (see 6.1.2), the HAP1 TRPM7 KI cells do not reveal any changes 
regarding these four divalent cations: As illustrated in Figure 6.16, kinase activity neither affects Mg2+ 
(Figure 16A) nor Ca2+ homeostasis (Figure 6.16B) in a significant manner. Likewise, also levels of the trace 
elements Zn2+ and Cu2+ are the same for both the HAP1 TRPM7 KI and WT clone (Figure 6.16C and D). 
Thus, one can conclude that kinase depletion does not interfere with intracellular ion homeostasis in 
resting HAP1 cells.  
However, due to the above-mentioned sensitivity of intracellular Ca2+ measurements to 
contamination by residual external Ca2+ (see 6.1.2), Ca2+ concentrations in the HAP1 TRPM7 KI 
clone were additionally acquired via the ratiometric Fura-2 AM based Ca2+ imaging technique 
analogously to the previous experiments with the KO-mutant form (see 6.1.2). Comparing the 
340/380 nm ratios of TRPM7 WT and KI shows that kinase-inactivation does not change basal 























































































Figure 6.16 Ion levels in HAP1 TRPM7 WT and KI cells. Concentrations of (A) Mg2+, (B) Ca2+, (C) Zn2+ 
and (D) Cu2+ measured via ICP-MS in resting HAP1 TRPM7 WT (black) and TRPM7 KI (blue) cells (n=4). 
Concentrations are displayed as raw data (counts of respective ion in ppm, normalized to counts of sulphur 
(S) in ppm, left panels) as well as normalized to WT for direct comparison (set to 100 % right panels). Both 
evaluations reveal no alterations regarding concentration of investigated ions in the HAP1 TRPM7 KI clone 






consistent with the ICP-MS results regarding Ca2+ and thus substantiates the hypothesis that TRPM7 
kinase activity is not altering basal Ca2+ levels in HAP1 cells.  
6.2.3 Regulation of COX-2  gene expression by TRPM7 kinase 
activity in HAP1 cells 
As COX-2 is essential for controlling the immune response but also promotes tumor progression (see 
6.1.8 and 6.1.9, respectively), it is important to understand whether the observed differences in the 
COX-2 gene expression in the TRPM7-deficient HAP1 cells are due to the lack of TRPM7 kinase 
activity. Therefore, I examined if COX-2 mRNA levels are affected by impairment of the TRPM7 
kinase function. Since COX-2 in some organs is constitutively expressed whereas in other systems it 
is induced by specific signals (e.g. LPS [293]), RT-qPCR experiments were performed to compare 
COX-2 mRNA concentrations of resting HAP1 TRPM7 WT and KI cells as well as upon increasing 
cAMP production caused by forskolin stimulation (analogously to the previous experiments, see 6.1.7 
and 6.1.9) [280-285, 287]. 
6.2.3.1 Impact of TRPM7 kinase activity on constitutive COX-2  gene 
expression 
To properly analyze COX-2 gene expression via its mRNA concentration, RT-qPCR WT and KI COX-2 
mRNA data were normalized to the housekeeping gene HPRT1 and expressed as relative COX-2 
expression (2(-ΔCP)). The evaluation reveals a substantial reduction of COX-2 mRNA concentration in the 
HAP1 TRPM7 KI clone when compared to WT (Figure 6.18). In comparison to the WT, the COX-2 
mRNA level is significantly decreased in the TRPM7 KI clone when data are referenced to HPRT1 (WT: 
















Figure 6.17 Single cell analysis of internal calcium concentration in HAP1 TRPM7 WT and KI 
cells. Ca2+ levels in resting HAP1 TRPM7 WT and KI cells acquired via ratiometric Fura-2 AM based 
Ca2+ imaging (n=10-22). Ca2+ concentrations are displayed as ratio of fluorescence at 340 and 380 nm. 
Intracellular Ca2+ concentration is about the same in HAP1 TRPM7 WT and KI cells. Data are presented as 





6.2.3.2 Impact of TRPM7 kinase activity on inducible COX-2  gene expression 
Similar to the previously described experiments, COX-2 mRNA synthesis in the HAP1 cells was 
stimulated by addition of 50 µM of the adenylyl cyclase activator forskolin to fresh culture medium 
followed by an one hour incubation. In addition, cells were either incubated with 0.1 % DMSO (drug 
diluent, applied in the same concentration as forskolin) for one hour or left untreated; both of theses 
samples served as controls (also see 6.1.9). Data evaluation was accomplished by normalization of raw 
data to the housekeeping gene HPRT1 (shown as 2(-ΔCP)).  
First of all, in comparison to the respective DMSO samples, forskolin treatment significantly enhances 
COX-2 mRNA production in HAP1 WT cells (from ~0.001 to ~0.005), whereas it has a smaller, but still 
significant effect on HAP1 TRPM7 KI cells (from ~0.0009 to ~0.003, Figure 6.19). Thus, forskolin 
indeed induces COX-2 gene expression in both HAP1 TRPM7 WT and KI cells. However, direct 
comparison of the forskolin-treated WT and KI samples illustrates that the induced COX-2 mRNA 
synthesis in HAP1 TRPM7 KI clone is only about 60 % as much as in WT (WT: ~0.005, KI: ~0.003, 
Figure 6.19). Furthermore, the control samples reveal that DMSO has no effect on COX-2 gene 
expression in both investigated TRPM7 genotypes since there are no significant differences between the 
COX-2 mRNA concentrations of the respective untreated and DMSO-exposed samples (Figure 19).  
When comparing the HAP1 TRPM7 KI results to the results acquired for the TRPM7 KO clone, it 
becomes evident that the repressive effect of the TRPM7 kinase inactivation on inducible COX-2 gene 
expression is less pronounced as the one caused by depletion of the full-length protein; while HAP1 
TRPM7 KI cells display about 60 % as much COX-2 mRNA as WT upon forskolin stimulation (Figure 
























Figure 6.18 Constitutive COX-2 mRNA expression in HAP1 TRPM7 WT and KI cells. COX-2 
mRNA expression (measured via RT-qPCR) in resting HAP1 TRPM7 WT and KI cells (n=8-10). For 
analysis, the particular signals were first normalized to the reference gene HPRT1 and then presented as 
relative COX-2 expression (2(-ΔCP)). Note a significant reduction in COX-2 expression in HAP1 TRPM7 KI 






The results lead to the conclusion that the activity of the TRPM7 kinase has a significant impact on both 
constitutive as well as inducible COX-2 gene expression. As described above, COX-2 gene expression is 
directly controlled by the transcription factor NFAT (also see 6.1.7). Interestingly, results showed that 
NFAT nuclear localization as well as transcriptional activity is altered upon depletion respectively 
overexpression of full-length TRPM7 (see 6.1.4 and 6.1.5). Thus, the intact TRPM7 kinase might 
potentiate COX-2 gene expression by facilitating NFAT nuclear localization and NFAT-dependent 
transcription. To assess if TRPM7 kinase activity indeed modulates these NFAT parameters, I utilized 
antibody-directed detection of NFAT in Western Blot for investigating NFAT nuclear localization (in 
HAP1 TRPM7 KI cells) as well as the dual-luciferase reporter gene assay for studying NFAT 
transcriptional activity (in HEK-293 cells overexpressing a TRPM7 KI construct).   
6.2.4 Effect of TRPM7 kinase activity on subcellular NFAT 
localization  
Equivalent to the experiments with the HAP1 TRPM7 KO cells (see 6.1.4), I next examined the basal 
nuclear localization of NFATc1 in the HAP1 TRPM7 KI clone via immunoelectrophoresis. Again, the 
signal intensities were measured via ImageJ, the results normalized to the corresponding loading controls 
(LaminB1 and GAPDH) and the TRPM7 KI data were subsequently calculated in percent of WT (set to 






























Figure 6.19  Inducible COX-2 mRNA expression in HAP1 TRPM7 WT and KI cells. Relative COX-2 
mRNA expression (measured via RT-qPCR) in HAP1 TRPM7 WT and KI cells stimulated with 50 µM 
forskolin or treated with DMSO as control for 1 h (n=4-5). For analysis, the particular Cp values were 
normalized to the reference gene HPRT1. Treatment with forskolin significantly increases COX-2 mRNA 
expression in both HAP1 TRPM7 WT and KI cells, yet the increase is less distinct in the KI wherefore the 
mutant significantly differs from WT. Data are presented as mean ± s.e.m. Statistics: two-way ANOVA ### 





The representative Western Blot results shown in Figure 6.20A depict that, in contrast to the KO clone, 
lack of TRPM7 kinase activity does not influence the nuclear localization of NFATc1 in resting cells. Both 
the nuclear and the cytosolic level do not significantly differ in the HAP1 TRPM7 KI cells when 
compared to WT fractions (Figure 6.20A respectively B). The additional control regarding the total 
expression of NFATc1 via whole-cell lysates shows that total NFATc1 levels are about the same in 
TRPM7 WT and KI cells (Figure 6.20C). 
So far, the results suggest that the TRPM7 kinase activity is not linked to basal subcellular NFATc1 
distribution. However, whether transcription of NFATc1 is affected by kinase inactivation is not clear. 
Therefore, I proceeded with the above described dual-luciferase reporter gene assay (see 6.1.5) to 













































































Figure 6.20 Subcellular NFATc1 translocation in resting HAP1 TRPM7 WT and KI cells. 
Representative Western Blot images and statistical analysis of NFATc1 in (A) the nucleus and (B) the 
cytosol in resting HAP1 TRPM7 WT and KI cells (n=5-10). For statistical analysis, signal intensities of 
both family members were normalized to their corresponding nuclear (LaminB1) or cytosolic (GAPDH) 
loading control; subsequently, HAP1 TRPM7 KI values were calculated as percent of WT (set to 100 
%). Neither nuclear nor cytosolic concentration of NFATc1 of the HAP1 TRPM7 KI significantly differs 
from WT. (C) Representative Western Blot image and quantification analysis regarding the total 
concentration of NFATc1 in whole-cell RIPA lysates of resting HAP1 TRPM7 WT and KI cells (KI 
expressed as percent of WT). Consistent with the data presented in (A) and (B), total NFATc1 level is 
about the same in HAP1 TRPM7 WT and KI cells. Data are presented as mean ± s.e.m. Statistics: paired 






6.2.5 Regulatory effect of TRPM7 kinase on NFAT-dependent gene 
expression 
Again, when starting to investigate NFAT transcriptional activity via the above introduced dual-luciferase 
reporter gene assay (see 6.1.5), I faced the problem of the HAP1 cells being difficult to transfect. Hence, 
analogues to the experiments with the TRPM7 KO clone (see 6.1.5), I conducted the dual-luciferase 
reporter gene assay in HEK-293 cells overexpressing the murine TRPM7 KI construct carrying the kinase 
inactivating point mutation K1646R which is analogous to the K1648R mutation present in the HAP1 
TRPM7 KI cell line.  
6.2.5.1 Effect of the TRPM7 kinase-dead mutant on NFAT-dependent gene 
expression using the dual-luciferase NFAT-reporter gene assay in 
transiently transfected HEK-293 cells  
Initially, the effect of the TRPM7 kinase activity on NFAT-dependent gene expression was tested using 
transient overexpression; accordingly, HEK-293 cells were co-transfected with the NFAT firefly luciferase 
reporter gene and the expression control luciferase Renilla (for more details see 6.1.5), and in addition, 
either the control vector pcDNA3.1 (‘mock’) or the GFP-tagged TRPM7 kinase-inactivated construct 
carrying the point mutation K1646R (herein named TRPM7 KI) was inserted. Data were normalized by 
relating the firefly luciferase signal to the Renilla luciferase signal and TRPM7 KI values were subsequently 
calculated as percent of mock (set to 100 %). Figure 6.21A illustrates that the expression of kinase-
mutated TRPM7 does not significantly alter NFAT transcriptional activity in HEK-293 cells when 
compared to the control. Direct comparison of this result to the data acquired for the overexpression of 
TRPM7 WT protein in the dual-luciferase reporter gene assay (see 6.1.5.1) reveals that kinase inactivation 
significantly impacts the TRPM7 overexpression-promoted NFAT transcriptional activity which was 
previously reported herein (Figure 6.21D). While TRPM7 WT overexpression augments NFAT-
dependent gene expression about ~17 % in HEK-293 cells, TRPM7 KI overexpression has no effect 
(Figure 6.21D) in comparison to to mock. Accordingly, it seems that TRPM7-directed upregulation of 















































































































































































Figure 6.21 NFAT transcriptional activity in TRPM7 WT or KI overexpressing HEK-293 cells. (A) 
NFAT transcriptional activity in transiently transfected HEK-293 cells co-expressing the NFAT firefly 
luciferase reporter (500 ng) and the Renilla luciferase control vector (50 ng) together with 400 ng 
pcDNA3.1 as control (‘mock’, grey) or TRPM7 KI protein ([TRPM7 KI], blue, displayed as percent of 
mock, n=5). (B) NFAT transcriptional activity in the stable HEK-NFAT cell line transiently co-expressing 
pcDNA3.1 as control (‘mock’) or TRPM7 KI protein ([TRPM7 KI], displayed as percent of mock, n=19). 
Amount of transfected TRPM7 KI DNA ranged from 100-1000 ng and was complemented by pcDNA3.1 
DNA if necessary to reach a DNA amount of 1000 ng total. (C) NFAT transcriptional activity plotted as 
function of TRPM7 KI expression in the stable HEK-NFAT cell line (n=19). TRMP7 KI data were 
normalized to the control (‘mock’, set to 100 %) and subsequently, NFAT activity of the control (which 
equals 100%) was subtracted from the resulting TRPM7 KI NFAT activity values. Thus, TRPM7-
dependent increase in NFAT activity is expressed as ‘Δ above mock in %’. Amount of transfected 
TRPM7 KI DNA ranged from 100-1000 ng and was complemented by pcDNA3.1 DNA if necessary to 
reach a DNA amount of 1000 ng total. NFAT activity is displayed as RLU of the firefly luciferase 
substrate oxyluciferin (λmax = 560 nm), and KI data are normalized to mock (set to 100 %). TRPM7 
expression is displayed as RLU of GFP (λmax = 509 nm). While ineffective in the transient HEK-293 NFAT 
reporter cells, mutant TRPM7 overexpression in stable HEK-NFAT cells slightly but significantly elevates 
NFAT activity in comparison to mock (A and B). Furthermore, NFAT-dependent gene transcription is 
minimal augmented with increasing TRPM7 expression levels (C). (D-E) Direct comparison of NFAT 
transcriptional activity induced by TRPM7 WT and KI overexpression in (D) transiently transfected HEK 
cells and (E) the stable HEK-NFAT cell line (merged from Fig. 6.8 and 6.21A and B, displayed as percent 
of mock). (F) Comparison of the concentration-dependent increase in NFAT activity induced by TRPM7 
WT or KI overexpression in stable HEK-NFAT cells (merged from Fig. 6.8 and 6.21C). Statistical analysis 
shows that TRPM7 kinase-inactivation significantly decreases TRPM7-induced NFAT-dependent gene 
expression in both transient and stable HEK-293 NFAT reporter cells (D and E). Comparison of the slope 
describing the TRPM7 concentration dependence of NFAT activity is approximately ten times higher for 
the TRPM7 WT (0.0158) than for the TRPM7 KI (0.0018) construct (F), substantiating a role for the 
kinase domain in NFAT-dependent gene expression in HEK-293 cells. Data are presented as mean ± 





6.2.5.2 Effect of the TRPM7 kinase-dead mutant on NFAT-dependent gene 
expression in a stable HEK-293 reporter cell line  
As mentioned above, performing the dual-luciferase reporter gene assay in transiently transfected cells 
necessitates a control measuring the general gene expression rate (here: Renilla luciferase), which is 
predominantly dependent on cell number and transfection rate (see 6.1.5). To be able to exclude this 
additional control, make measurements more consistent and thus verify the obtained results, the NFAT 
firefly luciferase reporter gene assay was repeated in the herein generated stable HEK-NFAT reporter cell 
line overexpressing either the control vector pcDNA3.1 (‘mock’) or kinase-inactivated TRPM7 (see 
6.1.5.2). For analysis, TRPM7 KI data were calculated as percent of mock (set to 100 %).  
Surprisingly, introduction of enzymatically inactive TRPM7 in the stable HEK-NFAT reporter cell line 
only slightly but significantly increases NFAT transcriptional activity by about 13 % (Figure 6.21B). 
Furthermore, this effect is concentration-dependent, as elevated TRPM7 KI expression – measured via 
the GFP signal – directly correlates with a raise in NFAT-induced gene expression (Figure 6.21C). 
However, direct comparison of the results acquired for TRPM7 WT (see 6.1.5.2) vs. TRPM7 KI 
overexpression in the HEK-NFAT reporter cell line reveals that the promotion of NFAT-dependent 
gene expression by TRPM7 is significantly reduced upon kinase depletion (Figure 6.21E); thus, 
overexpression of the TRPM7 WT protein increases NFAT transcriptional activity by about 45 % (in 
comparison to mock, not shown here), whereas TRPM7 KI protein overexpression elevates NFAT-
dependent gene expression only by about 13 % (in comparison to mock, not shown here) in HEK-NFAT 
reporter cells (Figure 6.21E). In addition, correlation of the TRPM7 expression level and NFAT-
dependent gene expression which is reflected by the slopes in Figure 6.21F proves to be much higher for 
TRPM7 WT-transfected than in TRPM7 KI-transfected HEK-NFAT reporter cells (WT: 0.0158, KI: 
0.0018).  
While the experiments using transient transfection of HEK-293 cells suggest that the kinase function is 
required for the TRMP7-dependent enhancement of NFAT transcriptional activity, the results acquired 
with the stable HEK-NFAT cell line indicate that the kinase participates in, but not exclusively controls 
this TRPM7-directed NFAT transcriptional activation. As mentioned before, NFAT is directly activated 
by increasing cytosolic Ca2+ concentrations (see 6.1.5) [253]. Consequently, the observed increase in 
NFAT-dependent gene expression induced by the TRPM7 KI mutant (see 6.2.5.2) might be due to an 
enhanced Ca2+ influx through the functional TRPM7 channel. Potential differences in cytosolic Ca2+ 
concentrations could also explain the differential outcomes regarding NFAT nuclear localization (see 
6.2.4) in HAP1 TRPM7 KI cells and NFAT transcriptional activity (see 6.2.5) in TRPM7 KI 
overexpressing HEK-NFAT reporter cells. Hence, I next determined the Ca2+ concentrations in TRPM7 





6.2.6 Impact of TRPM7 kinase activity on Ca2+ homeostasis in HEK-
G5α cells  
Congruent to the previously described experiments (see 6.1.6), basal Ca2+ levels in HEK-293 cells were 
obtained with the HEK-G5α cell line stably expressing the Ca2+-binding protein apoaequorin fused to 
GFP introduced above (see 6.1.6). By CRET from Ca2+-bound apoprotein to GFP, these cells allow 
relative sensitive measurements of internal Ca2+ concentrations (for more details, see 6.1.6).  
Figure 6.22A depicts that transient overexpression of the kinase-dead TRPM7 mutant (TRPM7 KI) 
has no significant impact on the internal Ca2+ concentration in comparison to the control vector 
pcDNA3.1 (‘mock’) (Figure 6.22A). Direct comparison of this result obtained for the kinase-dead 
TRPM7 mutant to the results acquired for TRPM7 WT (see 6.1.6) demonstrates that TRPM7 kinase 
activity is required for TRPM7-induced increase in intracellular Ca2+ (Figure 6.22B); while the Ca2+ 
concentration is not (substantially) altered in TRPM7 KI overexpressing HEK-G5α (in comparison to 
mock, not shown), overexpression of TRPM7 WT significantly raises Ca2+ levels by almost 22 % (in 
comparison to mock, not shown) (Figure 6.22B). 
Assuming that in HEK-293 cells the TRPM7-induced effect on NFAT-dependent gene expression is 
conducted through Ca2+ as hypothesized (see 6.1.5), this result is in agreement with the inactivated 
kinase showing no increase in NFAT transcriptional activity in transient overexpression experiments 
(see 6.2.5.1). However, it contradicts the slight but significant augmentation of NFAT activity 












































Figure 6.22 Basal Ca2+ levels in TRPM7 WT or KI overexpressing HEK-G5α cells. (A) Ca2+ 
concentration in mock-transfected (grey) or TRPM7 KI-overexpressing (blue) HEK-G5α cells (n=8). Ca2+ 
concentration is illustrated as RLU of GFP (λmax = 509) and KI data were normalized to mock (set to 100 
%). Overexpression of the kinase-depleted TRPM7 protein does not change internal Ca2+ concentration 
in HEK-G5α cells. (B) Direct comparison of Ca2+ levels in TRPM7 WT or KI overexpressing HEK-G5α 
cells (merged from Figure 6.9 and 6.22, displayed as percent of mock). While TRPM7 WT 
overexpression significantly increases intracellular Ca2+ concentration in the HEK-G5α cell line in 
comparison to mock (not shown), TRPM7 KI overexpression has no effect regarding the intracellular 
Ca2+ level.  Data are presented as mean ± s.e.m. Statistics: paired and unpaired student’s t-test * p<0.05; 





Taken together, the results suggest that TRPM7’s kinase activity is required for Ca2+ homeostasis in HEK-
293 cells and thereby potentially controls NFAT-dependent gene expression.  
The finding that kinase activity is required for the TRPM7-directed rise in intracellular Ca2+ in HEK-
293 cells contradicts the experimental outcome of basal Ca2+ analysis in HAP1 TRPM7 KI cells (see 
6.2.2), where kinase depletion does not change intracellular Ca2+ concentrations (see 6.2.2). Thus, in 
contrast to HEK-293 cells, TRPM7 kinase activity shows to be dispensable for maintenance of basal 
internal Ca2+ levels in HAP1 cells.  
So far, the experiments lead to the conclusion that, although being redundant for basal Ca2+ 
homeostasis and NFATc1 nuclear localization, TRPM7 kinase activity is involved in COX-2 gene 
expression in HAP1 cells. Thus, the kinase-induced activation of COX-2 gene expression seems to 
occur independently from the transcription factor NFAT. Considering that the previous experiments 
in the HAP1 TRPM7 KO clone suggest that TRPM7 affects NFAT subcellular localization through 
promoting phosphorylation of the NFAT export kinase GSK3β (see 6.1.3), one would assume that the 
TRPM7 kinase inactivation has no impact on GSK3β phosphorylation either. Thus, to investigate this 
hypothesis and determine through which upstream signaling molecule(s) the TRPM7 kinase activity 
potentially regulates COX-2 gene expression, I next analyzed the phosphorylation status of Akt, GSK3β 
and ERK1/2 in the HAP1 TRPM7 KI mutant. 
6.2.7 Effect of the TRPM7 kinase activity on the phosphorylation of 
cell signaling proteins 
As Western Blot analysis via specific phospho-antibodies proofed to be suitable for visualization of Akt, 
GSK3β and ERK1/2 phosphorylation before (see 6.1.3), this technique was also applied for analysis of 
the TRPM7 kinase-dead HAP1 clone. Analogues to 6.1.3, cells were cultured with and without FBS for 
three hours, lysed and analyzed via Western Blotting and ImageJ. For data evaluation, phosphorylation 
signal intensities of the respective protein were normalized to the signal intensity of the loading control 
(either GAPDH or LaminB1) and subsequently the results acquired for the TRPM7 KI clone were 
calculated as percent of WT (set to 100 %).  Figure 6.23 illustrates that the kinase has differential effects 
on all three targets. At first sight, the Akt pSer473 Western Blot shows no alterations between the TRPM7 
WT and KI samples, which is mostly due to comparatively low signal intensities (Figure 6.23A, left panel). 
Evaluation of the bands via ImageJ yet reveals that Akt Ser473 phosphorylation in the HAP1 TRPM7 KI 
cells is, independently from FBS withdrawal, slightly reduced by ~11-13 % compared to WT (Figure 
6.23A, middle panel), but this reduction is only significant for the normally cultured but not for the serum-
starved cells (Figure 6.23A, middle panel). In contrast, kinase inactivation significantly enhances GSK3β 





cells however reveals that this effect is FBS-dependent, as there are no differences detectable between the 
mutated and wild-type HAP1 TRPM7 clone upon FBS withdrawal (Figure 6.23B, left and middle panel). 
Thus, in consideration of numerous potential off-target effects of FBS [207], I conclude that the TRPM7 
kinase is not involved in GSK3β phosphorylation at Ser9. The last signal transducer I examined was 
ERK1/2.  
Although visual analysis of the Western Blot images might suggest differences, statistical analysis via 




































































Figure 6.23 Basal phosphorylation levels of cell signaling molecules in HAP1 TRPM7 WT and KI cells. 
Representative Western Blot images (left panels) and statistical analysis (right panels) of (A) AKT pSer473 
(pAKT, 60 kDa), (B) GSK3β pSer9 (pGSK3β, 47 kDa) and (C) ERK1/2 pTyr204 (pERK, 42/44 kDa) in FBS-
treated (+) and untreated (-) HAP1 TRPM7 WT and KI cells (n=3-4). Band intensities of each phosphorylation 
signal was determined via ImageJ and normalized to the loading control LaminB1 (65 kDa). To cancel out 
larger variances between the individual experiments, KI values are calculated as percent of WT (set to 100 
%). Although not directly noticeable in the Western Blot images, statistical evaluation illustrates a significant 
reduction of pAKT (A) and a highly significant increase of pGSK3β (B) in FBS-treated HAP TRPM7 KI 
cells when compared to WT, whereas serum starved-samples reveal no differences regarding pAKT and 
pGSK3β between WT and KI samples (right panels). Also phosphorylation of ERK1/2 (C) is – 
independently of FBS treatment of the cells – the same in HAP1 TRPM7 WT and KI cells (right panels). 
Protein size is expressed in kDa. Data are presented as mean ± s.e.m. Statistics: paired student’s t-test * 





Tyr204 phosphorylation is altered in comparison to TRPM7 WT (Figure 6.23C, left and middle panel). 
Taken together, this indicates that the TRPM7 kinase is dispensable for ERK1/2 Tyr204 phosphorylation.    
In summary, the kinase domain seems to play a significant role in phosphorylation of Akt at Ser473 
phosphorylation but neither contributes to GSK3β Ser9 nor to ERK1/2 Tyr204 phosphorylation. With 
regard to the GSK3β being one of the main kinases priming NFAT for nuclear export [234], this outcome 
of the phosphorylation analysis of cell signaling kinases is in agreement with about equal NFAT amounts 
within the nucleus found in HAP1 TRPM7 WT and KI cells (see 6.2.4). If GSK3β is inhibited by 
phosphorylation at Ser9 [233] in the TRPM7 kinase-mutated HAP1 cells just as much as in the wild-type 
HAP1 cells, NFAT transport is unchanged. Interestingly, the activation-causing phosphorylation of the 
prevalent GSK3β upstream kinase Akt at Ser473 slightly decreases upon TRPM7 phosphotransferase 
inactivation. One would assume that this affects GSK3β as well, but several studies showed that there 
exist other kinases (such as PKA or PKC) that could compensate for the missing Akt phosphorylation-
dependent activation of GSK3β [233, 294-296]. Hence, the findings for Akt and GSK3β are not 
necessarily contradictory. 
6.3 Effect of pharmacological inhibition of the TRPM7 
channel and/or kinase on COX-2 gene expression in 
neutrophils 
Besides trying to elucidate the mechanism behind TRPM7’s regulative role in COX-2 gene expression 
and enzymatic activity, I wanted to test if TRPM7 represents a pharmacological target for attenuating 
inducible COX-2 gene expression. For this approach, I applied the two TRPM7 inhibitors NS8593 
and TG100-115 (also see introduction, 3.2.3) to freshly isolated, primary neutrophils to target both 
the full-length protein as well as its kinase activity only. As TG100-115 also blocks different PI3K 
isoforms, I additionally used a combination of the two inhibitors IPI-549 and GSK2292767 targeting 
PI3K-γ and PI3K-δ, respectively, to distinguish TRPM7 kinase and PI3K-specific effects on COX-2 
mRNA production [212, 297, 298]. Furthermore, the solvent DMSO (0.1 %, matching the highest 
employed drug concentration) served as control. Following a 30 min preincubation with the 
inhibitors listed above, COX-2 mRNA production in the neutrophils was induced with the common 
stimulus LPS. Already low concentrations of this bacterial endotoxin significantly upregulate COX-2 
gene expression and protein expression in neutrophils [213]. Samples were collected after 120 min of 
stimulation and COX-2 gene expression was subsequently analyzed via mRNA quantification using 
RT-qPCR. For comparison, the resulting COX-2 data for each sample was normalized to the 
respective values for the housekeeping gene HPRT1 (shown as 2(-ΔCP)). Figure 6.24 illustrates that neither 





expression in resting neutrophils. As expected, administration of 10 ng/ml LPS for two hours 
significantly increases COX-2 mRNA production in the control (from ~109 to ~370) and the DMSO 
(from ~94 to ~435) sample around fourfold. Preliminary incubation with 30 µM NS8593 for 30 min 
attenuates the LPS-caused effect by about half compared to DMSO (from ~88 to 225). Interestingly, 
kinase-specific inhibition with 20 µM TG100-115 represses LPS-stimulation even more and reduces 
induced COX-2 mRNA synthesis to one fifth in comparison to DMSO (from ~65 to ~120). This 
surprising effect could be explained by the side effect of TG100-115, which – next to the TRPM7 
kinase – simultaneously inhibits different PI3K isoforms with a much higher potency. Indeed, 
blocking both PI3K-γ and PI3K-δ together also counteracts LPS-driven COX-2 mRNA production, 


































Figure 6.24 LPS-triggered induction of COX-2 gene expression in primary human neutrophils 
treated with different TRPM7 inhibitors. Relative COX-2 gene expression (measured via RT-qPCR) 
in freshly isolated neutrophils treated with TRPM7 inhibitors. The cells were incubated with one of the 
following inhibitors: NS8593 (30 µM), TG100-115 (20 µM) or a combination of IPI-549 and 
GSK2292767 (160 and 100 nM, respectively), DMSO or nothing (ø, control) for 30 min and 
subsequently stimulated with 10 ng/ml LPS for 120 min (n=4-9). Unstimulated samples (left set of bar 
graphs) show that plain drug administration without subsequent LPS application has no effect on 
neutrophilic COX-2 mRNA levels. LPS-treatment for 120 min on the other hand highly significantly 
increases COX-2 mRNA expression in the control, DMSO- and NS8593-treated samples, yet the 
induction is only about half as high in presence of NS8593 when compared to DMSO. Furthermore, 
preliminary incubation with the TRPM7-kinase inhibitor TG100-115 almost fully prevents LPS-induced 
COX-2 mRNA upregulation in a highly significant manner in comparison to DMSO. However, specific 
inhibition of the PI3K isoforms PI3K-γ and PI3K-δ demonstrates that part of the TG100-115-caused 
inhibition of COX-2 mRNA production is due to the side effects of TG100-115 on those two kinases. In 
comparison to DMSO, administration of the respective inhibitors IPI-549 (abbreviated IPI) and 
GSK2292767 (abbreviated GSK) lowers inducible COX-2 mRNA production about half. Thus, the effect 
of TG100-115 on LPS-induced COX-2 mRNA production is not exclusively attributable to its inhibition 
of the TRPM7 kinase. Data are presented as mean ± s.e.m. Statistics: two-way ANOVA ## p<0.01, ### 





I conclude that the TRPM7 protein plays a significant role in inducible COX-2 mRNA gene 
expression in primary neutrophils, with both channel and kinase domain contributing to this 
regulation. Hence, TRPM7 might represent an interesting target when it comes to pharmacological 










































The ubiquitously expressed protein TRPM7 is defined by the unique fusion of an ion channel 
conducting divalent cations and an alpha-kinase domain phosphorylating serine and threonine 
residues. Besides being essential for survival, growth and reproduction, the channel-kinase functions 
in many pathological processes such as tumor development and metastasis, ischemic stroke as well as 
neurodegenerative and cardiovascular diseases [299]. Developing research shows that, aside from 
TRPM7’s impact on Ca2+ and Mg2+ homeostasis, the channel-kinase is implicated in numerous cell 
signaling events (see introduction, 3.2.6). Thus, various studies indicate a fundamental role for the 
TRPM7 in common signaling pathways such as PI3K/Akt, MAPK/ERK, JAK/STAT or TGF-
β/SMAD; yet, the so far presented results are partially contradictory and often do not differentiate 
between channel and kinase function [45, 83, 151, 155, 160, 169-172, 174, 177, 178, 184].  
Given this background, it was my attempt to clarify if and how TRPM7 operates in the signaling 
cascades mentioned above and thereby discriminate between channel- and/or kinase-directed 
mechanisms. Moreover, in terms of a TRPM7-dependent control of different signaling pathways, 
special focus was put on the new discovery of other downstream targets affected by the TRPM7 
chanzyme.   
Accordingly, the herein presented results depict that the channel-kinase TRPM7 has a significant 
impact on various cell signaling molecules in immune-derived cell culture (HAP1) cells. Its range of 
action includes specific channel- and/or kinase-mediated a) phosphorylation of the signal 
transmitting kinases AKT and GSK3β, b) the nuclear localization of the transcription factor NFAT 
and, most importantly, c) the regulation of COX-2 gene expression and enzymatic activity. Separate 
analysis of the different HAP1 TRPM7 cell models thereby shows that the channel and the kinase 
unit differentially contribute to these cell signaling events. Remarkably, the promoting effect of 
TRPM7 on COX-2 gene expression is also observed for primary immune cells, since pharmacological 
inhibition of the TRPM7 channel respectively its kinase domain diminishes LPS-induced COX-2 gene 
upregulation in neutrophils. In consideration of the pathophysiological background of COX-2, this 
suggests TRPM7 to be a valuable pharmacological target for future therapy of COX-2-driven 
diseases. In the following, I will review my results with special regard to domain-specific effects of 
TRPM7 on different cell signaling events and discuss TRPM7’s potential as a pharmacological target 






7.1 HAP1 TRPM7 cell models demonstrate to be a suitable 
tool to study the channel-kinase’s function in innate 
immune cells 
Preliminary to the actual experiments focusing on TRPM7’s impact on cell signaling, both the HAP1 
TRPM7 full-length protein knockout (KO) and the kinase-dead (KI) clone were genetically validated 
and characterized with respect to their functionality. DNA- respectively cDNA-sequencing of the two 
HAP1 TRPM7 cell models was able to confirm integrity of the anticipated genetic modifications (see 
Figures 6.1 and 6.14). In addition, TRPM7 current development was investigated in both HAP1 
TRPM7 cell models via the whole-cell patch clamp technique. While lack of the characteristic 
TRPM7-elicited current in the HAP1 TRPM7 KO clone confirms functional protein extinction [195], 
annihilation of TRPM7’s enzymatic function does not affect channel activity, as current amplitude 
and kinetics are not significantly altered in HAP1 TRPM7 KI cells compared to WT. This finding 
reflects the results acquired from TRPM7 kinase inactivation in mice, where the corresponding 
murine kinase mutation K1646R did not impact channel activity of TRPM7 [118]. Furthermore, 
phospho-specific Western Blot analysis targeting the TRPM7 autophosphorylation site Ser1511 in 
HAP1 TRPM7 KI displays that the genetic mutation indeed results in the intended kinase 
inactivation. Thus, the HAP1 TRPM7 KO model allows studying the role of the full-length protein 
while the KI model raises the possibility of investigating TRPM7 kinase-specific function(s) only.  
7.2 TRPM7 channel moiety is essential for maintenance of 
Mg2+, Zn2+, but also Cu2+ levels in resting cells 
At first hand TRPM7 being an ion channel, it was crucial to examine basal ion concentrations in the 
HAP1 TRPM7 KO and KI clones. Most importantly and in accordance with the literature declaring 
TRPM7 to be essential for Mg2+ homeostasis [34-36], knockout of TRPM7 leads to a significant 
reduction of the intracellular Mg2+ concentration (see Figure 6.2A) in the HAP1 cells. Moreover, 
culturing the HAP1 cells shows that this drop in internal Mg2+ caused by TRPM7 deficiency 
substantially affects cell cycle progression, as normally cultured HAP1 TRPM7 KO cells go into 
growth arrest which can be rescued by additional Mg2+ supplementation [195]. Together with the 
studies of Schmitz et al., this emphasizes TRPM7’s role for maintenance of cellular Mg2+ levels and 
indicates how TRPM7 controls important cell functions such as proliferation [43]. However, 
TRPM7’s impact on Mg2+ levels apparently occurs independently of its phosphotransferase activity, 
as the HAP1 TRPM7 KI clone does not display any changes regarding their intracellular Mg2+ 





papers, where the TRPM7 kinase activity showed to be redundant for maintenance of intracellular 
Mg2+ levels [36, 83, 116-118].   
Other than observed for Mg2+, Ca2+ homeostasis seems to be unaffected by TRPM7 depletion 
respectively its kinase inactivation, as ICP-MS reveals no significant alterations of Ca2+ levels in 
neither HAP TRPM7 KO nor KI cells (see Figure 6.2B respectively 6.16B). Nevertheless, 
intracellular Ca2+ concentrations are comparably low and ICP-MS resolution is limited, wherefore 
intracellular Ca2+ levels were additionally determined via the Ca2+ imaging technique. Yet, 
measurements with the Ca2+-specific fluorescent dye Fura-2 AM reflect the results acquired with ICP-
MS (see Figures 6.3 and 6.17, respectively), which indicates that absence of the TRPM7 channel-
kinase or its kinase inactivation do not significantly impact Ca2+ household in the HAP1 cells. This is 
surprising, as TRPM7 is a Ca2+ permeable channel and has been shown to function in Ca2+-mediated 
signaling and activation mechanisms in a channel as well as kinase-dependent manner [49, 119, 138, 
291, 292, 300, 301]. However, both ICP-MS and Ca2+ imaging experiments were conducted in resting 
cells, whereas most of the studies claiming TRPM7 and in particular its kinase domain to be relevant 
for internal Ca2+ are based on activated or stimulated cells which require increased Ca2+ influx. Hence, 
although TRPM7 contributes to Ca2+-mediated signaling in activated cells, it might be redundant for 
maintenance of basal Ca2+ levels. In agreement with this notion, several reports show that TRPM7 
does not substantially affect resting Ca2+ levels, eventually substantiating my findings obtained for the 
HAP1 cells showing TRPM7 to be dispensable the regulation of basal Ca2+ levels [83, 119, 302]. 
Next to the two main cations Ca2+ and Mg2+, I focused on two other divalent ions Zn2+ and Cu2+ 
whose concentrations also lay within the evaluable range of the ICP-MS measurements. Being an 
essential cofactor, Zn2+ plays an important role in enzymatic reactions, cell signaling and transcription 
factor remodeling [227]. Compared to other mono- and divalent cations, Zn2+ shows the highest 
driving force through TRPM7 channel, and several papers have already published TRPM7’s 
contribution to Zn2+ transport [51-54, 302]. Thus, the channel-kinase potentiates Zn2+-induced 
neurotoxicity by promoting Zn2+ accumulation in neurons followed by neuronal cell death for 
example [53, 54]. Furthermore, TRPM7 releases Zn2+ from intracellular storage vesicles upon reactive 
oxygen species (ROS) production and thereby controls cytosolic Zn2+ levels and oxidation state(s) 
[52]. In addition, Clapham et al. hypothesized that the channel and kinase domain work 
synergistically, as TRPM7 expression increases the intracellular Zn2+ concentration whereas the 
cleaved kinase domain binds to zinc-finger proteins in a Zn2+-dependent manner and thereby 
activates gene transcription [84]. Substantiating TRPM7’s role in Zn2+ homeostasis, a very recent 
paper showed that TRPM7 depletion in HAP1 cells results in a significant decrease of internal Zn2+ 





TRPM7 results in significantly reduced serum and bone Zn2+ levels in mice, indicating that TRPM7 is 
essential for epithelial transport of Zn2+ in the intestine [302]. However, this TRPM7-dependent 
regulation of organismal Zn2+ levels appears to occur separate of its kinase activity, as mutant mice 
globally expressing a kinase-dead (K1646R) form of TRPM7 reveal no alterations in serum or bone 
Zn2+ concentrations [302].  
Compliant with these findings, my investigations show that the internal Zn2+ levels are significantly 
reduced in the HAP1 cells if TRPM7 is absent (see Figure 6.2C). In addition, exploration of the 
HAP1 TRPM7 KI clone illustrates that TRPM7 most likely controls Zn2+ levels through its channel 
domain, as kinase inactivation has no effect on the internal Zn2+ concentration (see Figure 6.16C). 
Together with the literature, this substantiates the importance of TRPM7 for Zn2+ homeostasis, and, 
corresponding to the already published implications of TRPM7 in Zn2+-mediated events, one could 
speculate that TRPM7 also affects other processes, e.g. the development and function of the immune, 
nervous, digestive and skeletal system, by facilitating Zn2+ influx [303-305].  Furthermore, although 
the results suggest the kinase to be redundant for maintenance of Zn2+ in resting cells, it does not 
exclude that TRPM7 kinase-mediated mechanisms rely on Zn2+ influx mediated through an active 
TRPM7 channel domain as Clapham et al. hypothesized [84].  
Regarding the trace metal Cu2+, nothing is known yet about the effect of TRPM7 on Cu2+ 
homeostasis; actually, there is not even a proof that Cu2+ enters the cell through TRPM7. 
Nevertheless, the massive reduction of about ~34 % in HAP1 TRPM7 KO (see Figure 6.2D) cells 
strongly suggests a role of TRPM7 in the maintenance of intracellular Cu2+ levels.However, 
examination of the HAP1 TRPM7 KI cells simultaneously reveals that the TRPM7-dependent 
control of Cu2+ occurs independently of its kinase domain (see Figure 6.16D). Like Zn2+, Cu2+ 
functions as cofactor in enzymatic reactions, mainly enabling redox reactions as present in the 
respiratory chain or ROS homeostasis [228, 229, 306]. Consequently, by tightly regulating ROS 
production and elimination, Cu2+ is essential for survival, but at the same time Cu2+ overload is toxic 
to eukaryotes [307, 308]. Inherited or evolved dysregulation of the trace element leads to severe 
syndromes such as Wilson or Menkes disease, neurodegenerative diseases or cancer [309]. Although 
there is no paper stating a direct connection of TRPM7 and Cu2+ yet, some studies hint toward a 
correlation of TRPM7- and Cu2+-mediated actions. Thus, the channel-kinase has been shown to 
tightly regulate ROS levels and induces neuronal cell death in dependence of Ca2+, Mg2+and Zn2+, 
indicating that ions entering the cell through the TRPM7 channel contribute to neurodegeneration 
processes [53, 135, 310]. Accordingly, also Cu2+ could be implicated in the TRPM7-dependent 





Given the fact that TRPM7 affects the internal concentrations of Zn2+ and Cu2+ that both function as 
essential cofactors, it would be interesting to further evaluate the impact of TRPM7 on metabolic 
processes relying on Zn2+ and/or Cu2+ in future studies.  
Overall, elemental analysis of both HAP1 TRPM7 KO and KI clone underlines the current 
understanding of TRPM7 to resemble an essential, non-redundant entry mechanism for Mg2+ and 
Zn2+, whereas it is dispensable for cellular Ca2+ uptake under resting conditions. Moreover, the 
channel-kinase seems to have a significant impact on Cu2+ homeostasis, as knockout of TRPM7 
results in diminished Cu2+ levels. Conclusively, the experiments with the HAP1 TRPM7 KI cells 
indicate that the observed alterations for Mg2+, Zn2+ and Cu2+ are due to absence of a functional 
channel domain, as kinase inactivation has no effect on the influx respectively maintenance of these 
ions.  
7.3 Novel domain-specific role for TRPM7 in COX-2 gene 
expression and activity 
The immunologically relevant enzyme COX-2 is of great importance in mammalians [284, 311, 312]. 
Despite originally believed to be exclusively expressed upon gene induction, constitutive COX-2 
expression has been shown in various organs. Dependent on age, COX-2 is permanently present in 
tissues including the central nervous system, kidney, intestinal tract and placenta as well as heart, 
lungs and skin [283, 313-316]. Although COX-2 is not considered to be essential for survival, 
knockout experiments revealed that only 60 % of mice lacking COX-2 survive postnatal stage [311]. 
Moreover, viable COX-2-deficient animals often develop severe diseases such as cardiac fibrosis and 
ischemia, peritonitis or nephropathy (due to organ dysplasia), which emphasizes the importance of 
the constant expression of COX-2 in these organs [311, 317-319]. Nevertheless, induction of COX-2 
gene expression is just as important, as it is involved in many inflammatory processes and 
carcinogenesis; correspondingly, gene expression remains aberrantly high in mature cancerous tissues 
[320-324]. The contribution of COX-2 to these maladies originates from its enzymatic action: 
Cyclooxygenases initialize PG synthesis through conversion of arachidonic acid to PG H2 (PGH2), 
which is further metabolized into a variety of other lipid compounds [265-267]. Besides regulating 
elementary physiological functions, these biologically active substances play an important role in 
immune cell homeostasis and thereby contribute to inflammation as well as inflammation-caused 
cancer genesis [325-327]. By receptor-specific binding, PGH2 derivates such as PGE2 and PGJ2, for 
example, function in the proliferation, differentiation and cytokine production of T cells and B cells 
but also control innate immune reactions by affecting dendritic cells, macrophages and neutrophils. 





represents an interesting target for pharmacological treatment of inflammation and tumor 
progression [326, 328-336].  
Interestingly, some papers previously suggested TRPM7 to be implicated in COX-2 expression [91, 
337]. Thus, it was shown that TRPM7 promotes COX-2 protein expression in bradykinin-stimulated 
VSMCs [337]. However, in context of aldosteron-induced signaling, the same group controversially 
published that TRPM7 attenuates COX-2 protein expression in a kinase-dependent manner in 
TRPM7-overexpressing HEK-293 cells [91]. Yet, especially the second study lacks profound proof as 
it was a) was conducted in an overexpression system, thus the observed changes might be caused by 
compensatory mechanisms and not TRPM7-mediated actions and b) is deficient of adequate controls. 
Furthermore, both reports draw their conclusion that TRPM7 functions in COX-2 expression by 
application of the substance 2-APB for validation of TRPM7 specifity. Although this drug is known 
to block the TRPM7 channel in µM concentrations [71] (also see introduction, 3.2.3), it is very 
unspecific as it simultaneously affects a broad spectrum of other channels and transport proteins 
involved in Ca2+ homeostasis such as IP3Rs, SOCCs, SERCA, numerous TRP channels and 
potassium channels etc. [99, 100, 102-110]. Thus, just because one detects differences upon 2-APB 
administration, it would be presumptuous to ascribe specific functions to TRPM7, as the inhibitor at 
the same time targets the above-mentioned molecules and thus very likely causes severe side effects. 
Accordingly, the observed alterations could be explained via the effect of 2-APB on other channels 
and transporters regulating intracellular Ca2+ concentrations and thus downstream COX-2 expression.  
In the present study, I demonstrate that TRPM7 indeed promotes COX-2 gene expression and 
enzymatic activity in immune cells. Analysis of resting HAP1 cells via RT-qPCR demonstrates that 
knockout of TRPM7 leads to a significant reduction in constitutive COX-2 gene expression (see 
Figure 6.11C). Moreover, stimulation of the HAP1 cells shows that the channel-kinase likewise 
facilitates inducible COX-2 gene expression. Administration of forskolin, which increases cAMP 
levels and thus triggers COX-2 mRNA production, substantially augments COX-2 gene expression 
levels in HAP1 TRPM7 WT cells, whereas no significant change is observed for the HAP1 TRPM7 
KO cells (see Figure 6.13). Overall, this forskolin-induced COX-2 gene upregulation shows to be five 
times higher if TRPM7 is present. Thus, the channel-kinase is not only essential for constitutive, but 
also contributes to inducible COX-2 gene expression.  
Incorporating the HAP1 TRPM7 KI model in these studies, it becomes apparent that the kinase 
activity of TRPM7 carries a central role in the TRPM7-dependent regulation of both constitutive and 
inducible COX-2 gene expression. Comparable to the data acquired for the HAP1 TRPM7 KO clone, 
the HAP1 TRPM7 KI cells express about one third less COX-2 in comparison to WT under resting 





COX-2 gene induction by almost half in HAP1 cells (see Figure 6.19). Correlation of the experimental 
outcome of the HAP1 TRPM7 WT, KO and KI clone hints towards a TRPM7 kinase-specific 
regulation of constitutive COX-2 gene expression, while both channel and kinase mutually control 
inducible COX-2 mRNA upregulation.   
Intriguingly, further RT-qPCR experiments reveal that this phenotype observed for the HAP1 cells 
can be mimicked by pharmacological suppression of TRPM7. Primary neutrophils incubated with 
TRPM7 channel- and/or kinase-specific inhibitors and subsequently stimulated with LPS show 
significant changes regarding COX-2 gene induction. Complete block of the TRPM7 channel with 
NS8593 – which most likely also reduces enzymatic activity of the TRPM7 kinase [119] (also see 
introduction, 3.2.4) – results in a significant reduction of LPS-induced COX-2 gene expression by 
about half when compared to the DSMO control (see Figure 6.24). Interestingly, this repression is 
even more pronounced if only the TRPM7 kinase is inhibited by administration of TG100-115 (see 
Figure 6.24). These results are slightly differing from the results obtained with the HAP1 TRPM7 
models, where knockout of the full-length protein was more potent to block COX-2 gene expression 
than kinase inactivation (compare Figure 6.13 and 6.19). However, application of TG100-115 to 
neutrophils does not exclusively block the TRPM7 kinase, but primarily inhibits the PI3K isoforms 
PI3K-γ and PI3K-δ; thus, the results have to be directly compared to the impact of specific PI3K-γ 
and PI3K-δ inhibitors on inducible COX-2 gene expression. Corresponding application of the two 
PI3K inhibitors IPI-549 and GSK2292767 together clearly attenuates the LPS-triggered increase of 
COX-2 mRNA more than 25 %, but is way less effective than TG100-115. I conclude that part of the 
TG100-115-caused inhibition of COX-2 mRNA upregulation by LPS is indeed due to simultaneous 
PI3K inhibition, as PI3K is known to activate COX-2 mRNA and protein production through 
different pathways [338-341]. Nonetheless, this experiment at the same time demonstrates that the 
observed reduction of COX-2 gene expression in the TG100-115 treated samples is mainly 
attributable to pharmacological inhibition of the TRPM7 kinase. Hence, the comprehensive 
experimental outcome in the neutrophils supports the notion of both the TRPM7 channel and kinase 
being involved in inducible COX-2 gene expression.  
Given the physiological relevance of COX-2 in different diseases, TRPM7 might represent a valuable 
pharmacological target for treatment of numerous pathologies such as various types of cancer, 
Alzheimer’s respectively Parkinson’s disease, multiple sclerosis and other neurological disorders [269-
271, 273]. However, this necessitates that the depletion respectively inactivation of TRPM7 and/or its 
kinase activity also reduces COX-2 enzymatic activity. Examining the HAP1 cell models regarding 
the catalytic activity of cyclooxygenases demonstrates that TRPM7 indeed has a significant impact on 





results in a significantly diminished basal COX activity when compared to WT (see Figure 6.12A and 
B). Further differentiation between the activity of COX-1 and COX-2 shows that the monitored substrate 
conversion in the HAP1 TRPM7 WT cells is attributable to both isoforms (Figure 6.12C). Linking these 
results, I conclude that full-length TRPM7 is required for sufficient COX-2 and COX-1-dependent PG 
synthesis; yet, it remains unclear if this is due to the demonstrated facilitation of COX-2 gene expression 
or in some way through directly aiding the conversion process itself. 
To unravel if and to what extent the TRPM7 kinase is involved in COX-2 activity, the same fluorometric 
COX activity assay was conducted in the HAP TRPM7 KI clone. However, this approach did not lead to 
evaluable results as signal intensities showed to be very low and no cyclooxygenase-specific signal was 
measureable (results not shown). Thus, kinase impact on basal COX-2 activity still needs to be clarified. 
One possible experimental setup to do so would be to increase COX-2 protein expression in the HAP1 
cells by elevating cAMP levels via administration of forskolin and use these stimulated cell lysates for 
analysis. Moreover, the neutrophils represent another handy tool to further investigate TRPM7 channel- 
and/or kinase-specific effects on COX-2 activity. On the one hand, cells could be inhibited with NS8593, 
TG100-115 and the PI3K inhibitors prior to LPS stimulation (as done when examining inducible COX-2 
gene expression, see Figure 6.24), lysed and subsequently applied to the COX-2 activity assay. Another 
option is to change the chronological order of the experiment, thus first stimulate the neutrophils with 
LPS and apply the drugs directly in the COX activity assay. These two experimental setups would kill two 
birds with one stone, as they a) would clarify the role of TRPM7 respectively its kinase in COX-2 
enzymatic activity and b) elucidate if TRPM7’s impact on COX-2 activity is just due to upregulating its 
expression or if TRPM7 directly affects COX-2 enzymatic reactions. 
7.4 Cell signaling analysis shows: TRPM7 controls COX-2 
through the signaling kinase Akt 
Recent work has suggested a role for TRPM7 in cell signaling. The channel-kinase has been shown to 
operate in prominent pathways such as PI3K/Akt, MAPK/ERK, JAK/STAT and TGF-β/SMAD 
signaling. However, the individual studies led to partially ambiguous results regarding the exact 
function of TRPM7, and furthermore, only a few of them differentiated between the impact of the 
channel and kinase domain throughout the corresponding experiments. Now, given the herewith 
shown effect of TRPM7 on COX-2 gene expression and activity and its concomitant potential as an 
eventual target for attenuation of inflammation, it is of great importance to understand the mechanism 
behind the TRPM7-dependent regulation of COX-2. Hence, in the following paragraph, I will a) review 
the observations made for the TRPM7-dependent control of different pathways and b) put these 





Detailed analysis of different signaling pathways in the HAP1 TRPM7 cell models revealed several 
molecules to be affected by the channel-kinase. An initial comprehensive screen of various cell signaling 
kinases demonstrated that TRPM7 facilitates site-specific phosphorylation of Akt and GSK3β but not 
ERK1/2. Total knockout of TRPM7 in the HAP1 cells results in a significant reduction of Akt 
Ser473 and GSK3β Ser9 phosphorylation, while ERK1/2 Tyr204 phosphorylation remains 
unaffected (see Figure 6.4). Furthermore, analysis of the HAP1 TRPM7 KI model illustrates that the 
TRPM7-dependent promotion of Akt Ser473 phosphorylation is at least partially conducted through 
its kinase domain, as kinase inactivation leads to a small but significant reduction of the 
corresponding signal (see Figure 6.23). However, the same experiments reveal that the TRPM7 kinase 
unit is not involved in GSK3β Ser9 phosphorylation, nor does it affect ERK1/2 phosphorylation.  
From a mechanistical point of view, the post-translational modification of these molecules has 
opposing effects; while both Akt (Ser473) and ERK1/2 (Tyr204) are activated upon phosphorylation, 
phosphorylation of GSK3β (Ser9) results in its inhibition [231, 233, 342]. Taking this information 
into account, the herein presented results are predominantly congruent with what is known from the 
literature: TRPM7 has been published to positively regulate PI3K/Akt signaling by triggering Akt 
phosphorylation which in turn activates other downstream targets such as mTOR [151]. Accordingly, 
analysis of the phosphorylation status in the HAP1 TRPM7 cell models confirms the importance of 
TRPM7 for Akt activation. However, I herewith for the first time show that TRPM7 kinase activity is 
substantively involved in this TRPM7-induced activation of Akt. Moreover, my investigations 
demonstrate that full-length TRPM7 also inhibits GSK3β by enhancing its phosphorylation at Ser9; 
yet, this regulation happens independently from its kinase domain.  
Importantly, GSK3β itself is a downstream kinase of Akt [343]; thus, the detected diminution in 
GSK3β Ser9 phosphorylation in absence of TRPM7 (see Figure 6.4) might be directly caused by 
attenuation of Akt Ser473 phosphorylation. Nevertheless, the decrease in GSK3β Ser9 phosphorylation 
is not necessarily directly attributable to the reduction of Akt phosphorylation, as its phosphorylation at 
Ser9 is also regulated by other kinases (e.g. PKA and PKC) and furthermore indirectly controlled by the 
element lithium (Li2+) [296, 344-346]. Hence, TRPM7 potentially regulates GSK3β activity not through 
Akt, but instead promotes GSK3β phosphorylation at Ser9 via the activation of PKA and PKC 
and/or by facilitating Li2+ influx. 
In terms of MAPK/ERK signaling, TRPM7’s role in ERK1/2 activation is controversially discussed: 
Some groups demonstrated an increase and others a decrease of pERK1/2 signals upon TRPM7 
depletion [155, 160, 169-172]. My studies indicate that TRPM7 is not involved in ERK1/2 activation 
in the HAP1 cells, as ERK1/2 Tyr204 phosphorylation is not affected by knockout or kinase 





ERK1/2 is cell type- and stimulus-dependent, and that in resting HAP1 cells, the channel-kinase is 
dispensable for basal ERK1/2 phosphorylation.  
Downstream of the signaling kinases Akt and GSK3β, TRPM7 shows to function in NFAT nuclear 
localization and transcriptional activity. As mentioned, GSK3β has been shown to determine NFAT-
dependent gene transcription; counteracting the Ca2+- activated molecule calcineurin, which is 
responsible for NFAT dephosphorylation and subsequent nuclear import [347, 348], GSK3β 
phosphorylates NFAT within its NES and thereby induces its nuclear export [234, 349]. In addition, 
GSK3β attenuates NFAT transcriptional activity by preventing DNA binding [350, 351]. Thus, the 
herein observed TRPM7-caused inhibition of GSK3β (see Figure 6.4B) is likely to affect these NFAT 
parameters. Studying the localization of different NFAT family members in resting HAP1 cells 
reveals that TRPM7 effectively impacts the cellular distribution of NFATc1 and NFATc3: Knockout 
of the channel-kinase results in reduced levels of NFATc1 and NFATc3 in the nucleus (see Figure 
6.7A). Surprisingly, these reductions are not accompanied by a simultaneous increase of cytosolic 
NFATc1 and c3 concentrations, as one would expect. This led to the assumption that TRPM7 might 
affect the total protein expression of these NFAT members; however, analysis of whole-cell lysates 
indicates that neither NFATc1 nor NFATc3 expression is significantly reduced upon TRPM7 
depletion (see Figure 6.7C). Hence, the observed decrease of nuclear NFAT in the HAP1 TRPM7 
KO cells is indeed attributable to TRPM7’s promoting effect on NFAT nuclear localization and not 
caused by a TRPM7-dependent alteration of total protein expression of NFAT.  
Further investigating the impact of the TRPM7 kinase domain on NFAT nuclear localization in the 
HAP1 cells shows that the TRPM7-dependent control of nuclear NFATc1 levels occurs separate of 
its phosphotransferase activity. Thus, depletion of TRPM7 kinase activity does not alter NFATc1 
nuclear localization in the HAP1 cells (see Figure 6.20A). Following the hypothesis that TRPM7 
affects NFAT through the export kinase GSK3β, this finding is in accordance with the fact that 
kinase inactivation neither alters GSK3β Ser9 phosphorylation.  
Taken together, I presume that the TRPM7 channel-kinase, without its phosphotransferase activity 
being mandatory, contributes to nuclear NFAT localization through direct or indirect GSK3β 
phosphorylation in the HAP1 cells. Moreover, a luciferase gene reporter assay in HEK-293 cells 
shows that TRPM7 also affects NFAT-driven gene expression. In both a transiently transfected as 
well as in a stable HEK-NFAT reporter cell line, overexpression of TRPM7 WT results in 
significantly enhanced NFAT transcriptional activity compared to mock (increase of up to ~45 %, 
see Figure 6.8). Surprisingly, this observed increase in NFAT-driven gene transcription is significantly 
lower when overexpressing a kinase depleted TRPM7 (TRPM7 KI) vector (increase of ~13 %, see 





Assuming that NFAT transcriptional activity is directly related to its nuclear localization, these 
findings stand in contrast to the results obtained for the HAP1 TRPM7 KI cells, which showed no 
decrease in nuclear NFAT levels compared to WT (see Figure 6.20A). Nevertheless, TRPM7 is a Ca2+ 
permeable channel and NFAT induction strongly depends on Ca2+-dependent calcineurin activation 
[352]; thus, the increase in NFAT transcriptional activity observed for the transfected HEK-293 cells 
might be caused by an increased Ca2+ influx due to TRPM7 overexpression. Indeed, aequorin-based 
analysis of Ca2+ levels in HEK-G5α cells reveals that overexpression of the TRPM7 WT construct 
significantly elevates cytosolic Ca2+ concentration in HEK-293 cells. Overexpression of the kinase-
depleted protein however has no impact on the intracellular Ca2+ concentration, which suggests the 
kinase domain to be relevant for the observed overexpression-induced Ca2+ influx. Interestingly, this 
is in accordance with several recent studies that claim TRPM7’s kinase unit to be important for Ca2+ 
homeostasis. Accordingly, TRPM7’s phosphotransferase activity was shown to be required for store-
operated Ca2+ entry (SOCE) activation in TRPM7 overexpressing DT40 B-lymphocytes, murine 
platelets and activated primary T cells, potentially through targeting stromal interaction molecule 
(STIM) proteins [119, 138, 291]. In addition, TRPM7’s enzymatic domain controls Ca2+ store release 
through thrombin-induced G-protein-coupled receptor signaling [292]. Taken together, the Ca2+ 
experiments in the HEK-G5α cells show that TRPM7 overexpression elevates internal Ca2+ levels in 
a kinase-dependent manner. Correlating these results to the NFAT reporter assay, the observed 
increase in NFAT transcriptional activity in TRPM7 overexpressing HEK-NFAT reporter cells 
indeed might be caused by TRPM7’s impact on the intracellular Ca2+ concentration.  
In summary, the NFAT-reporter assay strongly suggests TRPM7 to be implicated in NFAT-
dependent gene expression in HEK-293 cells and highlights the kinase domain as an important player 
in these processes. Thus, the experiments illustrate that TRPM7 elevates NFAT-dependent gene 
expression in a kinase-dependent manner. However, overexpression of the kinase-dead TRPM7 
protein in the stable HEK-NFAT cell line still causes a slight but significant increase in NFAT-
dependent gene expression, suggesting that in parts, TRPM7 augments NFAT-dependent gene 
expression independently of its kinase activity. Hence, although the kinase shows to play a major role 
in the TRPM7-dependent induction of NFAT, it is not exclusively responsible for its activation. 
Further examination of the intracellular Ca2+ levels in TRPM7-overexpressing HEK-G5α cells reveals 
that the kinase-dependent increase of NFAT-dependent gene expression is most likely attributable to 
a kinase-dependent elevation of the internal Ca2+ levels, while the small but existent kinase-
independent induction of NFAT occurs separately from altering Ca2+ concentrations. Considering 
that TRPM7 kinase depletion had no effect on the internal resting Ca2+ concentration in HAP1 cells, 





overexpression apparently causes Ca2+ concentrations and possibly also other parameters to change 
that distort the results. 
Overall, my investigations show that TRPM7 promotes phosphorylation of the cell signaling kinases 
Akt and GSK3β and furthermore facilitates nuclear accumulation of the transcription factor NFAT. 
While the TRPM7-dependent Akt Ser473 phosphorylation is partially conducted through an active 
kinase domain, neither GSK3β nor NFAT are affected by TRPM7’s phosphotransferase activity. 
Relating these results to the differential effect of the TRPM7 channel and/or kinase on COX-2, I 
hypothesize that TRPM7 presumably controls COX-2 gene expression and enzymatic activity through 
two different pathways:  
In the first place, the TRPM7-dependent enhancement of COX-2 gene expression is mediated 
through the Akt-GSK3β -NFAT signaling axis (see Figure 7.1A). Full-length TRPM7 augments 
phosphorylation of both Akt at Ser473 and GSK3β at Ser9, thus causing Akt activation respectively 
GSK3β inhibition. The TRPM7-dependent block of GSK3β evokes nuclear accumulation of NFAT, 
which, according to the literature, in turn activates constitutive as well as inducible COX-2 gene 
expression [260, 261]. Moreover, increased gene expression is most likely accompanied by escalated 
protein expression, which would explain why TRPM7 also promotes COX-2 enzymatic activity; 
however, the experiments are not eligible to tell if the observed increase in substrate conversion is 
due to augmented protein expression or potentially caused by a direct interaction of COX-2 and 
TRPM7.  
Reviewing the results with focus on the TRPM7 kinase domain demonstrates that the channel-kinase 
seems to additionally control COX-2 gene expression through an alternative route. As shown by the 
RT-qPCR experiments, TRPM7 kinase activity is required for constitutive COX-2 gene expression 
and furthermore also participates in inducible COX-2 gene expression (see Figure 6.18 and 6.19, 
respectively). Yet, analysis of the HAP1 TRPM7 KI cells simultaneously reveals that the kinase unit is 
redundant for GSK3β phosphorylation and NFAT nuclear localization, indicating that the TRPM7 
kinase activity regulates COX-2 gene expression apart from these two molecules. Instead, aligning the 
results acquired for the molecule Akt in the HAP1 cells with the current literature illustrates that the 
TRPM7 kinase domain potentially promotes COX-2 gene expression through the cell signaling kinase 
Akt. Thus, HAP1 TRPM7 KI cells display a significant decrease in the activation-causing Akt Ser473 
phosphorylation. However, several papers have shown that Akt significantly affects COX-2 gene 
expression: as being part of the PI3K/Akt signaling pathway, Akt regulates COX-2 gene expression 
through the transcription factors nuclear factor kappa-light-chain-enhancer of activated B cells 
(NFκB) and CREB, and attenuation in Akt phosphorylation results in decreased NFκB nuclear 





demonstrate that TRPM7 functions in both activation and translocation of these Akt downstream 
targets NFκB and CREB. Schappe et al. for example showed that in bone marrow-derived 
macrophages (BMDMs), TRPM7 is necessitated for LPS-stimulated NFκB p65 phosphorylation 
initiating its nuclear translocation [360]. Moreover, an in vitro kinase assay identified CREB to be a 
potent substrate of the TRPM7 kinase [115]. In accordance, Ogata et al. demonstrated that the 
TRPM7 kinase unit promotes phosphorylation and thereby activation of CREB during teeth 
maturation in mice [361]. Overall, these findings substantiate the hypothesis that the observed 
TRPM7 kinase-dependent augmentation of COX-2 gene expression is caused by the activation of Akt 
which initiates a signaling cascade along the transcription factors NFκB and/or CREB (see Figure 
7.1B). Nevertheless, it can’t be excluded that the TRPM7 kinase potentially affects COX-2 gene 
expression by directly targeting nuclear structures that regulate transcriptional activity. According to 
Clapham et al., the TRPM7 C-terminus enclosing its kinase domain is truncated, translocates to the 
nucleus and eventually contributes to the expression of specific genes by histone H3 modification 
[84] (also see introduction, 3.2.6). Likewise, this mechanism could also apply for the HAP1 cells, 
implying that the enhanced COX-2 gene expression results from the direct interaction of the 
truncated TRPM7 kinase domain with corresponding histones in the nucleus (see Figure 7.1B).  
Hence, my studies not only uncover TRPM7 to be an important player in COX-2 gene induction but 
furthermore indicate that the channel-kinase controls COX-2 gene expression through more than one 
pathway. Together with the current literature, the experiments strongly suggest that TRPM7 
promotes COX-2 gene expression through the central molecule Akt, which further activates different 
downstream targets. On the one hand, the TRPM7-dependent activation of Akt induces inhibition of 
NFAT export kinase GSK3β, and the resultant nuclear accumulation of NFAT contributes to COX-2 
gene expression. On the other hand, I hypothesize that the TRPM7-induced phosphorylation of Akt 
stimulates activation and nuclear translocation of the transcription factors NFκB and CREB which 
again promote COX-2 gene expression. Most importantly, only the latter postulated Akt – 
NFκB/CREB – COX-2 cascade relies on TRPM7 kinase activity, whereas signaling along the Akt – 
GSK3β – NFAT – COX-2 axis occurs independently of the TRPM7 kinase domain. As I propose 
that TRPM7 presents a promising pharmacological target for the inhibition of COX-2-mediated 
inflammation and cancer, it is of great importance to further elucidate the mechanisms through which 
TRPM7 controls COX-2, as this knowledge will help to predict respectively reduce the risk of 
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Figure 7.1  Working model for the TRPM7-dependent regulation of COX-2 gene expression and 
enzymatic activity in respect to the impact of TRPM7’s kinase activity.  
(A) Full-length TRPM7 promotes COX-2 gene expression and activity via the cell signaling 
molecules Akt, GSK3β and NFAT. TRPM7 facilitates phosphorylation of the signaling kinase Akt 
(Ser473) and its downstream target GSK3β (Ser9), thus causing activation of Akt respectively inhibition 
of GSK3β. The phosphorylation-induced block of GSK3β leads to nuclear accumulation of the 
transcription factor NFAT, which in turn activates the transcription of COX-2. The resulting increase in 
COX-2 mRNA production is accompanied by enhanced COX-2 enzymatic activity. However, it remains 
unclear if the observed elevation of COX-2 activity is due to the upregulated COX-2 gene and thus 
protein expression or if TRPM7 facilitates COX-2-mediated enzymatic reactions through direct interaction 
with the enzyme. Moreover, it can’t be excluded that Akt stimulates COX-2 gene expression by affecting 
other signaling molecules promoting COX-2 gene expression.  
(B) The TRPM7 kinase-dependent regulation of COX-2 gene expression occurs through Akt which 
is known to control the activity of the transcription factors CREB and NFκB.Although the TRPM7 
kinase domain significantly contributes to TRPM7-induced COX-2 mRNA production by enhancing the 
phosphorylation of Akt (Ser473), this does not occur through the signaling molecules GSK3β or NFAT, 
as kinase inactivation has no impact on GSK3β phosphorylation or NFAT nuclear translocation. 
However, aligning these results with the current literature, one might speculate that TRPM7 kinase 
activity potentially controls COX-2 gene expression by activation of Akt which in turn stimulates the 
transcription factors NFκB and CREB, thereby initiating COX-2 gene transcription. 
Alternatively, the TRPM7 kinase might stimulate COX-2 mRNA production by directly interacting with 
nuclear components. As described by Clapham and coworkers, the C-terminus of TRPM7 enclosing the 
kinase domain can be truncated and translocate to the nucleus where the kinase then is able to induce 
transcription of selected genes by histone modification.  
Herein demonstrated regulations are indicated by solid lines; currently unknown regulatory mechanisms are indicated by dotted 
lines; inhibitory actions are indicated by a blunt arrow; activating actions are indicated by a pointed arrow; the green dotted line 
hints to the translocation of the kinase unit into the nucleus; red arrows point to an increase in COX-2 mRNA transcription and 






7.5 Perspective: TRPM7 kinase as a potential 
pharmacological target for attenuating COX-2-driven 
diseases 
Corresponding to its clinical relevance, search for COX-2 inhibitors started as early as in the 
seventies, when the non-steroidal anti-inflammatory drug (NSAID) aspirin showed to effectively 
block PG synthesis [362]. With evolving research, more and more beneficial actions of NSAIDs came 
to light, wherefore they found broad use in therapy. Unfortunately, increasing administration also 
unmasked that classical NSAIDs comprise severe adverse effects, including risk elevation for 
gastrointestinal injuries, cardiovascular diseases and, dependent on predispositions, renal dysfunction 
[363, 364]. Primarily believed to be caused by simultaneous inhibition of the second present 
cyclooxygenase isoform COX-1, side effects were to be reduced by improving NSAIDs to selectively 
inhibit COX-2 [365]. But despite all efforts, most of these new pharmaceuticals also show some of 
the side effects observed with the classical, non-selective NSAID (nsNSAID) administration [365-
368]. In many cases, these new substances called ‘coxibs’ negatively affect cardiorenal function, 
reproductive actions and thrombotic events [365-368]. Hence, to successfully treat respectively 
prevent inflammation and cancer, existing drugs have to be further developed but also other targeting 
strategies should be considered [369].  
Although there was a vague indication that TRPM7 functions in COX-2 gene expression in terms of 
bradykinin- and aldosterone-directed signaling [91, 337], I herewith for the first time present that 
depletion or inhibition of TRPM7 respectively its kinase activity lead to a significant reduction in 
constitutive and inducible COX-2 gene expression. Furthermore, preliminary experiments 
demonstrate that the channel-kinase – directly or indirectly – also impacts COX-2 catalytic function.  
Hence, the discovery of both the TRPM7 channel and kinase positively regulating COX-2 expression 
and activity offers great potential for future therapy. However, TRPM7 essentially contributes to 
many physiological processes, which raises the possibility of the pharmacological block of the 
channel-kinase causing severe side effects [120]. Judging by the outcome of various TRPM7 knockout 
respectively kinase inactivation studies, I hypothesize that exclusively targeting the TRPM7 kinase 
domain represents the more decent option, as its actions are more limited and thus the risk of 
potential adverse reactions might be reduced [35, 45, 117, 118, 291, 370]. Yet, the only better 
investigated TRPM7 kinase-specific inhibitor on the market so far is TG100-115, and although it has 
been tested for therapeutical use in a phase II clinical study in terms of it being a PI3K blocker, it is 
not yet known if it is safe to apply in humans [371, 372]. Thus, besides screening for other drugs 





TG100-115 application is feasible in mammals and if it is of use for attenuation of TRPM7 kinase-
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